Semi-synthesis of a biologically inspired library of sesquiterpene derivatives, from the lipophilic marine natural product (+)-β-gorgonene by Buchanan, Beth Margaret (author) et al.
 Semi-Synthesis of a Biologically Inspired Library of Sesquiterpene 
Derivatives, from the Lipophilic Marine Natural Product (+)-β-
Gorgonene 
 
 
 
A Thesis 
Submitted to the Graduate Faculty 
in Partial Fulfilment of the Requirements 
for the Degree of Doctor of Philosophy 
Molecular and Macromolecular Sciences 
 
Department of Chemistry 
Faculty of Science 
University of Prince Edward Island 
 
 
Beth Margaret Buchanan 
Charlottetown, Prince Edward Island 
April, 2014 
 
 
 
© 2014, B.M. Buchanan 
ii 
 
Conditions for the Use of the Thesis 
The author has agreed that the Library, University of Prince Edward Island, may make 
this thesis freely available for inspection. Moreover, the author has agreed that 
permission for extensive copying of this thesis for scholarly purposes may be granted by 
the professor or professors who supervised the thesis work recorded herein or, in their 
absence, by the Chair of the Department or the Dean of the Faculty in which the thesis 
work was done. It is understood that due recognition will be given to the author of this 
thesis and to the University of Prince Edward Island in any use of the material in this 
thesis. Copying or publication or any other use of the thesis for financial gain without 
approval by the University of Prince Edward Island and the authors’ written permission 
is prohibited.  
  
Requests for permission to copy or to make any other use of material in this thesis in 
whole or in part should be addressed to:  
Chair of the Department of Chemistry  
Faculty of Science  
University of Prince Edward Island  
550 University Avenue, Charlottetown, PE  
Canada C1A 4P3 
iii 
 
Permission to Use Postgraduate Thesis  
  
 Title of thesis: Semi-Synthesis of a Biologically Inspired Library of Sesquiterpene 
Derivatives, from the Lipophilic Marine Natural Product (+)-β-Gorgonene 
 
  
  
Name of Author:   Beth Margaret Buchanan 
Department:   Chemistry  
Degree:   Doctor of Philosophy                            Year:  2014  
 
In presenting this thesis in partial fulfillment of the requirements for a postgraduate 
degree from the University of Prince Edward Island, I agree that the Libraries of this 
University may make this thesis freely available for inspection and give permission to 
add an electronic version of the thesis to the Digital Repository at the University of 
Prince Edward Island. Moreover the author agrees that permission for extensive copying 
of this thesis for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work, or, in their absence, by the Chair of the Department or the 
Dean of the Faculty in which my thesis work was done. It is understood any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed 
without my written permission. It is also understood that due recognition shall be given 
to me and to the University of Prince Edward Island in any scholarly use which may be 
made of any material in my thesis.  
  
 Signature:  ________________________________  
 Address:  Faculty of Science  
University of Prince Edward Island  
550 University Avenue, Charlottetown, PE  
Canada C1A 4P3 
  
Date:            ________________________________  
 
iv 
 
University of Prince Edward Island 
Faculty of Science 
Charlottetown 
 
CERTIFICATION OF THESIS WORK 
We, the undersigned, certify that Beth M. Buchanan, candidate for the degree of Doctor of 
Philosophy has presented a thesis with the following title: Semi-Synthesis of a Biologically 
Inspired Library of Sesquiterpene Derivatives, from the Lipophilic Marine Natural Product (+)-
β-Gorgonene, that the thesis is acceptable in form and content and that a satisfactory knowledge 
of the field covered by the thesis was demonstrated by the candidate through an oral examination 
held on April 4, 2014. 
 
Examiners:  
 
 
Dr. Russell Kerr (Supervisor)    
 
 
Dr. Nola Etkin (Committee member)    
 
 
Dr. Barry Linkletter (Committee member)    
 
 
Dr. Richard Bethell (Committee member)     
 
 
Dr. Darren Derksen (external examiner)    
 
 
Dr. Jason Pearson - Chair    
 
 
 
Date _______________________________     
v 
 
Abstract 
Natural products and their mimics have a high probability of engaging with 
biological targets. Hence, natural products have historically been a valuable source of 
medicines. They continue to inspire the synthesis of biologically relevant compound 
libraries, useful for drug discovery. Over 50 % of the small molecule drugs approved in 
the last 30 years are natural products or natural product derived. Sesquiterpenes are 
widespread in nature and exhibit a range of notable biological activities including 
antimicrobial, anti-inflammatory, anti-viral and lipid lowering activity. Therefore, 
sesquiterpene frameworks are suitable templates for biologically relevant screening 
libraries.   
Inspired by selected natural bioactive sesquiterpenes, we have transformed a 
highly lipophilic, non-drug-like, marine natural product (+)-β-gorgonene, available as a 
by-product from the purification of pseudopterosins, into a library of more drug-like 
derivatives. Several semi-synthetic techniques were employed to attach suitable 
structures such as substituted aromatics and heteroaromatics to the gorgonene scaffold 
to increase its drug-likeness and probability of exhibiting biological activity. Each 
compound synthesized was chemically characterized, analyzed for drug-likeness and 
screened for PTP1B inhibition (potential therapeutic target for treatment of type 2 
diabetes), antimicrobial activity and cytotoxic properties.  
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With the goal of incorporating the desired substructures in a minimum number of 
steps, a 2+3 dipolar cycloaddition reaction was used to attach selected motifs to the 
gorgonene framework via an isoxazoline linker. The series of synthesized isoxazoline 
derivatives included decahydroazulene and cyclopropane-containing compounds. 
Several members of the isoxazoline-containing collection displayed selective inhibition 
of the PTP1B enzyme and others exhibited modest cytotoxic activity. 
Another family of gorgonene analogues was synthesized through a dione 
containing intermediate, a product of the ozonolysis of gorgonene. Carbonyl chemistry 
was then used to incorporate aromatic moieties into the structure such as the aldol 
reaction and nucleophilic addition. Gorgonene was observed to undergo an 
intramolecular Alder-ene reaction when catalyzed by FeCl3 or BF3 and produce novel 
tricyclic sesquiterpene-like hydrocarbons. A hydroboration/oxidation strategy 
highlighted the tendency for the 1,5-diene system to react intramolecularly to form 
additional five- and six-membered rings. A glycosyl-containing derivative was 
synthesized through a dihydroxy-gorgonene analogue. Biotransformation was used as an 
additional strategy to selectively oxidize synthetically inaccessible carbons on 
gorgonenes saturated decalin backbone to facilitate further transformations. Incubation 
of gorgonene with Bionectria ochroleuca resulted in the production of a novel 
trihydroxylated sesquiterpenoid. 
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Chapter 1 - General Introduction 
2 
 
 
1.1 The Need for New Therapeutics 
The pharmaceutical industry has made dramatic advances over the past hundred 
years, yet many diseases continue to lack efficacious treatments that are not associated 
with serious side effects, at a reasonable cost. There are urgent needs for novel 
therapeutics in the fields of oncology, medical microbiology and bariatrics providing 
vast opportunities for drug discovery and development. Cancer is consistently one of the 
two top causes of death in Canada and its treatments are plagued with low efficacy and 
painful side effects.
1
 The emergence of multi-drug resistant pathogenic bacteria 
necessitate the development of alternatives to current therapeutics.
2
 Obesity and diabetes 
are growing problems associated with major health complications and have few medical 
treatments.
3
 These examples illustrate the need for research invested in the development 
of new drugs designed to treat diseases lacking attractive therapeutic options. The first 
step of drug discovery is often the identification of lead compounds in screening 
libraries using appropriate biological assays. These hits are then optimized to improve 
pharmacological properties.    
1.2 Sources of Screening Libraries 
 In order to address the medical needs described above (diabetes, obesity and 
antibiotic resistant bacterial infections), screening libraries of small molecules are 
required for biological evaluation. Sources of screening libraries vary widely and there 
are many approaches to acquire compound collections likely to contain biologically 
active compounds.
4
 Some of these sources of screening libraries are outlined in Figure 
1.1. 
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Figure 1.1 - Synthetic and Biological Sources of Small Molecule Screening 
Libraries 
1.3 Natural Products 
Natural products have been a great source of medicines over the course of 
history and continue to be invaluable in the production of new drugs.
5
 Bioactive natural 
products often inspire the design and synthesis of libraries of molecules in the search for 
new pharmaceuticals
6 
and these natural product-like libraries have been successful at 
producing new drug candidates.
7
 Indeed, over 50 % of the drugs approved in the past 50 
years have been natural products themselves, or derivatives of natural products.
8
 
Further, 19 new drugs were approved between the years 2005-2010  that fall in this 
category.
9
 
Natural product based drug discovery programs produce a high percentage of 
bioactive compounds because natural products have evolved over millions of years to 
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interact with biological systems and control biological processes.
10
 Due to the 
conservation of protein domains across taxonomic groups in nature, many natural 
products can interact with more than one biological target
10
 and exhibit more than one 
type of biological activity within individual species or across species.
10
 Due to the 
biological relevancy of natural products, they are considered ``pre-validated``, 
``privileged`` structures for use in biological settings.
6
 Some biologically active natural 
products may be unsuitable for therapeutic use due to insufficient activity, toxicity or 
supply issues, but in these cases they can be used as advanced lead compounds in the 
design of optimized bioactive libraries.
11
   
1.3.1 Marine Natural Products 
Oceans cover 70 % of the surface of the Earth and account for 95 % of the 
Earth’s biosphere.12 This rich biodiversity in turn produces chemical diversity.13, 14 The 
marine environment has also been far less explored than the terrestrial environment, as 
many parts of the ocean were effectively inaccessible until the invention of scuba 
diving. Therefore, the marine environment is a promising source of novel biologically 
active compounds. Many marine organisms such as sponges and coral have little in the 
way of physical defense mechanisms (e.g. no mobility or physical protection) and often 
use chemical mechanisms in order to survive, such as the production of secondary 
metabolites that act as chemical defense against predation and pathogens.
5
 Secondary 
metabolites may be produced by these organisms for other purposes as well such as 
communication, reproduction and adaptation to harsh marine environments.
15
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1.3.2 Natural Product Isolation and Screening  
Due to the difficulty and time-consuming nature of purifying natural products 
from a crude extract it is impractical to purify each compound present in the extract 
prior to biological testing. Crude extracts or pre-fractionated libraries (partially purified 
extracts) are often screened for biological activity and only those fractions containing 
active components are purified further. The fractionation and biological testing 
processes are repeated until the bioactive compound is pure. This process is known as 
bioassay-guided fractionation (Figure 1.2).
16
 
 
Figure 1.2 - Bioassay-Guided Fractionation
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1.3.3 Challenges and Solutions for Natural Product Chemistry 
1.3.3.1 Supply of Natural Products 
One of the major challenges associated with the use of natural products as 
therapeutics is the issue of supply. Several natural products with exceptional activity and 
potential have been delayed in development, or not developed due to a lack of supply.
17-
20
 These compounds are often produced in very small amounts from organisms which 
are limited in nature and difficult or impossible to farm using agriculture or aquaculture 
methods. Researchers have developed several solutions to address the supply problem 
and these are outlined in the following sections.  
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1.3.3.2 Total Synthesis of Natural Products 
  Developing total syntheses of natural products is a popular challenge for 
synthetic chemists. Natural products are often complex molecules with numerous 
stereocenters and their total synthesis provides value to the field in the form of 
improvement of synthetic methods. Total synthesis can also provide structure activity 
relationship information and new therapeutic leads.
21
 Although great advances have 
been made in the recent past and amazing target molecules have been successfully 
constructed
22-24
, total synthesis is frequently too expensive, time consuming and low 
yielding to use in the industrial scale production of natural products. Some chemists 
claim that developments in the scalability of synthetic methods will make the supply of 
natural products practical via total synthesis in the near future.
25
 
1.3.3.3 Microbial Producers of Natural Products 
A growing body of evidence supports the production of many natural products, 
traditionally attributed to the whole organism they were isolated from, to microbes 
living within the host organism.
26
 If a microbial producer of a natural product can be 
identified and cultured, the production of the natural product can be accomplished via 
fermentation. Bacterial and fungal fermentation are often more financially viable than 
agriculture or aquaculture of the associated macro-organism host, when sufficient 
amounts of the host cannot be collected.  
 One example of the production of a compound by a microbe that had previously 
been associated with its associated host organism is that of the cancer drug paclitaxel 
(Taxol™). Paclitaxel was originally isolated from the pacific yew tree, but the limited 
supply of the yew tree and length of time to grow the trees was a limiting factor in the 
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production of the natural product.
27
 Plant tissue culture has been since used to 
circumvent this issue and provides a significant portion of the industrially produced 
drug.
28
 However, paclitaxel is also produced from several fungal species, including 
Taxomyces andreanae
29
 and researchers are exploring this as a new potential source of 
the drug.
30
 
1.3.3.4 Semi-Synthesis of Natural Products 
 Semi-synthesis of a complex natural product from a structurally simpler natural 
product which is readily available from other methods (e.g. microbial fermentation) is a 
useful production method. Ecteinascidin 743 is a potent antitumor natural product 
isolated from the tunicate Ecteinascidia turbinata.
31
 A semi-synthesis of ecteinascidin 
743 from safracin B, produced by fermentation of Pseudomonas fluorescens was 
developed by Cuevas et al. and is currently used in the production of the cancer drug.
31
 
1.3.3.5 Agriculture and Aquaculture 
Agriculture or aquaculture of natural product producers can be a viable source of 
natural products.
32, 33
 There are many instances of these being unsuccessful when 
organisms are difficult to grow outside of their native environment, take many years to 
mature, or produce low concentrations of the desired metabolite.
34, 35
 
1.3.3.6 Heterologous Production 
Heterologous production of valuable and complex natural products is a 
promising alternative to large scale synthesis. It involves cloning the biosynthetic genes 
responsible for the production of the natural product from the natural producer into an 
easily fermented and well-studied host organism such as E. coli to enable the compound 
to be manufactured via fermentation.
36, 37
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1.3.3.7 Chemical Dereplication 
A high percentage of organic extracts from marine invertebrates exhibit activity 
in antimicrobial or anticancer screening. The activity of many of these fractions is due to 
natural products that have been previously studied. Reisolation of known compounds is 
a recurring problem in natural products chemistry and tools such as LCMS and NMR 
can be used to “dereplicate” the extracts at an early stage. Dereplication is the process of 
identifying and eliminating those fractions that possess activity due to known bioactive 
compounds. LCMS can be used to create profiles for organisms or fractionated extracts, 
where molecular weight, UV absorbance and retention time can be used to identify 
known compounds. Many natural products are listed in databases such as MarinLit
38
 and 
AntiBase
39
 where the chemical characterization data is listed along with the taxonomy 
of the producing organism and known biological activity. The search options and 
information provided by the databases can be used to rapidly identify which fractions 
contain compounds that have been previously reported and can account for observed 
bioactivity. Computer software can be used to perform complicated mathematical 
transformations (e.g. principal component analysis, PCA)
40
 to organize large sets of data 
generated by LCMS, group together similar compounds and identify unique chemical 
outliers. 
The application of novel screening assays to known organisms increases the 
opportunity for the isolation of new compounds. New, active compounds are often 
found with the use of new biological targets. 
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1.4 Combinatorial Chemistry  
Combinatorial chemistry is an approach which generates large numbers of 
compounds by applying reaction conditions to mixtures of reagents. This technique 
became very popular and has been successful at producing millions of compounds for 
high throughput screening campaigns; however, it has failed to live up to expectations 
and has only produced one drug since its conception (Sorafenib
41
). This is attributed to 
the nature of combinatorial libraries which commonly represent a small area of chemical 
space and lack the qualities of biological compounds such as stereogenic centers and 
complex ring systems.  
1.5 Biologically-Inspired Synthetic Strategies 
1.5.1 Target-Oriented Synthesis and Diversity-Oriented Synthesis 
 Target-oriented synthesis focuses on the production of a single compound 
(similar to total synthesis, vide supra). Diversity-oriented synthesis, alternatively, is a 
strategy to generate libraries of compounds with the aim of diversity (Figure 1.3), often 
with a focus on biologically relevant chemical space.
42
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Figure 1.3 - Target-Oriented and Diversity-Oriented Synthesis
42
 
1.5.2 Natural Product - Like Compounds 
Compounds structurally resembling natural products are often designed to mimic 
natural product activity in vivo. Mimetic compounds often contain the entire natural 
product or the pharmacophore present in the parent natural product. The best examples 
of this approach are when the structure activity relationship studies allows the synthesis 
of simplified analogues that retain or increase potency of the natural product.
43
 This 
often involves identifying the pharmacophore of the natural product and the design of 
families of compounds that contain the molecular features necessary for activity.  
11 
 
1.5.3 Target-Based Drug Discovery 
This approach centers around the identification of a cellular target, such as a 
gene or a molecular mechanism, that is associated with a disease state and then small 
molecules are designed to interact with the active site specifically.
44
 This is a promising 
approach, but has not achieved much success to date. Identification of a target that is 
altered in a disease state is relatively straightforward; validation of this target as a 
promising therapeutic target is far more challenging. The target must be established to 
have a therapeutic benefit and not be a consequence of the disease; this process is 
reported to be very complex and time consuming.
44
 
 Once a target is established, however, researchers can use computational 
chemistry and virtual screening methods to minimize the number of screening library 
members to synthesize.
45
 Candidates for library synthesis can be analyzed using 
computational methods to assess their ability to interact with an active site on a known 
target. This narrows down the need for large screening libraries and can help drastically 
reduce synthetic time and resources required to arrive at a lead compound.  
1.5.4 Lead-Oriented Synthesis  
Lead-oriented synthesis focuses on the synthesis of molecules that have the 
pharmacological properties associated with bioavailability. Bioavailable compounds 
possess specific molecular properties associated with solubility and absorption that 
allow them to reach systemic circulation in vivo, making them good leads and/or good 
drugs.
46, 47
 
Lipinski’s rule of five48 defines the characteristics of drug-like molecules as: 
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 Have no more than 5 hydrogen bond donors 
 Have no more than 10 hydrogen bond acceptors 
 Have a molecular mass less than 500 
 Have a Log P between 0-5 
Lead compounds have a separate set of rules for their optimal properties because 
they are to be further modified by definition. For example a lead compound should have 
a molecular weight less than 300 to allow for addition to the scaffold during lead 
optimization and ensure the final drug candidate has a molecular mass under 500 
daltons. Lead-oriented synthesis focuses on the production of compounds that fit the 
criteria for bioavailability.   
1.5.5 Lead-Directed Semi-synthesis 
Natural products can act as a source of molecular scaffolds that can be converted 
to combinatorial libraries either by direct chemical modification of the natural product 
or by providing inspiration for organic synthesis. Lead-directed semi-synthesis involves 
modifying a natural product lead compound or compounds to generate libraries with 
improved pharmacological properties. An example of this is the semi-synthesis of β-
lactam antibiotics that display greater resistance than their parent compound.
49
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Figure 1.4 - Natural Products as a Source of Drugs and Lead Compounds
4
 
1.5.6 Chemically Engineered Extracts 
 This process involves the treatment of a crude natural product extract or extract 
fraction with chemical reagents designed to perform specific transformations.
50
 The 
semi-synthetic mixture is produced by transforming functional groups that are common 
in nature to moieties less common in nature. The resulting engineered extract is 
processed with bioassay-guided fractionation. Using this process, many diverse and 
even unknown inactive metabolites can be altered simultaneously and only those 
products that possess the desired activity are isolated and investigated. This strategy has 
not been widely used to date and few examples of bioactive compound generation have 
been reported.
51
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1.5.7 Biology-Oriented Synthesis (BIOS)  
Natural products, as stated above, contain biologically relevant architectures.  
Natural products and similarly, their molecular targets (e.g. proteins) have evolved to 
occupy only a small fraction of vast chemical space. The biology-oriented synthesis 
approach focuses on creating libraries of compounds within the chemical space 
occupied by natural products and other biologically relevant molecules such as drugs.
6, 
10, 42, 52, 53
 Natural product frameworks are used as building blocks in the synthesis of 
libraries focused on biological relevancy. These high quality screening libraries have 
claimed hit rates in biological assays between 0.5-2%.
54
 It is difficult to compare these 
rates to other drug discovery programs because the criteria that defines a hit differs 
between studies and is often defined based on the activity of the collection. Compound 
libraries designed using this method are often complex and synthetically demanding, 
however, higher hit rates reduce the size of libraries required to produce a lead 
compound. This may balance out the higher synthetic cost of the individual library 
members.   
1.6 Diseases with a Need for New Drugs 
1.6.1 The Global Diabetes and Obesity Problem 
The rate of obesity worldwide has drastically increased in the past 50 years, and 
adiposity is widely recognized as one of the leading threats to human health.
55
 Obesity is 
a major risk factor for many health problems such as cardiovascular disease, 
hypertension and type 2 diabetes.
56
 Individuals diagnosed with type 2 diabetes have a 
higher risk of serious health complications such as cardiovascular disease, neuropathy 
(nerve damage), nephropathy (kidney damage) and retinopathy (eye damage) among 
15 
 
others.
57
 Global instances of diabetes and obesity are expected to continue to grow in the 
next 10 years and cause a massive and growing burden on health systems.
3, 57
  
1.6.2 PTP1B as a Drug Target for Diabetes and Obesity 
Protein tyrosine phosphatase 1B (PTP1B), has been identified as a promising 
new therapeutic target for the treatment of diabetes and obesity.
58
 Insulin resistance 
(failure of insulin receptors to recognize and respond to insulin in the body) is the major 
cause of type 2 diabetes. PTP1B is a negative regulator of the insulin signalling 
pathway, associating with and dephosphorylating activated insulin receptors or insulin 
receptor substrates, and contributing to insulin resistance.
58
 Overexpression of the 
PTP1B enzyme in culture has been demonstrated to increase insulin resistance
59
 and 
mice with under expressed PTP1B enzyme displayed increased insulin signaling
60
, 
therefore, PTP1B is an exciting new target for the management of insulin-resistance 
related diabetes. Over 300 natural product inhibitors of PTP1B have been reported to 
date.
61
    
Leptin is a hormone involved in the regulation of appetite and energy 
expenditure and leptin resistance has been linked to obesity in some cases.
51, 62
 PTP1B is 
a negative regulator of JAK2, an enzyme downstream from the leptin receptor.
63
 
Negative regulation of PTP1B was predicted to increase an individual`s sensitivity to 
leptin because of the enzyme’s role in leptin signaling. PTP1B knockout mice 
demonstrated resistance to diet induced obesity, which was attributed to increased 
sensitivity to leptin, resulting in increased energy expenditure.
64
 Pre-treatment of leptin-
resistant mice with a PTP1B inhibitor resulted in a suppression in food intake.
65
 Thus 
PTP1B inhibitors are of interest in both diabetes and obesity indications.
58
 
16 
 
The major challenge associated with targeting the PTP1B enzyme for drug 
discovery is selectivity. There are over 100 protein tyrosine phosphatases in the body 
that possess widely varying biological functions and a high degree of sequence identity 
at the active site.
66
 It is therefore important for PTP1B lead compounds to be tested for 
both activity and selectivity. The PTP1B active site is positively charged and has a side 
pocket adjacent to the main active site which causes the enzyme to favor bidentate 
ligands that can interact with both sites simultaneously.
58
 Thusfar, most of the reported 
PTP1B inhibitors are negatively charged or highly polar molecules not suitable for drug 
use.
58
  
A cysteine residue found in the active site of the PTP1B enzyme is susceptible to 
oxidation resulting in deactivation of the enzyme. Oxidative compounds are often 
associated with toxicity and are not good drug candidates. All active PTP1B inhibitors 
should be screened for oxidative behavior using other enzymes containing cysteine 
residues such as papain
61
 to eliminate those acting via an oxidative mechanism.   
1.6.3 Need for New Antimicrobial Drugs 
Antibiotic resistance is a major threat to human health worldwide.
67
 Bacterial 
resistance to antibiotics can develop through genetic mutation or acquisition of 
resistance genes from other bacteria through horizontal gene transfer.
68
 Mechanisms of 
bacterial resistance include drug inactivation or modification, alteration of target site or 
metabolic pathway and decreasing drug accumulation by increasing efflux or decreasing 
drug permeability. A small population of bacteria containing antibiotic resistance genes 
existed before the discovery of penicillin in 1928
69
, however, the increased prevalence 
of drug resistant and multi-drug resistant pathogens observed in recent years is largely 
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attributed to the overuse of antibiotics.
2
 As the prevalence of antibiotic resistant bacteria 
increases and the appearance of bacteria resistant to newer antibiotics rises, so does the 
need for new antibiotics. Many of the antibiotics introduced in the past 20 years are “me 
too” drugs70 and have similar structure and mechanism of action to current drugs. They 
are therefore ineffective against bacteria that have developed resistance to the original 
therapeutic and do not address the problem of resistance. With respect to this, Fenical 
stated “The fact is that no really new antibiotic has come out since the late 1980s. We 
are on a very dangerous collision course with a plague.”71 Scientists, health 
professionals and the world health organization have called for researchers to devote 
time and energy to the discovery and development of novel antimicrobial drugs and 
classes of drugs with new mechanisms of action.
72, 73
 
1.6.4 Need for New Cancer Drugs 
 Cancer is second only to heart disease for the leading cause of death in Canada.
1
 
The number of different types and treatments for cancer is staggering. There have been 
many breakthroughs in the detection and treatment of cancer over the past decades, but 
many types of cancers remain without effective treatment options and many of those 
treatments involve serious risks. 
1.7 Sesquiterpenoids and Meroterpenoids 
Sesquiterpenes and sesquiterpenoids are ubiquitous in nature, isolated from 
plants
74, 75
, insects
76
, fungi
77, 78
, bacteria
79, 80
, sponges
81, 82
 and coral.
83, 84
 They have been 
reported to exhibit a broad range of bioactivity including antibacterial
85
, antifungal
86
, 
cytotoxic
87
, antiviral
88 
and anti-inflammatory
89
 activities. 
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Meroterpenoids
90, 91
 are natural products that have mixed biosynthetic origin and 
contain a terpenoid fragment. Many of the biologically interesting meroterpenoids are 
polyketide/terpenoid hybrids
92, 93
 but alkaloid/terpenoid meroterpenes
94
 are known as 
well.  
1.7.1 Antimicrobial Decalin Containing Sesquiterpenoids and Meroterpenoids 
Sesquiterpenes/meroterpenes containing two fused cyclohexane rings, a decalin 
skeleton, are common secondary metabolites isolated from marine sponges.
95
 These 
sesquiterpenes, particularly derivatives of bicyclofarnesols with appended lactone
96
, 
substituted aryl or quinone rings
97
 commonly exhibit a range of biological activity 
including antimicrobial properties. The production of antibiotic and antifungal 
compounds protects the marine invertebrate against pathogenic or unwanted 
microorganisms and gives them an evolutionary advantage.
98
 Sesquiterpene/aromatic, 
sesquiterpene/quinone and sesquiterpene/heterocycle skeleton are often discovered by 
researchers looking for antimicrobial compounds in marine sponges.
99
 
The siphonodictyal (1 – 4, Figure 1.5) and siphonodictyol (5, 6) family of 
compounds, isolated from the sponge Siphonodictyon coralliphagum, showed activity in 
disc diffusion assays against the Gram positive bacteria Staphylococcus aureus and 
Bacillus subtilis. Siphonodictyals C and D (3 and 4) were also active against the Gram 
negative bacterium Vibrio anguillarum.
100-102
 These metabolites are of mixed 
biosynthetic origin containing a decalin skeleton connected to a hydroquinone moiety.   
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Figure 1.5 - Antimicrobial Siphonodictyals and Siphonodictyols 
 Ilimaquinone 7 and dictyoceratins A (8) and B (9), all isolated from marine 
sponge Hippospongia sp. display antimicrobial activity against Staphylococcus aureus 
and Bacillus subtilis
103
 with dictyocaratin-A being the most potent with an MIC of 6.3 
µg/ml against S. aureus and 3.1 µg/mL against B. subtilis (Figure 1.6). Ilimaquinone has 
a quinone moiety attached to the decalin skeleton and the dictyoceratins have phenols 
linked to the decalin scaffold. 
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Figure 1.6 - Ilimaquinone, Dictyoceratin and Avarol Derivatives 
 Avarol (10) and avarone (11)
104
, marine natural products isolated from the 
sponge Dysidea avara and their synthetic derivatives 12-16 (Figure 1.6) were tested for 
antimicrobial activity against marine bacteria Cobetia marina, Marinobacterium 
stanieri, Vibrio fischeri and Pseudoalteromonas haloplanktis by Tsoukatou et al.
104
 and 
displayed MIC values of 0.5-5.0 µg/mL for C. marina, 0.5-5.0 µg/mL for M. stanieri, 
1.0-10.0 µg/mL for V. fischeri and 1.0-10.0 µg/mL for P. haloplanktis. Sulfide 
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containing compounds 13 and 15 were found to be the most active against all strains. 
These compounds were also tested and found to have activity against the marine fungi 
Halosphaeriopsis mediosetigera, Asteromyces cruciatus, Lulworthia uniseptata and 
Monodictys pelagica.
104
 
  Avarone (11) showed antibacterial activity against Staphylococcus aureus with a 
reported MIC of 1.56 µg/mL.
105
 Derivatives of avarone were synthesized (Figure 1.7), 
with a variety of amino appendages on positions R1 and R2, however these semi-
synthetic compounds showed significantly weakened activity in S. aureus assays. 
Compounds 16 – 22 had MIC’s of 50 µg/mL or greater, however, compounds 23, 24 
and 25 were more effective inhibitors of S. aureus with MIC’s between 6.25 and 12.50 
µg/mL.
105
 The presence of a larger electron rich moiety at R1 or R2 appears to cause 
increased inhibition vs. primary or secondary amine substituents.    
 
Figure 1.7 - Avarone and Related Synthetic Compounds 
Sesquiterpenoid 26, isolated from the tree Pleodendron costaricense is the only 
included example not containing a third ring. It was found to have antifungal activity 
against Alternaria alternate, Candida albicans D10 (azole resistant) and Wangiella 
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dermatidis with MICs of 3.9, 15.6, and 15.6 µg/mL respectively.
106
 Compound 27, 
isolated from the stem bark of the African tree of Irvingia gabonensis  had an MIC value 
less than 5 µg/mL against Gram negative bacteria E. cloacae, M. morganii, N. 
gonorrhoeae, N. flexneri and S. typhi as well as Gram positive bacteria B. cereus, B. 
megaterium, B. stearotherm and B. subtilis.
107 
Compound 29 was tested in assays for bacterial inhibition and had an MIC of 15 
µg/mL (S. aureus, B. cereus, B. subtilis), 20 µg/mL (B. anthracis) 17 µg/mL (M. luteus), 
7 µg/mL (M. smegmatis) and 9 µg/mL (M. phlei). Interestingly, its close analogues, 28 
and 30, did not inhibit any bacterial growth at the 50 µg/mL level. The presence of the 
carboxylic acid or ester at this position may reduce activity for electronic or steric 
reasons.    
 
Figure 1.8 - Potent Antimicrobial Sesquiterpenes and Meroterpenes 
Meroterpenoids containing a pyranone ring (31 and 32), isolated from an 
unidentified fungus, were active in antibiotic assays; 31 was found to have MICs of 20 
and 24 µg/mL against A. flavus and F. verticillioides respectively and both showed clean 
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inhibition zones between 9 and 30 in disk diffusion assays against F. verticillioides 
(fungus), S. aureus and C. albicans.
109
  
Antimicrobials with a decalin/methyladenine hybrid framework, agelasine B 
(33) and ageline B (34)
110
, originating from an Agelas sponge, both inhibited S. 
cerevisiae at 10 µg/mL. Neither the inversion of the stereochemistry on C6 or C7 or the 
presence of the attached pyrrole ester appears to affect the activity of the compounds. 
 
Figure 1.9 - Antimicrobial Compounds Agelasine B, Ageline B and Prianicin B 
Prianicin B (35) has a unique peroxide containing ring attached to the bicyclic 
framework. It was isolated from the marine sponge Diacarnus cf. spinopoculum by 
Sokoloff et al.
111
and displayed promising inhibition against two β-hemolytic 
Streptococcus strains (MIC: 1.0 and 4.0 µg/mL). 
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Figure 1.10 - Kalihinol Family of Compounds 
The kalihinol family of compounds (36-46, Figure 1.10) were isolated from a 
fraction of a sponge extract (Acanthella sp.) that displayed antibiotic activity against test 
strains Bacillus subtilis, Staphylococcus aureus and Candida albicans.
112, 113
 The 
efficacy of the natural products was not reported. They are comprised of a decalin core 
with an attached tetrahydropyran or tetrahydrofuran heterocycle and an interesting 
isocyano-functional group that has been observed in natural products isolated from 
terrestrial microorganisms and marine sponges.   
Sesquiterpene lactones, 47 and 48 (Figure 1.11)
96
 are potent antimicrobial 
compounds. With MICs between 0.2-0.5 µg/mL against a panel of bacteria including M. 
flavus, B. subtilis, P. tolaasii, S. epidermidis, S. enteritidis and E. coli as well as fungi A. 
flavus, A. niger, A. ochraceus, P. funiculosum, P. ochracholoron, T. viride, F. tricintum 
and A. alternate; these are very intriguing skeletons.  
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A series of compounds represented by the scaffold 49 were major components 
from an antibacterial fraction extracted from the sponge Spongia officinalis.
114
 The 
fraction was active against S. aureus, P. aeruginasa and B. sphaericus. Detailed analysis 
of the activity of each compound was not disclosed.  
 
Figure 1.11 - Antimicrobial Terpenoids 47-50 
The sesquiterpene sorangiadenosine (50)
115
 was isolated from bacterium 
Sorangium cellosum and has moderate activity against Gram positive and Gram 
negative bacteria. MIC’s of 25, 12.5, 6.25, 6.25 and 12.5 µg/mL were observed assays 
against S. aureus, B. subtilis, M. leuteus, P. vulgaris and S. typhimurium. Again we see 
an adenine moiety within the active structure and in this case a tetrahydrofuran group is 
present as well.   
Summary 
The sesquiterpenoids and meroterpenoids discussed above all contain a bicyclic 
decalin skeleton, but vary greatly in their substitution patterns, stereochemistry, 
unsaturation and functional groups attached. There are common substitution patterns; 
however, such as C5 and C10 (Figure 1.12); either one or both of which is substituted 
with a methyl group in every case except the kalihinols, 32 and 33, however, the 
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stereochemistry varies among the examples. C1 is often substituted with one or two 
methyl groups, an olefin or another substituent and endo- and exocyclic unsaturation is 
found throughout the examples. The attached ring is commonly separated from C6 by a 
one-carbon linker, however, examples of 0, 2 and 5 carbons separating the decalin 
system from the attached ring are observed. The identity of the rings vary from 
substituted phenols, quinones, hydroquinones, furan, lactones, tetrahydropan, 1,2-
dioxane and methyladenine units. These rings can also have two points of attachment to 
the main sesquiterpene unit creating a fourth ring. 
 
Figure 1.12 - Bicyclofarnesol Skeleton 
As mentioned earlier, many of these compounds are part of a large subclass of 
sesquiterpenes called bicyclofarnesols based on their biosynthesis, outlined in Figure 
1.13.  
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Figure 1.13 - Biosynthesis of Bicyclofarnesol and Maaliane Sesquiterpenes 
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1.7.2 Sesquiterpene and Meroterpenes that Inhibit the PTP1B Enzyme   
 In addition to antimicrobial activity, sesquiterpene quinones and hydroquinones 
are known to inhibit the PTP1B enzyme. Sesquiterpene quinones 51-54 were isolated 
from the Hainan sponge, Dysidea villosa and possess PTP1B inhibitory activity. 
 
Figure 1.14 - Sesquiterpene Quinones that Inhibit PTP1B
116-118
 
  21-Dehydroxybolinaquinone (51, Figure 1.14) possesses moderate PTP1B 
inhibition, with an IC50 value of 39.5 µM. This compound is also cytotoxic with an IC50 
of 19.5 µM.
116
 Dysidine (52) was shown to activate the insulin signaling pathway, 
promote glucose uptake in 3T3-L1 cells and increase insulin sensitivity all of which was 
linked to PTP1B inhibition.
117
 Dysidavarones A (53) and D (54) also showed inhibition 
of the PTP1B enzyme with IC50 values of 9.98 and 21.6 μM, respectively.
118
 
1.7.3 Cytotoxic Sesquiterpenes 
 Cytotoxicity is extremely common among sesquiterpenoids, indeed there are too 
many examples to list here. Some of the most well-known of these are the terpene 
lactones
119
 and terpene quinones/hydroquinones.
95
 The reader is directed to several well 
written reviews and book chapters on the subject for more information.
120-123
 Of notable 
mention are the eudesmanolides, a family consisting of hundreds of sesquiterpene 
lactones that contain a decalin scaffold
124
 and have the general structure of the 
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eudesmane-12,6-olides (55) or eudesmane-12,8-olides (56, Figure 1.15). The 
sesquiterpene lactone parthenolide (57) is currently in clinical trials for cancer therapy 
(Figure 1.15).
120
  
 
Figure 1.15 - Eudesmanolide Backbone and Parthenolide  
1.8 Precedent for Decalin Containing BIOS Libraries 
The abundance of biologically active, decalin-containing natural products 
suggests the decalin scaffold is a biologically validated building block useful for 
biologically inspired screening libraries. An illustrative example of a decalin containing 
BIOS collection is one containing 300 compounds that were synthesized in a three step 
sequence from androprapholide (58). Ozonolysis of androprapholide yielded the key 
synthetic intermediate 59 (Figure 1.16). This intermediate was used in parallel syntheses 
to generate a library of analogues containing a thiazole moiety (60). Further library 
diversification was established by esterification or amide formation of the carboxylic 
acid (61).
125
 The library members were then assessed for their physiochemical properties 
and drug-likeness.  
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Figure 1.16 - Androphapholide Inspired BIOS Compound Collection
125
 
 
Figure 1.17 - Sulfricin 
Sulfricin (62) is a natural product with Cdc25A (a protein phosphatase) 
inhibitory activity. A study replacing the decalin skeleton of the compound with 
benzimidazole, benzothiazole and naphthalene moieties produced analogues that lacked 
the activity of the parent natural product. This result supports the proposal that the 
decalin scaffold is indeed a privileged structure.
6
 
One biologically relevant example of a BIOS library built around a decalin 
skeleton is the synthesis of a dysidiolide (63) inspired collection of 162 compounds and 
their biological evaluation for 11β-HSD (11β-hydroxysteroid dehydrogenase) inhibition. 
Thirty members of the synthetic library had IC50 values lower than 10 µM and four (64-
67) showed inhibition in the nM range (Figure 1.18).
126
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Figure 1.18 - Dysidiolide Inspired Inhibitors of 11-β-HSD126 
 
Figure 1.19 - Santonin Inspired Library of 5-Lipoxygenase Inhibitors 
 Santonin (68), a known inhibitor of 5-lipoxygenase (possible target for 
atheroclerosis, cancer, osteoporosis and inﬂammation) was used as inspiration for the 
synthesis of a natural product based combinatorial library.
127
 Four out of the 23 
synthesized analogues (69 - 72, Figure 1.19) showed potent inhibition of the enzyme 
with IC50
’
s 0.8-8.0 µM.   
1.8.1 Summary 
Decalin containing sesquiterpenoids are common in nature and possess a range 
of pharmacological activity. Synthetic libraries inspired by these secondary metabolites 
have successfully produced pharmacologically relevant compound collections with a 
high hit rate for biological activity.      
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1.9 Research Goals 
1.9.1 (+)-β-Gorgonene 
The sesquiterpene (+)-β-gorgonene128-130 (73, Figure 1.20) was isolated by 
Weinheimer et al. as a major component (55 %) of the sesquiterpene hydrocarbon 
mixture from Pseudopterogorgia americana and was identified as a non-isoprenoid 
sesquiterpene related to monoterpene sylvestrene. The biosynthesis resulting in the 
production of the scaffold was also proposed by Weinheimer in 1968.
128
 
(+)-β-Gorgonene was isolated by our lab, from Antillogorgia elisabethae 
(formerly Pseudopterogorgia elisabethae), a sea whip found in the tropical West 
Atlantic, as a by-product of an industrial scale production of pseudopterosins (anti-
inflammatory and analgesic family of diterpene glycosides used as additives in the 
cosmetic industry and being developed for therapeutic applications).
131-134
  
 
Figure 1.20 - Structure of (+)-β-Gorgonene 
(+)-β-Gorgonene is a sesquiterpene hydrocarbon containing a decalin skeleton, 
three stereocenters and two exocyclic, terminal olefins (Figure 1.20). It is a member of 
the maaliane class of sesquiterpenes
135, 136
; a vastly understudied family with few 
examples reported in the literature. 
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The acquisition of a sustainable supply of gorgonene, coupled with the biological 
activity displayed by decalin containing sesquiterpenes and meroterpenes, warranted 
further investigation into the structure-activity relationship of this bicyclic framework. 
Semi-synthetic and biocatalytic manipulations allow exploration of the bioactive 
potential for a library containing a gorgonene backbone.   
 
Figure 1.21 - Comparison of (+)-β-Gorgonene and Bicyclofarnesol Skeleton 
 Gorgonene is non-drug-like mainly due to its high log P value (lipophilicity), 
however, gorgonene contains a privileged decalin skeleton and is a great starting point 
for a semi-synthesis of a natural product-like collection of compounds. It was chosen as 
the foundation for the semi-synthetic BIOS library because it possesses a pre-validated 
structure, handles for reactivity and is readily available. A semi-synthetic family of 
natural product derivatives was designed according to the principles of lead-based drug 
discovery, complying with Lipinsky’s rule of 5 for bioavailability (Figure 1.22). 
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Figure 1.22 - Strategy to Convert Gorgonene to Drug-Like Library of Natural 
Product Derivatives 
1.9.2 Hypothesis 
A rationally designed semi-synthetic library of gorgonene derivatives will be 
efficient in producing biologically relevant compounds; specifically possessing PTP1B 
inhibition activity, antimicrobial and/or cytotoxic activity.   
1.9.3 Objectives 
      Design, synthesize and biological evaluate families of natural product mimics 
derived from (+)-β-gorgonene. 
1. Identify natural products with the desired biological properties and use these as 
inspiration for a semi-synthetic library of gorgonene derivatives. 
2. Design and synthesize a library of new chemical entities containing the 
gorgonene skeleton by synthetically modifying the gorgonene framework 
following these fundamental principles: 
35 
 
 Produce a library of compounds with physiochemical properties associated 
with bioavailability. 
 Synthetically incorporate desirable functionality using short linear sequences 
adaptable to parallel synthesis to produce a high quality, biologically relevant 
screening library. 
3. Characterize each gorgonene derivative using 1 and 2D NMR, HRMS and IR.   
4. Evaluate the semi-synthetic compound collection in bioassays for PTP1B 
inhibition, antimicrobial and cytotoxic activity.  
1.9.4 Experimental Design 
1.9.4.1 Strategy:  Rapid Chemical Diversification 
With the intention of rapidly creating a diverse library of compounds, several 
synthetic strategies are employed to produce a number of small libraries derived from 
(+)-β-gorgonene. Reactions were selected to produce families of compounds containing 
the desired substructures (present in biological molecules or derivatives thereof) in a 
minimum number of steps, varying only the linker and the position of attachment to 
gorgonene (Figure 1.23). The ideal syntheses may be performed in parallel to increase 
the diversity of the libraries. The semi-synthetic derivatives must have a reduced log P 
in comparison to the starting natural product.  
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Figure 1.23 - Modular Composition of Screening Libraries 
1.9.4.2 Building Block Selection  
The decalin skeleton is a privileged scaffold because it is present in many 
biologically active ligands. In order to design the rest of the library, other privileged 
structures have been identified to use as complementary building blocks to combine 
with gorgonene and produce the derivatives. Molecule fragments that are present in 
numerous biologically active molecules and their congeners were chosen. Substituted 
aromatics and hetero-aromatics are ubiquitous in natural products and drugs. Quinones 
are present in some interesting natural compounds, but are also associated with 
oxidative behavior and toxicity and were therefore avoided. Glycosylated natural 
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products are also common and often some very active terpenes are glycosides.
134, 137
 The 
selected substructures are to be attached to the gorgonene skeleton using several 
different synthetic strategies that will result a number of modular collections that vary in 
the identity of the linking moiety and the position of attachment to gorgonene (Figure 
1.23). 
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Chapter 2 - Regioselective Intramolecular Alder-Ene Reaction of Un-
activated Sesquiterpene (+)-β-Gorgonene 
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2.1 Introduction 
2.1.1 Alder-Ene Reaction 
 The Alder-ene reaction is an electrocyclic group transfer reaction in which an 
olefin with an allylic hydrogen (the ene) reacts with a compound containing a double or 
triple bond (the enophile) to form an adduct having the two reactants connected by a 
new sigma bond (C3-C4, Figure 2.1).
138
 The product contains one double bond located 
at the previous allylic position (C1-C2).  
 
Figure 2.1 - Alder-Ene Reaction Scheme 
The Alder-ene reaction, although similar to the Diels-Alder cyclization reaction 
mechanistically, is more energetically demanding and is performed at high temperatures 
or with the use of catalysts.
139
 Several factors can affect the reactivity of the Alder-ene 
reaction. Methyl protons in the allylic position (C1, Figure 2.1) of the ene are more 
reactive than methylene protons which in turn are much more reactive than methine 
protons.
140
 This is particularly pronounced in the case of thermal rearrangements, 
however, with catalyzed reactions methylene and methyl protons possess similar 
reactivity. The central atom (C2 - Figure 2.1) on the ene substrate bears a significant 
positive charge in the transition state and therefore disubstituted central vinylic carbons 
are more reactive than mono substituted or 1,2-disubstitutued ethylene groups.
139
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2.1.2 Application of Alder-Ene Reaction to the Functionalization of Gorgonene 
 
Figure 2.2 - Retrosynthetic Analysis of Desired Alder-Ene Product 
 Identifying reagents capable of modifying gorgonene in regio- and 
stereoselective manner is challenging due to the similarity of the two terminal alkenes. 
An Alder-ene reaction with 73 was predicted to favor the production of one major 
product or a minimum number of major products for the following reasons: 
1.  The C11-C12 double bond should be more reactive than the alternative 
alkene (C4-C14) for steric reasons.  
2.  No new stereocenters would be formed on the gorgonene scaffold during the 
reaction, reducing the number of possible products, although new 
stereocenters may be formed on the enophile segment and diastereomers may 
be formed.  
Both alkenes in 73 are 1,1-disubstituted and therefore no difference in reactivity 
would be predicted to occur due to this. A series of new compounds was proposed to be 
synthesized by applying Alder-ene conditions to gorgonene (ene) and a variety of 
enophiles.  
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2.2 Results and Discussion 
2.2.1 Thermal Alder-Ene Reaction 
Maleic anhydride
141
 was chosen as a reactive enophile to optimize the conditions 
of the ene reaction with 73. The two reactants were heated to reflux temperature in a 
solution of xylenes (140 
o
C), however, no reaction was observed. The reaction was also 
attempted using other solvents such as dry benzene (80 
o
C) and 1-methyl-2-pyrrolodone 
(200 
o
C) however starting materials were recovered in each case.    
2.2.2 FeCl3 Catalyzed Intramolecular Alder-Ene Rearrangement of (+)-β-Gorgonene  
After several unsuccessful attempts using thermal conditions, a Lewis acid 
catalyzed Alder-ene reaction was attempted. (+)-β-Gorgonene was treated with maleic 
anhydride and FeCl3-(H2O)6 (catalytic) in DCM at room temperature. TLC showed the 
disappearance of 73 and the appearance of a less polar substance after stirring for only 
five minutes. After work-up, the crude product was analyzed using NMR and UPLC-
HRMS and had a molecular formula identical to gorgonene (C15H24) with four degrees 
of unsaturation. The 
13
C NMR spectrum contained 15 carbon signals, only two of which 
appeared in the alkene region at 141.7 and 128.9 ppm, a tetra-substituted alkene. The 
presence of only one double bond within the structure suggested a third ring must 
account for the other degree of unsaturation. Methylene hydrogen atoms, H14a and 
H14b, exhibited HMBC correlations with the C4 and C5 as well as two of the three 
singlet methyl groups, C12 and C13. This indicated that a new δ bond was formed 
between C14 and C11 to create the new five-membered ring. Further analysis of the 2D 
NMR data confirmed the structure of the product was 74 (Figure 2.3). The 
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intramolecular reaction was then attempted without the presence of the maleic anhydride 
and the Alder-ene reaction proceeded similarly to the initial conditions.  
Table 2.1 - NMR Spectroscopic Data (CDCl3) for Compound 74 
  δC, type δH (J in Hz) COSY HMBC  
1 39.3, CH2 1.54, m 
 
2; 15 
  1.28, m 
  2 20.0, CH2 1.66, m 3 
 3 26.2, CH2 1.88, m 2 2 
4 128.9, C  
 
14a,b; 3; 2 
5 141.7, C  
 
14a,b; 3; 1a; 15 
6 53.1, CH 
2.14, dd (2.0, 
12.4) 7b 7b; 8a,b;  9b; 12; 13 
7 30.0, CH2 1.70, m 
    1.01, m 6; 7a 
 8 22.9, CH2 1.63, m 
    1.56, m 8a 
 9 41.6, CH2 1.50, m 9b 3a; 15 
  1.10, m 
  10 33.8, C  
 
2; 3a; 15 
11 38.3, C  
 
12; 13 
12 31.9, CH3 1.07, s 
 
14a,b; 13 
13 25.5, CH3 0.94, s 
 
12; 14a,b 
14 52.1, CH2 2.03, d (15.4) 
 
12; 13 
  2.08, d (15.4) 
  15 24.1, CH3 1.03, s 
 
3a 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC experiments. HMBC correlations from the 
carbon stated to the indicated proton.  
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Figure 2.3 - FeCl3 Catalyzed Intramolecular Alder-Ene Reaction of (+)-β-
Gorgonene 
Alder-ene reactions are typically performed in organohalide or aromatic 
solvents. To test whether the reaction would occur in an aromatic solvent, gorgonene 
was treated with FeCl3-(H2O)6 in benzene; 74 was produced in quantitative yield after 
stirring for an hour at room temperature. 
2.2.3 Proposed Mechanism for Intramolecular Alder-Ene Reaction of Gorgonene 
The annulation reaction resulted in a single novel product containing a tricyclic 
core in quantitative yield. Unactivated alkenes (enophiles) are relatively unreactive in 
Alder-ene reactions.
140
 Literature examples of intermolecular Alder-ene reaction with an 
unsubstituted hydrocarbon ene and enophile are rare.
139, 140, 141 
 This fact combined with 
the involvement of the sterically hindered methine allylic proton (H5) made this a 
surprising result, however, intramolecular Alder-ene reactions are more facile than 
intermolecular reactions due to their entropic advantage.
142
 This is most likely the 
driving force for the exclusive formation of the intramolecular cyclization product, 74 .  
Lewis acid catalyzed Alder-ene reactions can proceed through one of two 
mechanisms: (1) with a zwitterionic intermediate, or (2) in a concerted fashion with a 
polar transition state. The more reactive the ene or the enophile, the more likely the 
reaction is to occur in a stepwise fashion.
139
 Neither the ene (C5-C4-C15, tertiary allylic 
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carbon) or the enophile (C11-C12, no polar functional groups) are exceptionally reactive 
and therefore this reaction likely proceeds through a concerted mechanism with a 
bridged bicyclic intermediate (Figure 2.4). According to the classification of Alder-ene 
reactions, this is a 1,4-ene cyclization. The involvement of the least reactive allylic 
proton present (H5) in the molecule is attributed to the geometry of the cyclic transition 
state.
142
 
 
Figure 2.4 - Proposed Mechanism for Formation of 74 
2.2.4 Synthetic and Biocatalytic Work with 74 
The new skeleton 74 is a promising starting point for the semi-synthesis of 
another family of natural product mimics. All initial attempts to functionalize this 
compound, however (epoxidation, ozonolysis, addition reactions), resulted in extremely 
complex and inseparable mixtures of products that could not be isolated. Biocatalytic 
efforts to functionalize 74 are discussed in Chapter 6. 
2.2.5 BF3 Catalyzed Intramolecular Alder-ene Rearrangement of (+)-β-Gorgonene 
In an effort to expand on the chemistry of the Alder-ene reaction, several other 
Lewis acids were used to try to promote a rearrangement. Catalytic BF3-THF was 
combined with 73 in DCM which resulted in the production of a new compound that 
appeared from NMR to be very similar, but not identical to the previously isolated 
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intramolecular ene-product, 74. The product had the molecular formula C15H24 
according to HRMS and contained one tetrasubstituted alkene similar to compound 74.  
 
Figure 2.5 - BF3 Catalyzed Intramolecular Alder-Ene Reaction 
Table 2.2 - NMR Spectroscopic Data for Compound 75 (CDCl3) 
 
δC, type δH (J in Hz) COSY HMBC NOESY 
1 41.7, CH2 1.07, m  15  
  1.52, m 2a,b   
2 22.3, CH2 1.53, m 3b; 1b 1b  
3 37.0, CH2 0.83, m    
  1.92, m 2   
4 39.5, CH 2.50, m 14a,b  3a; 2; 13; 14a,b; 15  
5 140.6, C   14b; 9b; 15  
6 138.8, C   7; 8b; 12; 13; 14b  
7 21.8, CH2 1.83, m 8a,b 8a,b; 9b   
8 20.1, CH2 1.61, m 7 7  
  1.68, m 9a,b; 7   
9 39.3, CH2 1.22, m 8b; 9b   15 
  1.50, m 8b; 9a    
10 33.2, C   8b; 15   
11 45.1, C   12; 13 14b 
12 28.1, CH3 0.99, s  13  
13 27.2, CH3 0.91, s  12  
14 47.9, CH2 1.14, m 14b 12; 13  
  1.89, dd 
(7.8, 12.5) 
4   
15 23.8, CH3 0.98, s  9a  
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton 
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The protons on the methylene bridging carbon (C14, Figure 2.6) exhibited 
COSY correlations to a proton on C4 that was not present in the structure of 74. 
Similarly to 74, C14 was HMBC coupled to the protons on C12 and C13; once again, a 
new five membered ring was formed to create a tricyclic structure. No other CH groups 
were present in the molecule and HBMC helped confirm the double bond was formed 
between C5 and C6. The newly formed stereocenter (C4) was assigned an S 
configuration using NOESY correlations between H4 and H15 (Figure 2.6). 
 
Figure 2.6 - Stereochemical Assignment of 75 
The reaction was optimized by varying the ratio of solvent:73:BF3 to give a 
maximum yield of 80 %. BF3 is a known promoter of the Alder-ene reaction but is also 
known to lead to proton-catalyzed isomerization, as is seen in this case.
143, 144
 The 
proposed mechanism for this isomerization is shown in Figure 2.7. The proton-
scavenging nature of FeCl3 and AlCl3 minimizes the number of protons in solution that 
can catalyze such an isomerization and therefore reduces or eliminates the production of 
isomer by-products.
145
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Figure 2.7 - Mechanism of BF3 Catalyzed Production of 75  
AlCl3 and FeCl3 are often used interchangeably in Lewis acid catalyzed Alder-
ene reactions, as well as other Lewis acid catalyzed reactions (Friedel crafts, etc). 
Gorgonene was treated with catalytic and stoichiometric AlCl3 in DCM at room 
temperature, however, no intramolecular Alder-ene reaction was observed. Since AlCl3 
was unable to catalyze the intramolecular Alder-ene reaction observed with FeCl3, it 
was used to try to promote the intermolecular Alder-ene reaction between gorgonene 
and maleic anhydride. No reaction was observed between gorgonene and maleic 
anhydride when treated with AlCl3 in DCM or benzene, at room temperature and at 
reflux temperature.   
2.2.6 Stability Studies of Gorgonene 
(+)-β-Gorgonene was reported to undergo acid induced rearrangement to give 
(+)-α-gorgonene (76) and (-)-maaloxide (77) when treated with an ion exchange resin in 
n-hexanes (Figure 2.8).
146
 This prompted a study to try to repeat these results and help 
explore the reactivity of 73. Gorgonene was treated with Amberlyst 15 in a solution of 
hexane:DCM at room temperature as per Hackl’s protocol, however, no reaction was 
observed. Further treatment of gorgonene with Amberlyst 15 in a polar aprotic solvent 
(acetone) and a polar protic solvent (methanol), both with and without heating, resulted 
in recovery of starting materials.  
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Figure 2.8 - Acid-Induced Rearrangement of (+)-β-Gorgonene146  
The stability of gorgonene to Brǿnsted acid and heat treatment was further 
explored (Table 2.3). Combinations of heat and acid treatment of gorgonene in non-
polar (hexane), polar aprotic (acetone) and polar protic (methanol) solvents were 
examined. Toluene sulfonic acid and hydrochloric acid were used as proton sources in 
addition to Amberlyst. Each example was performed using 30 mg of 73 in 5 mL of the 
indicated solvent. No changes to the starting material were observed in any of the 
reactions. 
Table 2.3 - Reaction Conditions Employed to Analyze the Stability of Gorgonene to 
Acid and Heat Treatment 
Acid Mass acid Temperature Solvent 
Amberlyst 15 5 mg RT Hexanes/DCM 
None 0 Reflux Hexanes 
None 0 Reflux Acetone 
None 0 Reflux Methanol 
Amberlyst 15 5 mg Reflux Hexanes 
Amberlyst 15 5 mg RT/Reflux  Acetone 
Amberlyst 15 5 mg RT/Reflux Methanol 
Toluene 
sulfonic acid 
5 mg RT Toluene 
HCl (conc.) 50 µL RT Hexanes 
HCl (conc.) 50 µL RT DCM 
Migration of one of gorgonene’s terminal double bonds could result in an 
endocyclic alkene or a more substituted olefin. This would be desirable for several 
reasons: (1) access to more diverse scaffold and (2) aid regioselectivity for future 
synthetic steps. Rh catalysts are known to promote olefin isomerization
147, 148
 and Alder-
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ene reactions
149
, therefore 73 was treated with RhCl3 in several solvents; no reaction, 
however, was observed (Table 2.4). 
Iron chloride, being a strong Lewis acid, was tested with 73 in solvents not 
known to facilitate the Alder-ene reaction to determine if a rearrangement such as that 
observed by Hackl was possible. In an effort to further explore this chemistry, the 
substrate 73 was treated with catalytic FeCl3 in a variety of solvents including methanol, 
tert-butyl methyl ether, acetone, ethyl acetate, diethyl ether and acetonitrile (Table 2.4) 
Starting material was recovered in each case. (+)-β-Gorgonene was also treated with a 
variety of other metals without any change being observed, see Table 2.4. 
Table 2.4 - Reaction Conditions Employed to Analyze Gorgonenes Stability to 
Lewis Acid and Metal Catalysts.  
Catalyst Temperature Solvent Result 
FeCl3-(H2O)6 RT MeOH SM`s recovered 
FeCl3-(H2O)6 RT MeOH/H2O SM`s recovered 
FeCl3-(H2O)6 Reflux MeOH SM`s recovered 
FeCl3-(H2O)6 RT TBME SM`s recovered 
FeCl3-(H2O)6 RT Acetone SM`s recovered 
FeCl3-(H2O)6 RT Diethyl ether SM`s recovered 
FeCl3-(H2O)6 RT Acetonitrile SM`s recovered 
AlCl3 RT DCM SM`s recovered 
CuCl2-(H2O)2 RT DCM SM`s recovered 
CuCl2-(H2O)2, 
Zn dust 
RT DCM SM`s recovered 
ZnCl2 RT DCM SM`s recovered 
ZnCl2, Zn dust RT DCM SM`s recovered 
FeCl2-(H2O)6 RT DCM SM`s recovered 
RbCl RT DCM SM`s recovered 
Na2MoO4-(H2O)2 RT DCM SM`s recovered 
SrCl2-(H2O)6 RT  DCM SM`s recovered 
MnCO3 RT DCM SM`s recovered 
RhCl3 Reflux EtOH SM’s recovered 
RhCl3-(H2O) Reflux (N2) EtOH/DCM SM`s recovered 
RhCl3-(H2O) RT Acetone/DCM SM`s recovered 
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2.2.7 Biological Assessment of Gorgonene (73) and Synthetic Derivatives (74, 75) 
2.2.7.1 Evaluation of Antimicrobial Activity 
Gorgonene (73) and compound 74 were tested for antibacterial and antifungal 
properties using four test organisms, two representing Gram positive bacteria: 
Staphylococcus aureus and Enterococcus faecalis, one Gram negative bacteria: 
Pseudomonas aeruginosa and a fungus: Candida albicans. The compounds did not 
inhibit the growth of these microorganisms at a concentration of 128 µg/mL. All 
antimicrobial assays were performed in conformance with the standards published in 
“Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow 
Aerobically; Approved Standard – Sixth Edition” by Martin Lantaigne at UPEI.150 
2.2.7.2 Evaluation of 73, 74 and 75 for Protein Tyrosine Phosphatase Inhibition 
Gorgonene (73), 74, and 75 were tested for inhibition and selectivity for the 
PTP1B enzyme. All PTP assays were performed by Michel Tremblay`s group at McGill 
University. The compounds were tested for inhibition of seven protein tyrosine 
phosphatases from class I. Testing the compounds for inhibition of PTP`s other than 
PTP1B gives an indication of the compounds’ ability to selectively inhibit the PTP1B 
enzyme activity. The PTP class I subdivisions that are represented in the assay are: 
receptor-like (LAR D1D2 and SigmaD1D2), intracellular (PTP1B, TC-PTP, SHP-1) and 
dual-specific (MKPX, PRL2 A/S) (Figure 2.9).
66, 151
 
The activity of the enzyme is measured by its ability to de-phosphorylate pNPP 
and produce p-nitrophenol, which generates an intense yellow color at an alkaline pH 
that can be measured at 405 nm using a spectrophotometer.
152
 All pure compounds were 
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tested at a single concentration (25 µg/mL) for inhibition and IC50`s were collected for 
compounds that showed activity at that concentration. The initial single data point 
collected describes the inhibitory effect the compound has on the enzyme at the 
concentration tested (25 µg/mL) with a numerical value between 0 and 1. A value of 1.0 
in the assay indicates there is no inhibition of the enzyme and a value of 0.0 corresponds 
to complete inhibition.
152
 Compounds were selected for further study if: (1) the PTP1B 
enzyme activity was reduced to 0.7 or less and (2) no inhibition of the other  PTP 
enzymes was observed (value of 0.8 or greater). The exception to this was inhibition of 
the enzyme TC-PTP; TC-PTP inhibition did not exclude compounds from further study 
due to its similarity to PTP1B. 
  Compounds that exhibited selective inhibition of PTP1B were also screened for 
oxidative behavior in a papain assay. Papain, or papaya proteinase 1 is a cysteine 
proteinase unrelated to the protein tyrosine phosphatase family of enzymes and can be 
inactivated by oxidative compounds.61 It is used in this context to identify compounds that 
inactivate PTP1B via an oxidative mechanism. Gorgonene did not show any inhibition of 
PTP1B or any of the other PTPs tested. Compound 74 showed modest inhibition and 
selectivity for the PTP1B and TC-PTP enzymes and produced a negative result for papain 
inactivation. Compound 74 was determined to have an IC50 of 62.05 µg/mL against PTP1B 
and 104.7 µg/mL against TC-PCP. Compound 75 showed even stronger inhibition of the 
panel of enzymes, but did not show specificity for the PTP1B enzyme and was not studied 
further. 
 The PTP1B inhibition observed by 74 and 75 is unprecedented. The active site in 
the PTP1B enzyme is known to be positively charged, electrophilic and the vast majority of 
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known PTP1B inhibitors are negatively charged molecules.58 However, an allosteric site has 
been identified on the protein which is much less polar. This is a much more likely place 
where compound 74 and 75 could be binding to exert their effect. Table 2.5 summarizes 
the results of the PTP assay of gorgonene, 74 and 75.  
 
Figure 2.9 - PTP Enzymes and their Subclasses Used in Bioassay  
Table 2.5 - PTP1B Inhibition of Gorgonene, 74 and 75 
Enzyme Screening Relative Rate, % Control 
 73 74 75 
PTP1B  0.95 0.74 0.45 
SigmaD1D2 1.06 0.88 0.73 
SHP-1 0.94 0.88 0.57 
MKPX 1.08 0.94 0.89 
LAR D1D2 1.16 1.16 1.21 
TC-PTP 0.84 0.61 0.42 
PRL2 A/S 0.95 1.01 0.88 
Papain Not tested Negative Not tested 
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2.3 Significance and Future Work 
 Synthetic access to unactivated C-H bonds as well as regio- and stereoselective 
functionalization of substrates that lack directing groups are common goals for modern 
day organic chemists.
153-156
 The intramolecular Alder-ene described in this chapter 
contributes to the scientific knowledge of the reaction scope to include unfunctionalized 
hydrocarbon reagents. The use of a safe and inexpensive catalyst, FeCl3, adds to the 
attractiveness of this method.   
The novel tricyclic scaffolds produced in this reaction may be used in future 
semi-synthesis of an expanded library of natural product mimics.  
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2.4 Experimental Section 
2.4.1 General Experimental 
All flash chromatographic separations were performed using prepackaged 
RediSep® columns (silica gel, diol and C18 stationary phases) and a CombiFlash® RF 
system with UV-dependent fraction collection. Thin layer chromatography was 
performed using aluminum-backed silica plates. Separation of products by HPLC was 
performed on a Thermo HPLC equipped with ELSD (Sedex 60 LT) and UV detectors. 
HPLC runs were performed with Phenomenex Luna C6-Phenyl 110 Å column (250 x 10 
mm, 5 µ), Phenomenex Gemini 5 µ C18, 110 Å column (250 x 10 mm), Phenomenex 
Luna 5 µ silica column (2), 100 Å (250 x 10 mm) or Phenomenex Luna 5 µ PFP (2), 
100 Å column (250 x 10 mm) columns at a flow rate of 2.5 mL/min. Analysis of 
samples by UPLC-HRESIMS with ELSD and UV detection was performed on a 
Thermo Scientific Exactive™ mass spectrometer, using Kinetex C18 (50 x 2.14 mm, 1.7 
µm) column. The mass spectrometer was operated by Tricia Boland. GC-MS 
experiments were run on a Finnigan Polaris Q bench-top ion trap mass spectrometer 
with a Thermo Focus GC using an Agilent J&W DB-23 GC Column, (60 m, 0.25 mm, 
0.15 µm). Infrared spectra were acquired with a Thermo Scientific 6700 FT-IR 
spectrometer.  
All NMR data was collected by Dr. Chris Kirby, Lloyd Kerry or Maike Fischer 
on a Bruker Avance III 600 MHz NMR spectrometer operating at 600 and 150 MHz for 
1
H and 
13
C, respectively. Chemical shifts are reported in PPM relative to solvent signal 
CDCl3 (
1
H: 7.26 ppm, 
13
C: 77.16 ppm) and CD3OD (
1
H: 3.31 ppm, 
13
C: 49.05 ppm). 2D 
NMR experiments aided structural assignment, COSY, HSQC, HMBC, NOESY and 
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ROESY. Coupling constants are reported in Hz, with their multiplicity, singlet (s), 
doublet (d), triplet (t), quartet (q) and multiplet (m). Deuterated NMR solvents were 
purchased from Sigma-Aldrich. X-ray crystallography was performed by Dr. Andreas 
Decken at the University of New Brunswick on a Bruker AXS SMART 1000 CCD 
single crystal diffractometer at cryogenic temperatures. Melting points were collected on 
a Melt-Temp™ apparatus. Ozonolysis was performed using a Welsbach ozone generator 
operated at 70 V. 
All solvents were ordered from Sigma-Aldrich or VWR and used as received 
unless otherwise noted. Anhydrous solvents were stored over molecular sieves.  
Molecular sieves (3Å pore size) were activated by microwave heating. All reagents were 
ordered from Sigma-Aldrich, VWR or Fischer Scientific and used as received and stored 
according to label instructions. Rotary evaporation was performed at room temperature.  
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2.4.2 General Procedure for Anti-Microbial Assays 
Microbial assays were performed under sterile conditions and were performed by 
myself, or Martin Lantaigne at the AVC, UPEI. A single use cryovial of each organism 
was thawed and 20 µL was inoculated into 20 mL of sterile broth (CaMHB : DIFCO 
CA90000-602 for bacteria and DSD:DIFCO 0003-096 for fungi) in a 250 mL non-
baffled, autoclaved Erlenmeyer flask. The cultures were incubated at 37 
o
C for 18 h at 
220 rpm, then transferred by pipette into a sterile 50 mL falcon tube containing sterile 
beads, vortexed (30 seconds) and allowed to sit for 5 minutes. The supernatant (100 uL) 
was removed and combined with broth (5 mL; CaMHB : DIFCO CA90000-602 for 
bacteria and DSD:DIFCO 0003-096 for fungi) in a 15 mL glass tube. The turbidity of 
the dilution was adjusted to be visually equal to the McFarland Standard. This prepared 
dilution (25 µL)(1-2 x 10
8
 CFU/mL) was added to broth (10 mL- CaMHB : DIFCO 
CA90000-602 for bacteria and DSD:DIFCO 0003-096 for fungi)) to give a 
concentration of 2.5 x 10
5 
CFU (dilution A - for assay). A (100 µL) was added to 10 mL 
of broth (CaMHB : DIFCO CA90000-602 for bacteria and DSD:DIFCO 0003-096 for 
fungi) to give 2.5 x 10
3
 CFU/mL (dilution B - for plate count) which was streaked (100 
µL) onto prepared agar plates (bacteria - LB, fungus - SD) and incubated overnight (37 
o
C) to confirm CFU concentrations and purity of the cultures. Prepared assay stock 
solution (A - 80 µL) was added to each well of a sterile 96 well plate containing solution 
of test compound (0.7-25 µg in 20 µL solution 2:8 DMSO: H2O) to give a final volume 
in the well of 200 µL. Each plate contained 3 positive controls (media + 10 % 2:8 
DMSO: H2O) 3 negative controls (Media + 10 % 2:8 DMSO: H2O + cells) and a column 
containing a concentration range of antibiotic control (Penicillin G for S. aureus, 
vancomycin for E. faecalis and MRSA, gentamycin for P. aeruginosa, nystatin for C. 
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albicans). The plates were wrapped with parafilm and placed in an incubator (37 
o
C) for 
20 hours. The OD600 (optical density at 600 nm) of the plates was measured using a 
BIOTEC plate reader before and after incubation to calculate the % inhibition of each 
test compound.  
2.6.5.1 Kerr Lab Bioassay Strain Information 
MRSA: ATCC 33591 
VRE: Ef 379, Wyeth 
S. aureus ATCC 375 
E. faecalis: ATCC 10741 
C. albicans:  ATCC 14035 
P. aeruginosa: ATCC 14210 
P. vulgaris:  ATCC 12454 
M. furfur:  ATCC 38593 
P. acnes:  ATCC 6919 
S. warneri:  ATCC 17917 
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2.4.3 General Procedure for Cytotoxicity Assay 
The antiproliferative assays were performed using the reduction of rezasurin to 
resorufin (Alamar blue) as an indicator of cell health. These assays were performed by 
Martin Lantaigne and Kate McQuillan at the Kerr Research Laboratory, AVC, UPEI.
157
 
Cell line and Growth Conditions 
Human foreskin BJ fibroblast cells (ATCC CRL-2522) were grown and 
maintained in 15 mL of Eagle’s minimal essential medium supplemented with 10 % 
fetal bovine serum and 100 µU penicillin and 0.1 mg/mL streptomycin in T75 cm
2
 cell 
culture flasks at 37 
o
C in a humidified atmosphere of 5 % CO2. Culture medium was 
refreshed every two to three days and cells were not allowed to exceed 80 % confluency.   
Human breast adenocarcinoma cells (ATCC HTB-26) were grown and 
maintained in 15 mL of Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 
Ham (500 mL) supplemented with 10 % fetal bovine serum and 100 µU penicillin and 
0.1 mg/mL streptomycin in T75 cm
2
 cell culture flasks at 37 
o
C in a humidified 
atmosphere of 5 % CO2. Culture medium was refreshed every two to three days and 
cells were not allowed to exceed 80 % confluency.   
59 
 
 
Cytotoxicity Assay 
At 80% confluency, the cells were counted, diluted and plated into 96 well 
treated cell culture plates at a cell density of 10000 cells per well in 90 µL of respective 
growth medium. The assays were performed in the maintenance medium without the 
addition of antibiotics. The plates were incubated at 37 
o
C in a humidified atmosphere of 
5% CO2 to allow cells to adhere to the plates for 24 hrs before treatment. DMSO was 
used as the vehicle at a final concentration of 1 % in the wells. All compounds to be 
tested were resolublized in sterile DMSO and a dilution series was prepared for each cell 
line using the respective cell culture growth medium of which 10 µL were added to the 
respective assay plate well yielding eight final concentrations ranging from 128 µg/mL 
to 1 µg/mL per well (final well volume of 100 µL) and incubated at 37 
o
C in a 
humidified atmosphere of 5 % CO2 for 24 hrs.  All samples were tested in triplicate. 
Each plate contained eight uninoculated positive controls (media + 20% DMSO), eight 
untreated negative controls (Media +20 % DMSO + cells), and one column containing a 
concentration range of zinc pyrithione. Alamar blue was added, 24 hrs after treatment, to 
each well at 10 % of the culture volume (11 µL in 100 µL). Fluorescence was monitored 
using a BioTek Synergy HT plate reader at 530/25 excitation, 590/35 emission and 35 
sensitivity at both time zero and 4 hours after Alamar blue was added. After subtracting 
the time zero emission 590 nm measurement from the final reading the inferred 
percentage of cell viability relative to vehicle control wells were calculated and the IC50 
was determined.    
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2.4.4 General Procedure for PTP1B Assays 
PTP assays were performed at McGill University by the Tremblay lab according 
to the following procedure: 
A PTP enzyme solution (93.13 ng/mL) was prepared in the assay buffer (50 µM 
HEPES; pH 7.0; 0.1 mg/mL BSA; 3 mM DTT), and was transferred (50 µL) to each 
well in a 96 well plate containing a solution of test compound (1 µL, 10 µg/µL in 
DMSO). The plate was incubated at 30 
o
C for 2 mins and then the pNPP substrate 
solution (50 µL, 2x desired final concentration, 18.55 mg/mL for 50 mM) in assay 
buffer was added and the plate was incubated again at 30 
o
C for 2 minutes. The 
absorbance at 405 nM was recorded in 30 sec. intervals for 10 minutes. Enzyme activity 
is calculated from data that fall in the linear range.  
Enzyme activity (µM/min µg) = 50 (vol) x OD405 nm x 1/time(min) x enzyme (µg) x 
1/18000 (molar extinction coefficient) 
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Isolation of Gorgonene 
Antillogorgia elisabethae was collected from the Tropical West Atlantic in early 
2010, sun-dried and weighed (96.0 kg). The coral was then ground in 400 g batches and 
extracted with methanol (1.6 L) for 4 hour with shaking. The mixture was filtered 
through a Whatman # 4 filter and the solid cake was washed with methanol (0.8 L). A 
2
nd
 filtration through glass frit funnel was performed on the extract. The solvent was 
removed in vacuo at 40 
o
C. The crude extract was separated on a C18 flash column into 
three fractions (50:50 MeOH:H2O, 100 % MeOH and 100 %  acetone). The acetone 
fraction was dried and was further separated using flash chromatography (diol stationary 
phase, 100 % hexanes) and the first fraction to elute was further purified using silica gel 
flash chromatography (100 % hexanes). The first compound to elute was a clear, 
colorless oil (0.79 % yield) and identified as (+)-β-gorgonene.128 
1
H NMR (600 MHz, CDCl3) δ 4.78 (s, 1H),  4.71 (s, 2H), 4.58 (s, 1H), 2.32 (dt, J = 4.0, 
11.9 Hz, 1H), 2.27 (m, 1H), 1.99 (m, 1H), 1.86 (d, J = 11.3, 1H), 1.70 (m, 1H),  1.64 (m, 
2H),  1.63 (s, 3H), 1.62 (m, 1H), 1.55 (m, 1H), 1.48 (m, 1H),  1.45 (m, 1H), 1.34 (m, 
1H), 1.31 (m, 1H), 1.23, (dt, J = 3.8, 13.2, 1H), 0.83 (s, 3H). 
13
C NMR (600 MHz, CDCl3) δ 150.5, 148.6, 110.3, 107.8, 52.6, 43.0, 42.7, 41.7, 38.3, 
36.8, 34.9, 24.5, 21.7, 19.3, 17.5.  
FTIR (CH2Cl2): νmax 3068.6, 2924.4  cm
-1
. 
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Synthesis of 74 
 
To a stirring solution of gorgonene (100 mg, 0.49 mmol) in DCM (10 mL) was 
added FeCl3-(H2O)6 (15 mg, 0.056 mmol) at room temperature. After 5 minutes, 
complete conversion to a new product was observed by TLC. The solvent was removed 
in vacuo and the residue was re-suspended in hexanes and filtered through a plug of 
silica. The title compound (clear, colorless oil) was characterized without further 
purification (99.0 mg, 99 % yield). 
1
H NMR (600 MHz, CDCl3) δ 2.14 (dd, J = 2.0, 12.4 Hz, 1H), 2.08 (d, J = 15.4 Hz, 
1H), 2.03 (d, J = 15.4 Hz, 1H), 1.88 - 1.85 (m, 2H), 1.71 – 1.67 (m, 1H), 1.66 – 1.63 (m, 
2H), 1.65 – 1.62 (m, 1H), 1.58 – 1.55 (m, 1H), 1.55 - 1.52 (m, 1H), 1.50 - 1.47 (m, 1H), 
1.30 - 1.28 (m, 1H), 1.29 - 1.26 (m, 1H), 1.11 - 1.09 (m, 1H), 1.07 (s, 3H), 1.03 (s, 3H), 
0.94 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 141.7, 128.9, 53.1, 52.1, 41.6, 39.3, 38.3, 33.8, 31.9, 
30.0, 26.2, 25.5, 24.1, 22.9, 20.0. 
FTIR (CH2Cl2): νmax 3056.7, 2927.2 cm
-1
. 
(+) HRESIMS m/z 227.1753 [M + Na]
+
 (calcd for C15H24Na, 227.1776) 
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Synthesis of 75 
 
To a solution of gorgonene (100 mg, 0.49 mmol) in DCM (10 mL) was added 3 
drops of BF3-ethyl etherate (approx. 45 mg, 0.32 mmol) at room temperature with 
stirring. The solution was stirred for 1 hour during which time it turned a yellow color. 
The solution was washed with distilled water, the solvent was removed in vacuo and the 
product was purified using silica gel flash chromatography (100 % hexanes) to give 75 
as a clear, colorless oil (80 mg, 80 % yield). 
1
H NMR (600 MHz, CDCl3) δ 2.54 – 2.47 (m, 1H), 1.95 – 1.90 (m, 1H), 1.88 (dd, J = 
12.5, 7.8 Hz, 1H), 1.85 – 1.80 (m, 2H), 1.69 – 1.66 (m, 1H), 1.66 – 1.58 (m, 1H), 1.55 - 
1.52 (m, 2H), 1.53-1.51 (m, 1H), 1.51 – 1.45 (m, 1H), 1.26 – 1.18 (m, 1H), 1.17 – 1.11 
(m, 1H), 1.09 – 1.04 (m, 1H), 0.99 (s, 3H), 0.98 (s, 3H), 0.91 (s, 3H), 0.88 – 0.79 (m, 
1H). 
13
C NMR (151 MHz, CDCl3) δ 140.6, 138.8, 47.9, 45.1, 41.7, 39.5, 39.3, 36.9, 33.2, 
28.1, 27.2, 23.8, 22.3, 21.8, 20.1. 
FTIR (CH2Cl2): νmax 3162.18, 2929.2 cm
-1
. 
(+) HRESIMS m/z 205.1939 [M + H]
+
 (calcd for C15H25, 205.1956) 
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General Procedure for Brǿnsted Acid/Heat Experiments 
 Gorgonene (30 mg) was dissolved in 5 mL of the indicated solvent (Table 2.3) 
and the acid (Table 2.3) was added with stirring. The reaction was allowed to stir for 3 
hours at the indicated temperature (Table 2.3). The reactions were either filtered 
(Amberlyst™) or extracted with NaHCO3(aq) (HCl and toluene sulfonic acid), before the 
solvent was removed in vacuo and the crude product was analyzed using 
1
H NMR.  
General Procedure for Lewis Acid and Metal Catalysis Experiments  
 The Lewis acid or metal reagent (5 mg) was weighed and added to a solution of 
73 (50 mg) in the specified solvent (Table 2.4, 10 mL). The reaction was stirred at the 
indicated temperature for one hour and monitored for changes using TLC.  
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Chapter 3 - Semi-synthesis and Biological Evaluation of Isoxazoline-
Containing (+)-β-Gorgonene Derivatives 
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3.1 Introduction 
3.1.1 Isoxazolines and Related Heterocycles  
Isoxazolines (4,5-dihydro-1,2-oxazole) are members of the azole family of 5-
membered heterocycles. Azoles contain one nitrogen atom and at least one other non-
carbon atom within the ring. In a sub-class containing one nitrogen and one oxygen 
(oxazoles) the substitution pattern and number or of double bonds vary giving rise to the 
six congeners shown in Figure 3.1. These oxazole derivatives are commonly associated 
with biological activity including antibiotic and anti-proliferative activity and are 
present in a number of current drugs on the market.
158,159,160
  
 
Figure 3.1 - Oxazole and Related Ring Systems 
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3.2 Results and Discussion 
3.2.1 Preparation of Isoxazoline-Containing Compounds Using a 2+3 Dipolar 
Cycloaddition 
In a strategy to attach biologically relevant molecular fragments to the 
gorgonene scaffold, an isoxazoline-containing compound collection was synthesized 
using a 2+3 dipolar cycloaddition reaction. This approach incorporated the desired 
substructures (substituted aromatics, heteroaromatics and aliphatic groups) in one step 
from gorgonene through an isoxazoline linker.
161-163
 A series of aldehydes (Figure 3.3) 
was used in parallel syntheses to produce a collection of related compounds. 
The first step in the synthesis of the natural product analogues was to convert the 
selection of aldehydes containing the desired substructures (Figure 3.3) to the 
corresponding oximes by treatment with hydroxyl amine hydrochloride in an 
ethanol/water solution. The oximes were then converted to nitrile oxides through a two-
step process with a chloroxamic acid as a non-isolated intermediate (Figure 3.2). The 
nitrile oxide undergoes the cycloaddition reaction with the alkene. 
 
Reaction Conditions: 1: a. NH2OH*HCl, H2O/EtOH, b. NCS, Pyridine, DCM, c. 
gorgonene, Cs2CO3, TBME (0
 o
C – rt, 15 h).  
2: a. NH2OH*HCl, H2O/EtOH, b. NCS, ACN c. gorgonene, TEA, ACN (0
 o
C – rt, 11 h). 
3: a. NH2OH*HCl, H2O/EtOH, b. ACN, NCS c. gorgonene, DBU, ACN.  
Figure 3.2 - Isoxazoline Reaction Scheme 
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Multiple isoxazoline-containing compounds were isolated from each reaction 
mixture including some containing unexpected carbon architectures. Three major 
products were typically isolated from each reaction with an average isolated individual 
yield of 6 %. Although this yield is low, much of the unreacted gorgonene was 
recovered for re-use. Aldehydes 76 - 84 (Figure 3.3) produced the desired isoxazoline 
containing family members under the reaction conditions; however examples 85 - 88 
resulted in no isoxazoline-containing products. These examples had no reaction 
observed and resulted in complete recovery of the starting sesquiterpene. This lack of 
reactivity was attributed to instability of the chloroxamic acid and nitrile oxide or 
solubility issues of the aldehydes.   
 
Figure 3.3 - Aldehyde Starting Materials Containing Desired Substructures 
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3.2.1.1 2+3 Cycloaddition Reaction Optimization  
To improve the yield of the cycloaddition reaction, several strategies were 
explored. Bishta’s conditions were applied, wherein steps b and c (Conditions 2, Figure 
3.2) were performed in one pot in acetonitrile and TEA
164
 replaced Cs2CO3 as the base. 
These conditions resulted in lower yield and increased recovery of starting materials. 
DBU
165
 was also tested as a possible base for the reaction where steps b. and c. were 
performed, again, in one pot in acetonitrile (Conditions 3, Figure 3.2). These conditions 
also resulted in lower yields than the original reaction and were not explored further.   
3.2.2 Isoxazoline Containing Compound Library 
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Figure 3.4 - Synthesized Isoxazoline-Containing Compound Collection 
3.2.2.1 2+3 Cycloaddition Regioselectivity  
 The compound collection synthesized from the 2+3 cycloaddition is summarized 
in Figure 3.4. Similar regio- and stereoselectivity occurred in each example. The 
predicted configuration of the isoxazoline (oxygen attached to the more hindered 
carbon) was formed in each case. This is confirmed by the 
13
C chemical shift of the sp
3
 
methylene carbon (C15, Figure 3.5)  in the isoxazoline ring being more shielded (~50 
ppm) than would be expected (~65 ppm) if attached to an oxygen atom. Also, the 
quaternary carbon (C4) would be expected to be much more shielded (~30 ppm) than 
observed (~90 ppm) if it was not attached to an oxygen atom.  
The nitrile oxide dipole consistently cyclized regioselectively with the C4-C15 
double bond preferentially over the iso-propylene moiety (C11-C12). This was 
determined by key HMBC correlations C3/H15 and C4/H15. This selectivity is 
attributed to elevated energy of the HOMO of the reactive caused by the angular strain 
associated with being connected to the cyclohexane ring. It therefore has a reduced 
energy of activation comparatively with the lower energy propylene HOMO void of 
angular strain.  
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3.2.2.2 2+3 Cycloaddition Stereoselectivity 
 
Figure 3.5 - Stereochemical Assignment of Compound 92 
The key NOESY correlations that lead to the stereochemical assignment of the 
newly formed stereocenter (C4) in the isoxazolines 89, 92, 95, 98, 101, 103, 106 and 
107 are shown in the representative example above (92, Figure 3.5). NOESY 
correlations between H15 and H6, as well as between H15 and H14 support the 
proposed stereochemistry. These correlations were present in each example mentioned 
above representing every library member that contained the isopropylene-substituted 
decalin skeleton.  
The stereochemical outcome of the cyclization can be predicted by analysis of 
the reaction transition state. The two approaches of the dipole resulting in the two 
possible diastereomers are shown in Figure 3.6. The stereoisomer that is not observed 
would have the dipole approach the dipolarophile from the bottom face (A, Figure 3.6) 
which may be prevented due to steric hinderance between the methyl group (C14) and 
the approaching dipole. The observed diastereomer forms from the dipole approaching 
the top face (B) where there is less steric interaction and a favorable pi-pi interaction 
between the propylene group and the dipole (and aromatic groups in relevant examples). 
These two forces are enough to cause > 99 % de in every example.  
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Table 3.1 - NMR Spectroscopic Data for Compound 92 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC NOESY 
1 43.4, CH2 1.39, m       
    1.27, m       
2 18.4, CH2 1.54, m   5   
3 39.7, CH2 1.77, m   15a,b   
    1.52, m       
4 87.7, C     5; 15a,b   
5 50.5, CH 1.83, d (13.5) 6 14; 15a 15a 
6 44.6, CH 
2.35, ddd (4.1, 
10.8, 10.8)   12; 13   
7 33.9, CH2 1.56, m       
            
8 21.4, CH2 1.61, m       
    1.55, m       
9 42.0, CH2 1.37, m   14   
    1.25, m       
10 36.3, C     5; 14   
11 149.7, C     5; 13   
12 109.7, CH2 4.34, s 13 13   
13 18.2, CH3 1.73, s 12 6; 8; 12   
14 18.7, CH3 0.94, s     15 
15 40.9, CH2 3.12, d (16.0)     5, 14 
    2.73, d (16.0)     14 
16 149.7, C     15a,b; 13   
17 124.087, C     18; 20; 21   
18 112.6, CH 6.30, m 20; 19 20   
19 107.7, CH 6.13, m   20  
20 126.8, CH 6.70, m 19; 18 21; 19   
21 37.6, CH3 3.84, s       
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
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A B  
Figure 3.6 - Rational for Stereoselectivity Observed in Isoxazoline Library 
3.2.2.3 Unexpected Products of Isoxazoline Reaction 
Cyclopropane- (examples 90, 93, 96, 99, 104 and 108), and decahydroazulene 
containing analogues (examples 91, 94, 99, 100, 105) were isolated from several 
reaction mixtures. The formation of a chlorinated analogue was observed in two cases 
(102 and m/z ion consistent with the molecular formula C22H34ClNO in the product 
mixture of reaction with 84). The yield of the three major products formed (expected 
product, cyclopropane and decahydroazulene) was relatively consistent throughout each 
reaction and was close to a 1:1:1 ratio. The product distribution and yields are displayed 
in Table 3.2. 
Table 3.2 - Products Yields of 2+3 Cycloaddition Reaction with 73 
Aldehyde 
Starting Material 
  
 
Chlorinated 
Product 
  
89 >99 % pure 
Yield: 7.1 % 
90 >99 % pure 
Yield: 6.4 % 
91 >99 % 
pure 
Yield: 6.1 
%  
Not 
observed 
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92 >99 % pure 
Yield: 5.5 % 
93 >99 % pure 
Yield: 6.3 % 
94  
85-90 % 
pure 
Not 
observed 
 
95 >99 % pure 
Yield: 7.5 % 
96 
85-90 % pure  
Yield: 
8.0 % 
97 >99 % 
pure 
Yield: 7.2 
% 
Not 
observed 
 
98 >99 % pure 
Yield: 6.3 % 
99 >99 % pure 
Yield: 6.1 % 
100 >99 % 
pure 
Yield: 6.1 
% 
Not 
observed 
 
101 >95 % pure 
Yield: 3.7 % 
Not observed Not 
observed 
102  
>99% pure 
Yield:  
6.1 % 
 
103 99 % pure 
Yield: 5.4 % 
104 99 % pure 
Yield: 6.5 % 
105 99 % 
pure 
Yield 
4.8 % 
Not 
observed 
 
106 99 % pure 
Yield: 8.5 % 
Not observed Not 
observed 
Not 
observed 
 
107 99 % pure 
Yield: 7.1 % 
108 99 % pure 
Yield: 3.5 % 
Not 
observed 
Not 
observed 
 
Not observed Observed in 
inseparable 
product mixture 
Observed in 
inseparable 
product 
mixture 
Observed in 
product 
mixture 
 
3.2.2.4 Cyclopropane-Containing Library Members 
The [M+H]
+
 of compound 90 was 342.2217 corresponding to the molecular 
formula C22H29FNO. Two signals with unexpected chemical shifts in the 
1
H NMR 
spectrum of compound 90 (0.29 and 0.57 ppm) suggested the presence of a 
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cyclopropane ring. 2D NMR analysis, particularly COSY correlations H5/H6 and 
H6/H7 as well as HMBC correlations C6/H13, C7/H13, C11/H12, C11/H13, C11/H6 
and C11/H7 aided assignment of the cyclopropane moiety (Table 3.3). Signals 
corresponding to the isoxazoline moiety and phenyl group were observed and HMBC 
correlations supported the connectivity shown in Figure 3.7. The stereochemistry at C4 
was confirmed by NOESY correlations between H15/H14 and H15/H6. NOESY 
correlations between H5 and H12 confirmed the stereochemistry at C6. Similar 
observations for other cyclopropane-containing library members support a consistent 
stereochemical configuration in each example.   
 
 
Figure 3.7 - NOESY Supported Stereochemical Assignment of 90 
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Table 3.3 - Spectroscopic Data for Compound 90 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC NOESY 
1 39.1, CH2 1.10,m 2; 1b 13  
  
1.36, m 1a; 2 
  
2 19.2, CH2 1.64, m 1a, b   
3 38.8, CH2 1.60, m   
3b 
  
1.94, m 3a 
  
4 90.8, C 
 
 15a,b; 5; 6 
 
5 44.8, CH 1.44, d (5.8) 6 
  
6 20.6, CH 0.29, m 5, 7 13 
 
7 19.0, CH 0.58, dd (8.5, 8.5) 6 13 8a,b; 6 
8 15.7, CH2 1.57, m    
  
1.83, m 9a,b 
 
8a; 9b; 7 
9 39.9, CH2 0.91, m  13  
  
1.19, m  5 8a; 9a 
10 33.9, C 
 
 
5; 8; 9a, b; 14; 
15  
11 17.5, C 
 
 12; 13; 6; 7 
 
12 15.6, CH3 1.00, s  6; 13  
13 29.3, CH3 0.98, s  12  
14 18.6, CH3 0.92, s  1; 9; 5 
8b; 2; 5; 
9b 
15 40.2, CH2 2.96, d (16.6) 15b  
14; 2; 3b; 
15a 
  
3.33, d (16.6) 15a 
 
6; 14; 15a 
16 162.6, C 
 
 18; 22; 19 
 
17 154.6, C 
 
 18; 22; 15a,b  
 
18, 22 128.4, CH 7.68, m 19; 21 19, 21 15a 
19, 21 115.9, CH 7.08, m 18; 22 18; 22 
 
20 164.2, C 
 
 18; 22; 19, 21  
 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
3.2.2.5 Isolation of Decahydroazulene-Containing Library Members 
 There is evidence in nearly all of the 2+3 cycloaddition reaction mixtures for a 
decahydroazulene containing product. 1D and 2D NMR supported the general structure 
represented by compound 97, proposed in Figure 3.8. Compound 97 produced an 
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HRESIMS m/z ion of 354.2403 corresponding to a molecular formula of C23H32NO2. 
The first indication that the products contained a decahydroazulene bicyclic scaffold 
was the appearance of the methyl group (H14) as a doublet in the 
1
H NMR spectrum. 
Four aliphatic methine groups were present, two more than expected for the decalin 
containing product. COSY correlations H1/H2, H2/H3, H3/H4, H4/H5, H5/H6, H6/H7, 
H7/H8, H8/H9 and H5/H1 aided the elucidation of the new skeleton. HMBC 
correlations C10/H15, C10/H5 and C9/H15 helped assign the rest of the ring 
connectivity and indicated the isoxazoline was formed at C10. NOESY spectroscopy 
was extensively utilized to assign the stereochemistry of the 97 and the key correlations 
used are shown in Figure 3.8. 
 
Figure 3.8 - Key 2-D NMR Data for Structure Elucidation of Compound 97 
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Table 3.4 - NMR Spectroscopic Data for Compound 97 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC NOESY 
1 50.1, CH 2.74, m 2a, b; 5 15 
2b; 5; 
9a 
2 27.8, CH2 1.46, m 1, 3a   
  
1.99, m 1 
  
3 33.0, CH2 1.37, m 2a 14 14 
  
1.57, m 4 
  
4 36.4, CH 2.05, m 3b; 5; 14 5; 14 5; 14; 4 
5 47.4, CH 
2.32, ddd (12.3, 
6.5, 6.5) 
1; 4; 6 14 
13; 3b; 
12; 6; 1 
6 47.9, CH 1.89, m 5; 7a 12; 13 
13; 15; 
14 
7 36.4, CH2 1.43, m 6   
  
1.66, m 8b 
  
8 25.1, CH2 1.50, m 9a,b   
  
1.81, m 7b 
  
9 41.5, CH2 1.77, m 8a 15  
  
2.02, m 8a 
 
15 
10 92.7, C 
  
5; 15 
 
11 149.7, C 
  
22 
 
12 19.4, CH3 1.69, s 13  
13 
13 109.7, CH2 4.70, m 12 12  
14 15.8, CH3 0.83, d (7.2) 4   
15 39.0, CH2 3.15, s   
18; 22; 
6 
16 155.2, C 
  
15 
 
17 123.1, C 
  
19; 21 
 
18, 22 128.1, 2xCH 7.64, m (8.9)    
19, 21 113.9, 2xCH 6.93, m (8.9) 
   
20 160.6, C 
  
18; 19; 21; 
22; 23  
23 55.5, CH3 3.84, s   
19; 21 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
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 Stack plots of the 
1
H NMR spectrum of the three isomers generated from the 2+3 
dipolar cycloaddition of 73 with 2-methoxybenzene nitrile oxide (98, 99, 100) are 
shown in Figure 3.9 and Figure 3.10 (enlarged).  
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-  
Figure 3.9 - Stack Plot of 
1
H NMR Spectra (600 MHz, CDCl3) of Semi-synthetic Compounds 98 (bottom), 99 (middle) and 100 
(top). (δ in ppm Relative to Solvent Signal) 
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Figure 3.10 - Enlarged Stack Plot of 
1
H NMR Spectra (600 MHz, CDCl3) of Semi-synthetic Compounds 98 (bottom), 99 
(middle) and 100 (top). (δ in ppm Relative to Solvent Signal) 
83 
 
3.2.2.6 - Source of Unexpected Cyclopropane and Decahydroazulene Products 
The isolation of the unexpected cyclopropane and decahydroazulene containing 
products was originaly thought to be the result of a skeletal rearrangement of the 
gorgonene skeleton under the reaction conditions. The family of compounds 
biosynthetically related to gorgonene is reported to be very labile. Hackl, for example, 
reported that bicyclogermacrene A (110), underwent extensive rearrangements upon 
treatment with an acid ion exchange resin to produce known and unknown 
sesquiterpenes with widely varying skeletons (Figure 3.8).
130  
The unexpected sesquiterpenoid frameworks isolated from the reaction mixture 
may, alternatively, have arisen from the reaction of other hydrocarbons present in the 
coral extract. Naturally occurring sesquiterpene hydrocarbons produced within the coral 
from farnesyl pyrophosphate are a possible source of the unexpected products. 
Compound 115, the logical synthetic precursor of the cyclopropane containing 
isoxazolines, belongs to the same biosynthetic class as gorgonene and was co-isolated 
with gorgonene from the sea whip Antillogorgia americana in a previous study 
performed by Hackl in a ratio of 8:55 (115: Gorgonene). The proposed precursor (116) 
to the decahydroazulene-isoxazoline products is not reported in the literature, but a 
similar scaffold was also isolated by Hackl from Antillogorgia americana (117), 
suggesting that the compound 116 could be present in the Antillogorgia elisabethae 
extract. The stereochemistry of the natural product precursers is consistent with the 
stereochemistry observed in the products.   
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Figure 3.11 - Acid-Induced Rearrangement of Bicyclogermacrene (110)
130 
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The purity of the gorgonene starting materials was thoroughly investigated and 
there was evidence of the presence of other minor sesquiterpene hydrocarbons 
components. There were several batches of starting materials that had NMR spectra 
containing signals that could be attributed to the presence of the proposed cyclopropane 
(115) and decahydroazulene (116) starting materials in 6-8 %.  
 
Figure 3.12 - Theoretical Starting Materials for Cyclopropane and 
Decahydroazulene Containing Products 
The hydrocarbon skeletons of 73 and other sesquiterpene hydrocarbons present 
in the coral extract are not trivial to separate. Many of them share a molecular formula 
and contain no heteroatoms causing them to lack significant interaction with normal 
phase chromatography stationary phases. The hydrocarbons were not separable in our 
hands using reverse phase chromatography. Distillation was also attempted as mode of 
purification, however tandem diol-silica column flash chromatography resulted in the 
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highest purity of gorgonene out of all of the methods tested. The loss of purity in 
subsequent purifications of the starting materials is attributed to the repeated use of 
silica columns and variation in the mass of crude mixture loaded onto the column. 
Figure 3.9 shows an NMR spectrum recorded in deuterated chloroform of a 
concentrated sample of gorgonene used for synthetic starting materials. In it, in the 
ranges of 0.65, 0.8, 1.0-1.1 and 4.8-5.0 ppm, signals proposed to correspond to the 
putative starting materials, 115 and 116 are seen in 6-8 % composition.  
 
Figure 3.13 - Batch of Gorgonene Starting Materials 
1
H NMR Spectrum in CDCl3  
Assuming the cyclopropane and decahydroazulene-containing products are the 
result of impurities present in the starting materials, those impurities evidently react 
much more readily than gorgonene under the reaction conditions. Indeed the impurities 
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must react in very high yield (approaching quantitative), whilst gorgonene reacts with a 
typical yield of 6 %. The reason for the vast difference in observed reactivity is not well 
understood, however both of these minor sesquiterpene components have terminal 
alkene motifs that are less sterically hindered than gorgonene. There may be an 
additional electronic interaction between the two alkenes in gorgonene that also leads to 
its lower reactivity compared with the two other two proposed starting materials.  
3.2.2.7 Regio- and Stereochemical Assignment of Chlorine Containing Analogue 
One of the products of the 2+3 cycloaddition reaction with dimethoxy-
benzaldehyde contained a chlorine atom according to HRMS (m/z 418.2141, 
C24H33ClNO3). Alkenyl carbon C13 appeared as a methine in the HSQC spectrum and 
the chemical shift of H13 was deshielded indicating the chlorine was substituted at this 
position. 1D and 2D NMR were used to assign the structure 102; a key HMBC 
correlation was between C3/H15 indicated the isoxazoline had been formed at C4. The 
configuration of the chloro-substituted double bond of 102 was supported by a chemical 
shift in the 
13
C NMR spectrum of 13.7 ppm corresponding to C12 which is closer to the 
predicted value for the E substituted double bond than the Z. An E configuration is also 
supported by NOESY correlations between H5 and H12. These details together suggest 
that the E isomer is a more likely structure than the Z. Trans- alkenes are more stable for 
steric reasons and the trans-geometry is more likely to be adopted in either mechanism 
proposed above.  
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Figure 3.14 - Stereochemical Assignment of Chlorinated Analogue 102 
3.2.2.8 Formation of Chlorinated Analogues 
Several reaction conditions were used to explore the cause of the formation of 
the chlorinated analogues. Due to the instability of the chloro-oxamic acid, no 
purification step was performed on the intermediate before the next step (C, Figure 3.2: 
one-pot conversion to the nitrile oxide and cyclization). Residual NCS may be converted 
to radical chlorine under UV irradiation which could facilitate a radical substitution 
reaction, followed by a tautomerization to result in a chloro-substituted vinyl group 
(Figure 3.15). Allylic chlorination (similar to Wohl-Ziegler reaction with NBS (N-
bromosuccinimide)) is most often performed in chlorinated solvents. To eliminate the 
possibility of residual NCS promoting radical allylic chlorination, gorgonene was 
treated with NCS in TBME (tert-butyl methyl ether) under UV irradiation. No reaction 
was observed, indicating that the residual NCS was not capable of causing the 
chlorination reaction to occur in TBME, even with UV irradiation. β-Gorgonene was 
then treated with NCS and Cs2CO3 in a solution of TBME  to mimic the conditions used 
in the final step of the reaction with UV irradiation, again with no reaction. However, 
when β-gorgonene was treated with NCS in dichloromethane, allylic chlorination was 
observed. The possibility of a small amount of residual dichloromethane being present 
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in the final step of the reaction was considered as a cause for the radical formation, 
however is unlikely responsible for the production of the chlorinated analogues.  
 
Figure 3.15 - Radical Mechanism for the Formation of Chlorinated Analogue 102 
 Since no chlorine radicals could be generated in the test reactions in the selected 
solvents, it is possible that the chlorination occurs via reaction of the alkene with Cl2. 
The chlorine may add to the double bond, followed by an elimination reaction resulting 
in the observed product (Figure 3.16). Due to the fact that the chlorination did not occur 
under the test conditions without the nitrile oxide present, nor are any chlorinated 
derivatives present in the product mixture that do not also contain an isoxazole ring, it is 
likely that the chlorination occurs simultaneously with formation of the isoxazoline. The 
exact mechanism is not known.   
 
Figure 3.16 - Addition/Elimination Mechanism for the Formation of 102 
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3.2.3 Analysis of the Drug-Likeness of Isoxazoline Library 
One of the primary aims of this study was to produce a compound library that 
was more drug-like than the starting material, gorgonene. Each compound was 
evaluated for characteristics associated with drug-likeness (physical properties 
consistent with the majority of known drugs).
175
 These properties are associated with the 
compounds’ solubility in both water and fat to facilitate absorption in the body, and 
molecular weight is important because small molecules diffuse more easily. Molecular 
flexibility is described using the number of rotatable bonds and decreased flexibility has 
been connected to better oral availability.
176
 The results of the analysis are summarized 
in Table 3.5. For the purposes of these calculations, proton acceptors are any atom 
possessing a lone pair of electrons. LogP was calculated using the chemical software 
ChemDraw. According to Lipinski, a LogP value of less than 5 is appropriate for drugs, 
however, a more recent study done by Ghose et al. based on the compounds in the 
comprehensive medical chemistry database, an upper limit of 5.6 is more appropriate.
177
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Table 3.5 - Analysis of Drug-Like Properties of Isoxazoline Compound Collection 
Compound 
Number 
Hydrogen 
Bond 
Acceptors 
Hydrogen 
Bond 
Donors 
MW LogP Rotatable 
Bonds 
89 3 0 341 5.64 2 
90 3 0 341 5.53 1 
91 3 0 341 5.5 2 
92 3 0 303 4.26 2 
93 3 0 326 4.15 1 
94 3 0 326 4.12 2 
95 3 0 353 5.35 3 
96 3 0 353 5.24 2 
97 3 0 353 5.21 3 
98 3 0 353 5.35 3 
99 3 0 353 5.24 2 
100 3 0 353 5.21 3 
101 4 0 383 5.23 4 
102 5 0 417 5.63 4 
103 2 0 317 6.24 5 
104 2 0 317 6.13 4 
105 2 0 317 6.1 5 
106 2 0 323 5.48 2 
107 3 0 341 5.64 2 
108 3 0 341 5.53 2 
 
 Every library member is within Lipinski’s limits for number of hydrogen donors 
(<5), hydrogen acceptors (<10) and molecular weight (<500).
48
 Using the LogP 
parameters suggested by Ghose, 14 of the 20 isoxazolines have an appropriate LogP, 
although they are approaching the upper limit. The number of rotatable bonds is a 
description of the flexibility of the molecule and each compound in this set has less than 
the maximum suggested number of 10.  
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3.2.4 Biological Evaluation of Isoxazoline-Containing Compound Collection 
3.2.4.1 Analysis of PTP1B Activity 
The compounds described in this chapter were tested for inhibition of seven 
protein tyrosine phosphatases from class I to determine their activity and selectivity for 
the target PTP1B enzyme. All PTP assays were performed by Michel Tremblay`s group 
at McGill University. The compounds were tested for PTP inhibition at 50 µM (See 
Chapter 2-experimental details for procedure). Compound 90 showed modest selective 
inhibition of the PTP1B and TcPTP enzymes. The most potent inhibitors of PTP1B in 
the collection, however, were two decahydroazulene containing compounds (Compound 
91, 131.4 µg/mL and 105, 105.1 µg/mL) and two ortho-fluoro phenyl containing 
members (107, 110.8 µg/mL and 108, 95.3 µg/mL). This activity was approximately 
half as potent as the model compounds for this collection, ilimaquinone (68 µg/mL) and 
5-epi-ilimaquinone (54 µg/mL).  
5.2.4.2 Evaluation of Anticancer Activity 
The compounds discussed in this chapter were tested for anticancer activity 
using a human foreskin BJ fibroblast cell line (ATC CRL-2522) and human breast 
adenocarcinoma cells (ATCC HTB-26) according to the procedure described in chapter 
2. The most active compounds, 106 and 107 had IC50 values of 16-32 µg/mL against 
breast cancer cells and 107 showed growth inhibition of the fibroblast cell line as well. 
These two compounds are very similar structurally, the only difference being the 
replacement of a hydrogen atom with a fluorine atom in the ortho-position of the 
aromatic ring. Cytotoxic activity was not observed in similar compounds: 89 (replace 
para-H of aromatic ring of 106 with a fluorine atom) and 108 (propylene group in 107 
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replaced by a cyclopropane ring - Figure 3.17). Perhaps a di-fluorobenzene, or a bromo- 
or chloro-substituted benzene derivative could possess increased cytotoxicity. 
Compounds 103-105 (N-hexyl isoxazoline substituent) each displayed activity between 
32-64 µg/mL in the HTB cell line assay and 103 also inhibited the growth of the BJ cell 
line at 64 µg/mL. Compounds 92-94 were not included in the assay due to their 
instability. An IC50 of compound 98 was not calculated due to degradation of the 
compound.  
Table 3.6 - Cytotoxicity of Isoxazoline Collection (IC50) 
 Cancer Cell Line 
Compound CRL-2522 HTB-26 
89 >64 µg/mL >64 µg/mL 
90 >64 µg/mL >64 µg/mL 
91 >64 µg/mL >64 µg/mL 
95 NT >100 µg/mL 
97 NT >100 µg/mL 
98 NT <100 µg/mL 
99 NT >100 µg/mL 
100 NT >100 µg/mL 
101 >64 µg/mL >64 µg/mL 
102 >64 µg/mL >64 µg/mL 
103 32-64 µg/mL 32-64 µg/mL 
104 >64 µg/mL 32-64 µg/mL 
105 >64 µg/mL 32-64 µg/mL 
106 >64 µg/mL 16-32 µg/mL 
107 32-64 µg/mL 16-32 µg/mL 
108 >64 µg/mL >64 µg/mL 
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Figure 3.17 - Cytotoxic Evaluation and Structure Activity Relationship of 
Isoxazoline Compounds (HTB-26) 
5.2.4.3 Evaluation of Antimicrobial Activity 
 The family of compounds described in this chapter was tested for antimicrobial 
activity against microbes: MRSA, VRE, C. albicans, P. aeruginosa, P. vulgaris and S. 
warneri using the assay protocol described in chapter 2. None of the compounds showed 
antimicrobial activity against any of the organisms up to 128 µg/mL.  
3.3 Conclusion 
A family of isoxazoline natural product mimics was synthesized from the marine 
sesquiterpene β-gorgonene using a 2+3 dipolar cycloaddition reaction. The resulting 
library was analyzed for PTP1B inhibition, anticancer and antimicrobial activities. The 
collection was then evaluated for drug-likeness. Several of the library members showed 
modest but selective inhibition of the PTP1B enzyme and modest cytotoxic activity.  
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3.4 Experimental Section 
3.4.1 General Procedure for Synthesis of Isoxazoline Derivatives 
An aqueous (5mL) solution of hydroxylamine hydrochloride (9.9 mmol) was 
added to a solution of aldehyde (4.6 mmol) in ethanol (5 mL) at room temperature with 
stirring. The reaction was monitored using TLC and was complete after 20 minutes. The 
reaction was diluted with distilled water (100 mL), extracted with chloroform (3 x 50 
mL), dried with magnesium sulfate and the solvent was removed in vacuo. The oxime 
product A was used in the next step without further purification.  
N-Chlorosuccinimide (1.1 mmol) and pyridine (5 µL) were added to a solution 
of oxime A (1.1 mmol) in dichloromethane (12 mL) in the dark and the reaction was 
stirred for one hour at room temperature. The solvent was then removed in vacuo. A 
solution of β-gorgonene (1.0 mmol) in diethyl ether (10 mL) was then added to the 
crude chloroxamic acid and the reaction was cooled to 0 
o
C. Cs2CO3 (1.0 mmol) was 
added as a solid and the reaction mixture was stirred vigorously for 15 hours while 
being allowed to come to room temperature. The reaction was then diluted with 
concentrated NaHCO3 (25 mL) and extracted with ethyl acetate (3x30 mL). The organic 
layer was dried with MgSO4 and the solvent was removed under a stream of air. The 
crude mixture was separated by C18 chromatography (50:50 H2O: MeOH – 100 % 
MeOH) and the fractions containing the products were identified using UPLC/MS and 
were further purified using HPLC.  
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Compound 89 
  
Compound 89 was synthesized according to the general procedure above and the 
product fraction purified using a semi-prep phenyl hexyl HPLC column (isocratic, 88:12 
MeOH:H2O, 2.5 mL/min) and was the first compound to elute (yield 7.1%). 
1
H NMR (600 MHz, CDCl3) δ 7.66 – 7.57 (m, 2H), 7.06 (m, 2H), 4.34 (s, 1H), 4.31 (s, 
1H), 3.13 (d, J = 16.1 Hz, 1H), 2.72 (d, J = 16.1 Hz, 1H), 2.36 (ddd, J = 10.7, 4.6, 4.6 
Hz, 1H), 1.85 (d, J = 11.1 Hz, 1H), 1.81 – 1.76 (m, 1H), 1.73 (s, 3H), 1.64 – 1.60 (m, 
1H), 1.59 – 1.56 (m, 1H), 1.57 - 1.55 (m, 1H), 1.57 - 1.53 (m, 2H), 1.57 - 1.53 (m, 2H), 
1.42 – 1.39 (m, 1H), 1.41 - 1.37 (m, 1H), 1.30 – 1.26 (m, 1H), 1.29 – 1.25 (m, 1H), 0.97 
(s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 163.6, 154.3, 149.6, 128.3, 128.2, 127.3, 115.8, 115.7, 
110.1, 90.1, 50.6, 44.8, 43.4, 41.9, 39.8, 39.3, 36.3, 33.9, 21.5, 18.7, 18.4, 18.1. 
FTIR (CH2Cl2): νmax 3068.5, 2927.6, 2855.0, 1641.8 cm
-1
. 
(+) HRESIMS m/z 342.2217 [M + H]
+
 (calcd for C22H29FNO, 342.2233). 
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Compound 90 
 
Compound 90 was synthesized according to the general procedure above and the 
product fraction was purified using a semi-prep phenyl hexyl HPLC column (isocratic, 
88:12 MeOH:H2O, 2.5 mL/min) and was the second compound to elute (yield 6.4 %). 
1
H NMR (600 MHz, CDCl3) δ 7.70 – 7.65 (m, 2H), 7.11 – 7.05 (m, 2H), 3.33 (d, J = 
16.6 Hz, 1H), 2.96 (d, J = 16.6 Hz, 1H), 1.94 (m, 1H), 1.86 – 1.77 (m, 1H), 1.67 – 1.60 
(m, 2H), 1.62 – 1.57 (m, 1H), 1.60 – 1.57 (m, 1H), 1.43 (d, J = 5.8 Hz, 1H), 1.36 (m, 
1H), 1.18 (m, 1H), 1.09 (m, 1H), 0.99 (s, 3H), 0.98 (s, 3H), 0.91 (s, 3H), 0.94 – 0.87 (m, 
1H), 0.57 (dd, J = 8.5, 8.5 Hz, 1H), 0.29 (m, 1H).
 
13
C NMR (151 MHz, CDCl3) δ 164.4, 162.6, 154.6, 128.4, 128.4, 115.9, 115.7, 90.7, 
44.8, 40.2, 39.9, 39.1, 38.8, 33.9, 29.2, 20.6, 19.2, 19.0, 18.6, 17.5, 15.7, 15.5. 
FTIR (CH2Cl2): νmax 3069.2, 2927.1, 2850.9, 1647.3 cm
-1
.  
(+) HRESIMS m/z 342.2217 [M + H]
+
 (calcd for C22H29FNO, 342.2233). 
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Compound 91 
 
Compound 91 was synthesized according to the general procedure above and the 
product fraction purified using a semi-prep phenyl hexyl HPLC column (isocratic, 88:12 
MeOH:H2O, 2.5 mL/min) and was the fourth compound to elute (yield 6.1 %). 
1
H NMR (600 MHz, CDCl3) δ 7.71 – 7.66 (m, 2H), 7.09 (m, 2H), 4.73 (s, 1H), 4.66, (s, 
1H), 3.15 (s, 2H), 2.79 – 2.68 (m, 1H), 2.32 (ddd, J = 12.3, 6.5, 6.5 Hz, 1H), 2.10 – 1.99 
(m, 1H), 2.05 – 1.97 (m, 1H), 2.02 – 1.96 (m, 1H), 1.90 – 1.85 (m, 1H), 1.85 – 1.78 (m, 
1H), 1.81 – 1.74 (m, 1H), 1.70 (s, 3H), 1.68 – 1.64 (m, 1H), 1.60-1.56 (m, 1H), 1.51 - 
1.46 (m, 1H), 1.47 - 1.43 (m, 1m), 1.45 - 1.40 (m, 1H), 1.39 - 1.36 (m, 1H), 0.83 (d, J = 
7.2 Hz, 3H). 
13
C NMR (151 MHz, CDCl3) δ 162.8, 154.8, 150.1, 128.4, 128.4, 126.8, 116.0, 115.8, 
109.8, 93.3, 49.9, 48.0, 47.4, 41.7, 38.7, 36.5, 33.0, 27.8, 25.0, 19.1, 19.1, 15.7. 
FTIR (CH2Cl2): νmax 3071.8, 2924.2, 2856.2, 1643.6 cm
-1
. 
(+) HRESIMS m/z 342.2218 [M + H]
+
 (calcd for C22H29FNO, 342.2233). 
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Compound 92 
 
Compound 92 was synthesized according to the general procedure and the product 
fraction purified using a semi-prep phenyl hexyl HPLC column (Isocratic, 90:10 
MeOH:H2O, 2.5 mL/min) and was the first compound to elute (yield 5.5 %). 
1
H NMR (600 MHz, CDCl3) δ 6.70 (m, 1H), 6.30 (m, 1H), 6.16 – 6.08 (m, 1H), 4.34 (s, 
2H), 3.83 (s, 3H),  3.12 (d, J = 15.9 Hz, 1H), 2.73 (d, J = 15.8 Hz, 1H), 2.34 (ddd, J = 
4.1, 10.8 Hz, 10.8, 1H), 1.83 (d, J = 11.1 Hz, 1H), 1.77 (m, 1H), 1.73 (s, 3H), 1.64 – 
1.58 (m, 1H), 1.57 (m, 1H), 1.56 – 1.53 (m, 2H), 1.55 – 1.52 (m, 2H), 1.48-1.52 (m, 
1H), 1.39 (m, 1H), 1.37 (d, J = 10.8 Hz, 1H), 1.29 – 1.25 (m, 1H), 1.26 (m, 1H), 0.94 (s, 
3H). 
13
C NMR (151 MHz, CDCl3) δ 149.7, 149.7, 126.8, 124.1, 112.6, 109.7, 107.7, 87.7, 
50.5, 44.6, 43.4, 42.0, 40.9, 39.7, 37.6, 36.3, 33.9, 21.5, 18.7, 18.5, 18.2. 
FTIR (CH2Cl2): νmax 3066.7, 2927.3, 2854.6, 1641.4 cm
-1
 
(+) HRESIMS m/z 327.2420 [M + H]
+
 (calcd for C21H31N2O, 327.2436). 
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Compound 93 
 
Compound 93 was synthesized according to the general procedure above and the 
product fraction purified using a semi-prep phenyl hexyl HPLC column (Isocratic, 90:10 
MeOH:H2O, 2.5 mL/min) and was the second compound to elute (yield 6.3 %). 
1
H NMR (600 MHz, CDCl3) δ 6.75 – 6.71 (m, 1H), 6.36 (dd, J = 3.8, 1.7 Hz, 1H), 6.15 
(dd, J = 3.7, 2.7 Hz, 1H), 3.89 (s, 3H), 3.35 (d, J = 16.3 Hz, 1H), 2.96 (d, J = 16.3 Hz, 
1H), 1.94 – 1.89 (m, 1H), 1.82 (m, 1H), 1.65 – 1.59 (m, 2H), 1.62 – 1.56 (m, 1H), 1.56-
1.52 (m, 1H), 1.40 (d, J = 5.8 Hz, 1H), 1.34 (m, 1H), 1.17 (m, 1H), 1.11-1.05 (m, 1H), 
0.99 (s, 3H), 0.98 (s, 3H), 0.89 (s, 3H), 0.94 – 0.85 (m, 1H), 0.56 (m, 1H), 0.32 (dd, J = 
9.0, 5.8 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 150.0, 127.2, 123.8, 113.0, 107.9, 88.3, 44.7, 41.9, 40.0, 
39.2, 38.7, 37.8, 33.8, 29.2, 20.6, 19.3, 19.0, 18.5, 17.4, 15.8, 15.5. 
FTIR (CH2Cl2): νmax 3068.7, 2927.3, 2854.6, 1641.5 cm
-1
. 
 (+) HRESIMS m/z 327.2421 [M + H]
+
 (calcd for C21H31N2O, 327.2436). 
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Compound 94 
 
Proposed Structure 
Compound 94 was synthesized according to the general procedure and the product 
fraction was partially purified using a semi-prep phenyl hexyl HPLC column (Isocratic, 
90:10 MeOH:H2O, 2.5 mL/min) and was the third compound to elute. The title 
compound was isolated as a white solid (Yield 6.1 % (90 % purity)).  
(+) HRESIMS m/z 327.2423 [M + H]
+
 (calcd for C21H31N2O, 327.2436).
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Compound 95 
 
Compound 95 was synthesized according to the general procedure and purified 
using a semi-prep para-fluoro phenyl HPLC column (Isocratic, 12.5:85.5 H2O:MeOH, 
2.5 mL/min) and was the first compound to elute (yield 7.5 %). 
1
H NMR (600 MHz, CDCl3) δ 7.58 (m, 2H), 6.90 (m, 2H), 4.35 (d, J = 2.3 Hz, 1H) 4.27 
(d, J = 2.3 Hz, 1H), 3.83 (s, 3H), 3.13 (d, J = 16.0 Hz, 1H), 2.72 (d, J = 16.0 Hz, 1H), 
2.36 (ddd, J = 10.8, 10.8, 4.9 Hz, 1H), 1.84 (d, J = 11.1 Hz, 1H), 1.82 – 1.78 (m, 1H), 
1.74 (s, 3H), 1.58 – 1.55 (m, 1H), 1.57 – 1.55 (m, 2H), 1.58 – 1.55 (m, 1H), 1.56 – 1.53 
(m, 2H), 1.41-1.39 (m, 1H), 1.41 – 1.35 (m, 1H), 1.30 – 1.26 (m, 1H), 1.28 – 1.24 (m, 
1H), 0.97 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 160.4, 154.8, 149.6, 127.9 (2C), 123.6, 114.1 (2C), 
110.2, 89.5, 55.5, 50.7, 44.8, 43.4, 42.0, 39.9, 39.4, 36.3, 34.0, 21.5, 18.7, 18.5, 18.1. 
FTIR (CH2Cl2): νmax  3065.4, 2927.6, 2854.6, 1641.4 cm
-1
. 
 (+) HRESIMS m/z 354.2406 [M + H]
+
 (calcd for C23H32NO2, 354.2433). 
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 Compound 96 
 
Compound 96 was synthesized according to the general procedure and purified 
using a semi-prep para-fluoro phenyl HPLC column (Isocratic, 12.5:85.5 H2O:MeOH, 
2.5 mL/min) and was the second compound to elute (85-90 % pure, 8.0 %). 
13
C NMR (151 MHz, CDCl3) δ 160.3, 155.3, 128.0 (2C), 114.1 (2C), 90.1, 55.5, 44.8, 
40.3, 40.0, 39.2, 38.8, 33.9, 29.3, 20.7, 19.3, 19.0, 18.6, 15.8, 15.6.  
FTIR (CH2Cl2): νmax 3068.4, 2929.5, 2859.0, 1642.1 cm
-1
. 
(+) HRESIMS m/z 354.2407 [M + H]
+
 (calcd for C23H32NO2, 354.2433).
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Compound 97 
 
 
 
 
 
Compound 97 was synthesized according to the general procedure above and purified 
using a semi-prep para-fluoro phenyl HPLC column (Isocratic, 12.5:85.5 H2O:MeOH, 
2.5 mL/min) and was the third compound to elute (yield 7.2 %). 
1
H NMR (600 MHz, CDCl3) δ 7.64 (m, 2H), 6.93 (m, 2H), 4.73 (d, J = 2.0 Hz, 1H) 4.66 
(d, J = 2.0 Hz, 1H), 3.84 (s, 3H), 3.15 (s, 2H), 2.79 – 2.69 (m, 1H ), 2.31 (ddd, J = 12.3, 
12.3, 6.5 Hz, 1H), 2.08 – 2.03 (m, 1H), 2.05 – 2.00 (m, 1H), 2.00 – 1.97 (m, 1H), 1.92 – 
1.86 (m, 1H), 1.84 – 1.78 (m, 1H), 1.75 (m 1H), 1.70 (s, 3H), 1.66 (m, 1H), 1.57 (m, 
1H), 1.51 – 1.47 (m, 1H), 1.48 – 1.44 (m, 1H), 1.46 – 1.41 (m, 1H), 1.37 (m, 1H), 0.83 
(d, J = 7.2 Hz, 3H). 
13
C NMR (151 MHz, CDCl3) δ 160.6, 155.2, 149.7, 128.1 (2C), 123.2, 113.9 (2C), 
109.7, 92.7, 55.5, 50.1, 47.9, 47.4, 41.5, 39.0, 36.4, 36.4, 33.0, 27.8, 25.1, 19.4, 15.8. 
FTIR (CH2Cl2): νmax 3067.9, 2924.2, 2857.1, 1643.2 cm
-1
. 
(+) HRESIMS m/z 354.2403 [M + H]
+
 (calcd for C23H32NO2, 354.2433). 
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Compound 98 
 
Compound 98 was synthesized according to the general procedure and purified using a 
semi-prep para-fluoro phenyl HPLC column (Isocratic 84:16 MeOH:H2O, 2.5 mL/min) 
and was the first compound to elute (yield 6.3 %). 
1
H NMR (600 MHz, CDCl3) δ 7.62 (dd, J = 7.6, 1.7 Hz, 1H), 7.36 – 7.30 (m, 1H), 6.94 
(dd, J = 7.5, 7.5 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 4.46 (d, J = 2.6 Hz, 1H), 4.42 (d, J = 
2.6 Hz, 1H), 3.86 (s, 3H), 3.25 (d, J = 16.9 Hz, 1H), 2.89 (d, J = 16.9 Hz, 1H), 2.41-2.39 
(m, 1H), 1.85 - 1.82 (m, 1H), 1.83 - 1.81 (m, 1H), 1.75 (s, 3H), 1.60 – 1.54 (m, 2H), 
1.58 – 1.54 (m, 2H), 1.52 (m, 1H), 1.53 - 1.51 (m, 2H), 1.39 (m, 1H), 1.39 – 1.34 (m, 
1H), 1.27 (m, 1H), 1.25 (m, 1H), 0.94 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 157.3, 155.1, 149.7, 130.4, 129.6, 120.9, 119.6, 111.3, 
109.9, 89.4, 55.7, 50.7, 44.7, 43.2, 41.9, 41.7, 39.5, 36.1, 33.8, 21.4, 18.6, 18.5, 18.3. 
FTIR (CH2Cl2): νmax 3067.2, 2932.2.6, 2866.9, 1640.9 cm
-1
.  
(+) HRESIMS m/z 354.2407 [M + H]
+
 (calcd for C23H32NO2, 354.2433). 
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Compound 99 
 
Compound 99 was synthesized according to the general procedure and purified using a 
semi-prep para-fluoro phenyl HPLC column (Isocratic 84:16 MeOH:H2O, 2.5 mL/min) 
and was the second compound to elute (yield 6.1 %). 
1
H NMR (600 MHz, CDCl3) δ 7.71 (dd, J = 7.7, 1.7 Hz, 1H), 7.38 – 7.32 (m, 1H), 6.97 
(dd, J = 7.5, 7.5 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 3.87 (s, 3H), 3.44 (d, J = 17.4 Hz, 
1H), 3.12 (d, J = 17.4 Hz, 1H), 1.98 (m, 1H), 1.87 – 1.76 (m, 1H), 1.65 – 1.59 (m, 2H), 
1.59 – 1.53 (m, 1H), 1.58-1.56 (m, 1H), 1.39 (d, J = 5.8 Hz, 1H), 1.33 (m, 1H), 1.17 (m, 
1H), 1.11 – 1.03 (m, 1H), 1.00 (s, 3H), 0.99 (s, 3H), 0.90 (s, 3H), 0.93 – 0.86 (m, 1H), 
0.58 (m, 1H), 0.40 (dd, 8.6, 8.6 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) δ 157.4, 155.0, 130.9, 129.5, 120.9, 119.5, 111.5, 89.7, 
55.9, 45.2, 43.1, 40.3, 39.4, 38.9, 33.7, 29.2, 20.7, 19.5, 19.0, 18.6, 17.7, 15.9, 15.6. 
FTIR (CH2Cl2): νmax 3064.2, 2925.3, 2856.4, 1640.4 cm
-1
. 
(+) HRESIMS m/z 354.2406 [M + H]
+
 (calcd for C23H32NO2, 354.2433). 
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Compound 100 
 
Compound 100 was synthesized according to the general procedure and purified using a 
semi-preparatory para-fluoro phenyl HPLC column (Isocratic 84:16 MeOH:H2O, 2.5 
mL/min) and was the fourth compound to elute (yield 6.1 %). 
1
H NMR (600 MHz, CDCl3) δ 7.66 (dd, J = 7.1, 1.5 Hz, 1H), 7.35 (dd, J = 7.1, 7.1 Hz, 
1H), 6.97 (dd, J = 7.1, 7.1 Hz, 1H), 6.93 (d, J = 7.1 Hz, 1H), 4.71 (d, J = 1.8 Hz, 1H), 
4.65 (d, J = 1.8 Hz, 1H), 3.86 (s, 3H), 3.43 (d, J = 17.5 Hz, 1H), 3.20 (d, J = 17.5 Hz, 
1H), 2.71 (m, 1H), 2.30 (ddd, J = 12.3, 12.3, 6.5 Hz, 1H), 2.07 - 2.05 (m, 1H), 2.07 - 
2.04 (m, 1H), 2.01 - 1.99 (m, 1H), 1.92 – 1.86 (m, 1H), 1.81 - 1.79 (m, 1H), 1.77 – 1.71 
(m, 1H), 1.69 (s, 3H), 1.66 - 1.63 (m, 1H), 1.62 - 1.59 (m, 1H), 1.60 - 1.59 (m, 1H), 1.50 
- 48 (m, 1H), 1.43 - 1.42 (m, 1H), 141 - 1.39 (m, 1H), 0.87 (d, J = 7.2 Hz, 3H). 
13
C NMR (151 MHz, CDCl3) δ 158.0, 155.4, 150.4, 130.9, 129.6, 121.1, 119.7, 111.5, 
109.7, 92.4, 55.7, 50.2, 48.1, 47.5, 41.7, 41.6, 36.8, 36.6, 33.2, 27.9, 25.0, 19.3, 15.4. 
FTIR (CH2Cl2): νmax 3069.0, 2924.5, 2856.0, 1643.8 cm
-1
. 
 (+) HRESIMS m/z 354.2403 [M + H]
+
 (calcd for C23H32NO2, 354.2433). 
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Compound 101 
 
Compound 101 was synthesized according to the general procedure and the product 
fraction purified using para-fluoro phenyl semi-preparatory HPLC column (Isocratic 
82:18 MeOH:H2O) and was the fourth compound to elute (yield 3.7 %). 
1
H NMR (600 MHz, CDCl3) δ 7.30 – 7.22 (m, 1H), 6.94 – 6.86 (m, 1H), 6.92 – 6.82 (m, 
1H), 4.48 (d, J = 2.4, 1H), 4.45 (d, J = 2.4, 1H),  3.83 (s, 3H), 3.79 (s, 3H), 3.27 (d, J = 
16.9 Hz, 1H), 2.90 (d, J = 17.0 Hz, 1H), 2.41 (ddd, J = 10.9, 10.9, 5.1 Hz, 1H), 1.87-
1.84 (m, 1H), 1.87-1.83 (m, 1H), 1.76 (s, 3H), 1.66 - 1.62 (m, 1H), 1.62 – 1.54 (m, 2H), 
1.61 - 1.57 (m, 2H), 1.57 – 1.52 (m, 1H), 1.56 – 1.52 (m, 1H), 1.42 - 1.40 (m, 1H), 1.40 
- 1.36 (m, 1H), 1.31 - 1.27 (m, 1H), 1.27 - 1.25 (m, 1H), 0.95 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 155.2, 153.4, 151.4, 149.5, 120.8, 116.8, 113.7, 113.1, 
110.1, 89.3, 56.4, 55.7, 50.6, 44.5, 43.4, 42.0, 41.5, 39.6, 36.0, 34.0, 21.2, 18.5, 18.4, 
17.9. 
FTIR (CH2Cl2): νmax 3066.8, 2927.9, 2854.5, 1630.4 cm
-1
. 
 (+) HRESIMS m/z 384.2533 [M + H]
+
 (calcd for C24H34NO3, 384.2538). 
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Compound 102 
 
Compound 102 was synthesized according to the general procedure and the product 
fraction purified using para-fluoro phenyl semi-preparatory HPLC column (82:18 
MeOH:H2O) and was the first compound to elute (yield 6.2 %). 
1
H NMR (600 MHz, CDCl3) δ 7.29 (d, J = 3.1 Hz, 1H), 6.90 (dd, J = 9.0, 3.1 Hz, 1H), 
6.85 (d, J = 9.0 Hz, 1H), 5.57 (s, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 3.08 (d, J = 17.2 Hz, 
1H), 3.04 (d, J = 17.2 Hz, 1H), 2.36 – 2.29 (m, 1H), 1.87 (d, J = 8.1 Hz, 1H), 1.85 (d, J 
= 11.1 Hz, 1H), 1.76 (d, J = 1.1 Hz, 3H), 1.62 - 1.59 (m, 1H), 1.61 – 1.55 (m, 2H), 1.58 
- 1.54 (m, 1H), 1.56 – 1.53 (m, 2H), 1.56 – 1.49 (m, 1H), 1.42 – 1.37 (m, 1H), 1.39 – 
1.35 (m, 1H), 1.29 – 1.24 (m, 1H), 1.29 - 1.23 (m, 1H), 0.92 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 154.8, 154.0, 151.0, 142.5, 120.1, 117.3, 113.4, 112.8, 
110.5, 88.9, 56.2, 55.6, 50.7, 43.0, 42.8, 41.6, 41.3, 39.6, 35.9, 33.1, 20.9, 18.1, 18.0, 
13.7. 
FTIR (CH2Cl2): νmax 3066.1, 2928.8, 2855.3, 1643.3 cm
-1
. 
 (+) HRESIMS m/z 418.2141 [M + H]
+
 (calcd for C24H33ClNO3, 418.2149). 
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Compound 103 
 
Compound 103 was synthesized according to the general procedure and the product 
fraction purified using a silica semi-prep HPLC column (96:4 hexanes:ethyl acetate) and 
was the second compound to elute (yield 5.4 %). 
1H NMR (600 MHz, MeOD) δ 4.46 (d, J = 2.1 Hz, 1H), 4.35 (d, J = 2.1 Hz, 1H), 2.87 
(d, J = 16.9 Hz, 1H), 2.49 (d, J = 16.9 Hz, 1H), 2.39 (m, 1H), 2.27 (t, J = 7.6 Hz, 2H), 
1.74 (d, J = 11.1 Hz, 1H), 1.71 – 1.68 (m, 1H), 1.66 (s, 3H), 1.67 – 1.64 (m, 1H), 1.63 – 
1.59 (m, 1H), 1.58 – 1.50 (m, 2H), 1.56 - 1.53 (m, 1H), 1.56 - 1.52 (m, 2H), 1.51 – 1.47 
(m, 1H), 1.44 – 1.39 (m, 1H), 1.40 - 1.36 (m, 1H), 1.38 – 1.34 (m, 1H), 1.37 – 1.34 (m, 
2H), 1.36 - 1.30 (m, 2H),  1.30 – 1.24 (m, 1H), 1.27 – 1.22 (m, 1H), 0.93 (s, 3H), 0.91 (t, 
J = 7.1 Hz, 3H). 
13C NMR (151 MHz, MeOD) δ160.5, 150.8, 110.3, 89.5, 51.8, 45.8, 44.4, 43.0, 42.1, 
40.8, 37.1, 35.1, 32.6, 28.9, 27.2, 23.3, 22.4, 19.2, 18.8, 18.3, 14.3.  
FTIR (CH2Cl2): νmax 3066.3, 2925.7, 2855.6, 1640.2 cm
-1
. 
 (+) HRESIMS m/z 318.2795 [M + H]
+
 (calcd for C21H36NO, 318.2797).
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Compound 104 
 
Compound 104 was synthesized according to the general procedure and the product 
fraction purified using a silica semi-prep HPLC column (96:4 hexanes:ethyl acetate) and 
was the third compound to elute (yield 6.5 %). 
1H NMR (600 MHz, MeOD) δ 3.04 (d, J = 17.5 Hz, 1H), 2.73 (d, J = 17.5 Hz, 1H), 2.33 
(t, J = 7.4 Hz, 2H), 1.91 – 1.83 (m, 1H), 1.87 – 1.80 (m, 1H), 1.72 – 1.63 (m, 1H), 1.61 
– 1.58 (m, 1H), 1.61 - 1.56 (m, 2H), 1.60 - 1.55 (m, 1H), 1.49 – 1.40 (m, 1H), 1.39 – 
1.33 (m, 2H), 1.34 - 1.32 (m,1H), 1.33 – 1.28 (m, 2H), 1.31 – 1.28 (m, 1H), 1.21 – 1.14 
(m, 1H), 1.05 (m, 1H), 0.98 (s, 3H), 0.97 (s, 3H), 0.94 – 0.87 (m, 3H), 0.89 (s 3H), 0.90 
– 0.87 (m, 1H), 0.61 (dd, J = 8.6, 8.6 Hz, 1H), 0.31 (m, 1H). 
13
C NMR (151 MHz, MeOD) δ 160.6, 90.1, 46.1, 43.1, 41.0, 40.1, 39.9, 34.8, 32.4, 
29.5, 28.7, 27.0, 23.3, 21.9, 20.1, 20.0, 18.8, 18.1, 16.5, 15.7, 14.3. 
FTIR (CH2Cl2): νmax 3046.9, 2922.9, 2854.5, 1640.4 cm
-1
. 
 (+) HRESIMS m/z 318.2796 [M + H]
+
 (calcd for C21H36NO, 318.2797).  
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Compound 105 
 
Compound 105 was synthesized according to the general procedure and the product 
fraction purified using Silica Semi-Prep HPLC column (96:4 hexanes:ethyl acetate) and 
was the fourth compound to elute (yield 4.8 %). 
1
H NMR (600 MHz, MeOD) δ 4.71 (d, J = 1.3 Hz, 1H), 4.64 (d, J = 1.3 Hz, 1H), 2.93 
(d, J = 17.6 Hz, 1H), 2.83 (d, J = 17.6 Hz, 1H), 2.67 – 2.58 (m, 1H), 2.37 – 2.32 (m, 
1H), 2.37 – 2.28 (m, 1H), 2.04 (dt, J = 13.5, 6.8 Hz, 1H), 1.92 - 1.89 (m, 1H), 1.90 – 
1.87 (m, 1H), 1.90 - 1.85 (m, 1H), 1.80 – 1.74 (m, 1H), 1.68 (s, 3H), 1.67 – 1.62 (m, 
1H), 1.62 – 1.59 (m, 1H),1.61 - 1.56 (m, 1H), 1.61 - 1.56 (m, 1H), 1.53-1.49 (m, 1H), 
1.46 – 1.41 (m, 1H), 1.46 - 1.39 (m, 2H), 1.40 - 36 (m, 1H), 1.38 - 1.34 (m, 2H), 1.37 – 
1.32 (m, 2H), 0.92 (t, J = 7.0 Hz, 3H), 0.84 (d, J = 7.2 Hz, 3H). 
 
13
C NMR (151 MHz, MeOD) δ 160.8, 151.5, 110.2, 92.6, 51.1, 49.0, 48.4, 42.8, 41.6, 
37.7, 37.6, 33.8, 32.5, 28.8, 28.7, 27.1, 25.7, 23.3, 19.2, 16.0, 14.3. 
FTIR (CH2Cl2): νmax 3056.9, 2926.9, 2860.0, 1642.7 cm
-1
. 
 (+) HRESIMS m/z 318.2801 [M + H]
+
 (calcd for C21H36NO, 318.2797).  
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Compound 106 
 
Compound 106 was synthesized according to the general procedure. The product 
fraction was purified using phenyl hexyl semi-prep HPLC column (Isocratic 75:25 
ACN: H2O) and was isolated as a white solid (yield 8.5 %). 
1H NMR (600 MHz, MeOD) δ 7.63 – 7.60 (m, 2H), 7.42 – 7.37 (m, 2H), 7.40 – 7.37 (m, 
1H), 4.35 (d, J = 2.3 Hz, 1H), 4.27 (d, J = 2.3 Hz, 1H), 3.23 (d, J = 16.6 Hz, 1H), 2.94 
(d, J = 16.6 Hz, 1H), 2.45 (ddd, J = 11.0, 11.0 4.3 Hz, 1H), 1.83 (d, J = 11.1 Hz, 1H), 
1.80 – 1.75 (m, 1H), 1.69 (s, 3H), 1.74 – 1.64 (m, 1H), 1.71 – 1.64 (m, 1H), 1.60 – 1.52 
(m, 2H), 1.58 – 1.48 (m, 1H), 1.56 – 1.51 (m, 1H), 1.55 – 1.51 (m, 1H), 1.43 – 1.38 (m, 
1H), 1.41 – 1.37 (m, 1H), 1.32 – 1.25 (m, 1H), 1.30 – 1.23 (m, 1H), 1.01 (s, 3H). 
13C NMR (151 MHz, MeOD) δ 157.8, 150.5, 130.8, 129.7 (2C), 127.4 (2C), 110.7, 91.1, 
69.1, 51.9, 45.7, 44.4, 42.9, 40.9, 40.2, 37.2, 35.0, 22.3, 19.2, 18.9, 18.4. 
FTIR (CH2Cl2): νmax 3066.0, 2925.4, 2853.8, 1641.1 cm
-1
. 
 (+) HRESIMS m/z 324.2323 [M + H]
+
 (calcd for C22H30NO, 324.2327). 
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Compound 107 
 
Compound 107 was synthesized according to the general procedure and the product 
fraction purified using silica gel semi-prep HPLC column (99:1, hexanes:ethyl acetate) 
and was the fourth compound to elute (yield 7.1 %). 
1H NMR (600 MHz, MeOD) δ 7.66 (td, J = 7.6, 1.6 Hz, 1H), 7.47 – 7.39 (m, 1H), 7.21 
(td, J = 7.7, 1.0 Hz, 1H), 7.20 – 7.16 (m, 1H), 4.44 (d, J = 2.1 Hz, 1H), 4.32 (d, J = 2.1 
Hz, 1H), 3.31 (d, J = 17.0 Hz, 1H), 2.99 (d, J = 17.0 Hz, 1H), 2.47 (ddd, J = 10.8, 10.8, 
4.3 Hz, 1H), 1.86 (d, J = 11.1 Hz, 1H), 1.84 – 1.78 (m, 1H), 1.71 (s, 3H), 1.70 – 1.66 
(m, 1H), 1.69 – 1.65 (m, 1H), 1.60-1.55 (m, 1H), 1.58-1.54 (m, 2H), 1.56-1.52 (m, 1H), 
1.55 – 1.50 (m, 1H), 1.44 – 1.39 (m, 1H), 1.43 – 1.38 (m, 1H), 1.34 – 1.28 (m, 1H), 
1.32-1.28 (m, 1H), 1.00 (s, 3H). 
13C NMR (151 MHz, MeOD) δ 161.5, 154.2, 150.6, 132.7, 130.2, 125.6, 118.2, 117.4, 
110.7, 91.2, 51.9, 45.8, 44.4, 42.9, 41.9, 40.8, 37.2, 35.1, 22.4, 19.1, 18.9, 18.3. 
FTIR (CH2Cl2): νmax 3066.1, 2921.9, 2852.6, 1640.0 cm
-1
. 
 (+) HRESIMS m/z 342.2242 [M + H]
+
 (calcd for C22H29FNO, 342.2233). 
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Compound 108 
 
Compound 108 was synthesized according to the general procedure and the product 
fraction purified using a silica semi-prep HPLC column (99:1, hexanes:ethyl acetate) 
and was the third compound to elute (yield 3.5 %). 
1H NMR (600 MHz, MeOD) δ 7.74 (m, 1H), 7.50 – 7.41 (m, 1H), 7.25 – 7.22 (m, 1H), 
7.22 – 7.17 (m, 1H), 3.48 (d, J = 17.3  Hz, 1H), 3.22 (d, J = 17.3 Hz, 1H), 1.99 – 1.95 
(m, 1H) 1.79 – 1.69 (m, 1H), 1.66-1.59 (m, 1H), 1.60-1.52 (m, 1H), 1.42 (d, J = 5.9 Hz, 
1H), 1.39 – 1.35 (m, 1H), 1.31-1.23 (m, 1H), 1.25 – 1.17 (m, 1H), 1.16 – 1.07 (m, 2H), 
1.00 (s, 3H), 0.99 (s, 3H), 0.99-0.94 (m, 1H), 0.96 (s, 3H), , 0.66-0.61 (m, 1H), 0.39 (d, 
J = 6.0 Hz, 1H). 
13C NMR (151 MHz, MeOD) δ 159.3, 152.8, 131.4, 128.9, 124.4, 117.5, 116.3, 90.3, 
44.6, 41.1, 39.8, 38.6, 38.5, 33.6, 29.2, 27.9, 20.4, 18.9, 18.6, 17.3, 15.2, 14.1.   
FTIR (CH2Cl2): νmax 3064.4, 2927.2, 2855.5, 1642.4 cm
-1
. 
 (+) HRESIMS m/z 342.2234 [M + H]
+
 (calcd for C22H29FNO, 342.2233). 
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General Procedure for Reaction of Gorgonene with NCS and Cs2CO3 in TBME 
Gorgonene (100 mg, 0.49 mmol) was combined with NCS (150 mg, 1.2 mmol) and/or 
and Cs2CO3 (400 mg, 1.23 mmol) in a solution of TBME (10 mL) and the reaction was 
stirred at room temperature overnight. Analysis of the resulting solution using TLC and 
NMR indicated gorgonene was recovered in over 99 % yield.  
Procedure for Reaction of Gorgonene with NCS in DCM 
Gorgonene (100 mg, 0.49 mmol) was combined with NCS (200 mg, 1.5 mmol) in a 
solution of DCM (10 mL) and the reaction was stirred at room temperature overnight. 
TLC analysis showed no gorgonene left and the presence of two new products. The 
reaction was extracted with NaHCO3(aq), filtered through a plug of silica and analyzed 
using NMR and LCMS. The products were partially purified using silica 
chromatography and appeared as chlorinated derivatives, but did not ionize in the 
UPLC-HRMS. 
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Chapter 4 - Semi-Synthesis and Biological Analysis of β-Gorgonene 
Analogues Accessed through Ozonolysis Product 
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4.1 Introduction 
 Many of the natural products used as inspiration for the semi-synthetic 
compound collection described in this work have aromatic motifs attached to a decalin 
skeleton by a methylene group (compounds 1-26, Chapter 1). In the total synthesis 
developed for some of these natural products, the aromatic group is attached to the 
decalin skeleton using a nucleophilic addition to a carbonyl group.
178
 Carbonyl 
chemistry is investigated in this chapter as a synthetic means to produce analogues of 
gorgonene with similar connectivity to aromatic moieties. A carbonyl containing 
gorgonene analogue also dramatically increases the number and types of transformations 
that can be performed on the scaffold. Several routes to new gorgonene derivatives were 
investigated such as aldol, nucleophilic addition and condensation reactions.  
 
Figure 4.1 - Retrosynthetic Analysis of Diverse Compound Libraries Accessible 
through Carbonyl Containing Gorgonene Derivative 
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4.2 Results and Discussion 
4.2.1 Ozonolysis of Gorgonene 
The two terminal olefin moieties present in gorgonene are useful synthetic 
handles, however few known reactions will discriminate between the two 1,1-
disubstituted alkenes. The absence of heteroatoms on the natural product scaffold makes 
stereoselectivity difficult to control as well. Traditional methods to direct 
stereoselectivity such as catalysis, chiral pool reagents and the use of chiral auxiliaries 
are largely useless in this case. Although reactions producing multiple products can be 
desirable for the generation of diversity (e.g. glycorandomization
179
), they come at a 
cost of low individual yield. In the first step of a multiple step synthesis, high yield is 
crucial.  
A non-stereocenter generating reaction limits the number of possible products to 
regioisomers only. Ozonolysis was identified as a method to install a heteroatom into the 
scaffold without creating multiple stereoisomers. This maximizes the individual yield of 
the major product by minimizing the number of possible products.  
Ozonolysis is a cyclization reaction between a molecule of ozone and an alkene, 
resulting in the cleavage of the carbon-carbon double bond and its replacement with two 
carbonyl groups. The reaction proceeds through the Criegee mechanism
180
, shown in 
Figure 4.2. In the initial step, a 2+3-dipolar cycloaddition between the alkene and a 
molecule of ozone results in formation of molozonide, which decomposes (retro-
cycloaddition) to form a carbonyl compound and a carbonyl oxide (the Criegee 
intermediate). The two intermediates recombine in another 2+3-dipolar cycloaddition to 
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form a trioxolane which is converted to the final carbonyl containing products via 
reductive or oxidative workup.  
 
Figure 4.2 - Mechanism of Ozonolysis 
Ozone was generated by passing compressed air through an ozonator at 70 V. 
During optimization, ozone was bubbled at a moderate flow rate through a solution of 
(+)-β-gorgonene (120 mg) in the solvent (15 mL), length of time and temperature 
specified in Table 4.1. The end of the reaction was initially monitored by a color change 
(colorless – violet) of an ozone quench solution containing KI at which time all of the 
gorgonene was assumed to be reacted. This monitoring method was determined to be 
ineffective due to the recovery of significant amounts of unreacted starting materials 
despite dramatic color change of the indicator solution after approximately 10 minutes. 
TLC and GC were then used to monitor the reaction progression (disappearance of 
starting materials) which typically took 30-40 min, after which N2 was bubbled through 
the solution to displace dissolved O3. A reducing or oxidizing agent was then added to 
the reaction and the resulting solution was allowed to come to room temperature and 
stirred overnight. The product mixture was purified using silica gel chromatography.  
The traditional ozonolysis solvent, MeOH was unsuitable for the reaction due to 
insolubility of starting materials (A, Table 4.1). Triphenylphosphine was found to be 
inadequate at reducing the trioxolane and was difficult to separate completely from the 
product mixture (B-C).
181
 Reactions B and C resulted in loss of significant product mass 
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during the chromatography step and this was attributed to incomplete reduction of the 
trioxolane, which then bound irreversibly to the silica and was lost on the column.  
The mild triphenylphosphine reductant was replaced with more powerful acetic 
acid/zinc dust reductant in the next set of reactions (D-G).
182
 The ozonolysis was 
performed in DCM or hexanes at -30 
o
C and 0 
o
C (30-60 min) after which a zinc/acetic 
acid slurry was added and the solution was stirred for 24 h. The product mixture was 
fractionated using silica gel chromatography and analyzed using GCMS and NMR. It 
was noted that some of the product fractions showed no signals in the alkene or carbonyl 
regions of the 
13
C NMR spectrum indicating some unexpected compounds were being 
formed. A significant amount of the crude mass, again, was lost upon silica gel 
purification. Reaction and workup conditions were continually modified to optimize the 
production of one major ketone-containing product. The work-up was performed at 0 
o
C 
to try to reduce the number of products formed for kinetic reasons. This strategy did not 
affect the number of products or yield meaningfully (H). Several other workup 
conditions were used, both reductive (DMS (I, J))
181
 and oxidative (H2SO4 (N) and 
H2O2(O))
183
 but each produced a complex inseparable product mixture.   
Several unconventional workup methods were attempted to optimize the reaction 
for the production of one product and simplify purification. Performing the ozonolysis 
in an acetone/H2O solution has been successful in some literature examples to trap 
formed carbonyl oxides by water which then decompose under the reaction conditions 
resulting in the direct formation of the carbonyl from the alkene.
184
 This approach (K-
M) was attempted however unfortunately resulted in a complicated mixture.  
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Table 4.1 - Optimization of Ozonolysis Reaction Conditions 
 Solvent Temp Time Work-up 
Reagent 
Result 
A Methanol -30 
o
C 9 mins Triphenyl 
phosphine 
>90 % recovery of 73. 
B Hexanes -30 
o
C 19 mins Triphenyl 
phosphine 
Complex mixture / difficult to 
separate from reducing agent. 
C DCM -30 
o
C 30 mins Triphenyl 
phosphine 
Complex mixture / difficult to 
separate from reducing agent. 
D DCM -30 
o
C 30 mins Zn/Acetic 
acid 
Small amount of unreacted 73. 
Complex product mixture. 
E DCM -30 
o
C 60 mins Zn/Acetic 
acid 
Complex product mixture.  
F Hexanes -30 
o
C 60 mins Zn/Acetic 
acid 
~70% recovery of 73. 
G Hexanes 0 
o
C 60 mins Zn/Acetic 
acid 
Complex mixture with ~10 % 
unreacted 73. 
H Hexanes 0 
o
C 60 mins Zn/Acetic 
acid (0 
o
C) 
Fewer Products than G workup, still 
complex mixture. 
I DCM/MeOH -78 
o
C 15 mins DMS Complex product mixture. Some 
unreacted 73. 
J DCM/MeOH -78 
o
C 30 mins DMS Complex product mixture.  
K Acetone:H2O 0 
o
C 8 mins None Major product 73. 
L Acetone:H2O 0 
o
C 20 mins None 73 still present in > 50 %. Complex 
product mixture. 
M Acetone:H2O 0 
o
C 30 mins None Complex product mixture. 
N DCM -78 
o
C 15 mins H2SO4 Complex product mixture. 
O DCM -78 
o
C 30 mins H2O2 Complex product mixture. 
P DCM -78 
o
C 30 mins Triethyl 
amine 
One major product (118). 
Q DCM -78 
o
C 15 mins Triethyl 
amine 
30 % yield of 118. 
50 % recovery of 73. 
Finally, the use of basic work up conditions
185
 using TEA was determined to be 
the most effective method at converting the olefins to the corresponding ketones and the 
reaction favored one major product, 118, (P) with yields between 55-75 %. Compound 
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118 had an m/z ion consistent with the molecular formula of the diketone 118 and the 
product had two resonances in the 
13
C NMR spectrum typical of a ketone (211.7 and 
212.5 ppm, C4 and C11). Further analysis of the 1D and 2D NMR data confirmed the 
structure was 118 (Figure 4.3). 
4.2.1.1 Unexpected Side Products of Ozonolysis 
An enol tautomer of the diketone (119, Figure 4.3) was also isolated from the 
product mixture (P) in 11 % yield. The compound had the same molecular formula as 
118 according to HRMS and contained two carbons that resonated in the carbonyl 
region of the 
13
C spectrum (211.5 and 213.5 ppm). A set of peaks in the olefinic region 
of the 
1
H NMR spectrum for the mono-enol (C12, 119, Table 4.2) distinguished it from 
the dione 118 which instead had a singlet methyl group in the aliphatic region (C12, 
118, Compounds 118 and 119 were separable using flash chromatography and 
compound 119 was stable in chloroform solution for 24 hours at room temperature. This 
unusual stability of 119 is attributed to hydrogen bonding of the enolic proton (C11-OH) 
bridging the two oxygen atoms.   
 
Figure 4.3 - Products of the Ozonolysis of (+)-β-Gorgonene 
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Table 4.2 - NMR Spectroscopic Data for Compounds 118 and 119 (CDCl3) 
118 δC, type δH (J in Hz) 119 δC, type δH (J in Hz) 
1 39.9, CH2 1.46, m 1 40.5, CH2 1.69, m 
  1.32, m   1.60, m 
2 22.6, CH2 1.92, m 2 22.4, CH2 1.97, m 
  1.85, m   1.9, m 
3 41.1, CH2 2.33, m 3 41.0 2.31, m 
  2.24, m 4 211.6  
4 211.7, C  5 59.6 2.77, d (10.9) 
5 59.4, CH 2.63, d (11.3) 
6 40.8 
2.67, ddd (3.8, 
12.4, 12.4) 
6 45.0, CH 2.69, ddd (12.0, 
4.5, 3.0) 
7 29.9 1.84, m 
7 29.2, CH2 1.90, m   1.23, m 
  1.05, m 8 20.7 1.64, m 
8 20.8, CH2 1.58, m   1.56, m 
  1.51, m 9 39.8 1.39, m 
9 40.5, CH2 1.52, m   1.54, m 
  1.63, m 10 39.5  
10 39.4, C  11 213.5  
11 212.5, C  12 67.7 4.55, d (18.5) 
12 29.7, CH3 2.22, s   4.35, d (18.5) 
13 17.5, CH3 0.75, s 13 17.5 0.8, s 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC experiments.  
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Figure 4.4 - Stack Plot of 
1
H NMR Spectra (600 MHz, CDCl3) of Semi-synthetic Compounds 118 (Top) and 119 (Bottom) (δ in 
ppm Relative to Solvent Signal)
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Compound 120 was also isolated from the ozonolysis mixture as a colorless 
solid. It was determined to have a molecular formula of C14H23O2
 
(M+H) by HRMS 
(m/z 223.1686) indicating it had only lost one carbon and possessed four degrees of 
unsaturation.  
 
Figure 4.5 - Key NMR Correlations for Structure Elucidation of 120 
No NMR resonances in the carbonyl or alkenyl region of the 
13
C spectrum were 
present, however, two aliphatic singlet methyl groups were present (C12 and C14), as 
well as a ketal (96.6 ppm, C4) and two other C-O moieties (69.6 ppm – C13 and 69.7 
ppm – C11). HMBC correlations were used to determine the position of the oxygen 
atom in the new six membered ring (120, Figure 4.5) and the stereochemistry indicated 
at C4 and C11 (Figure 4.5) was supported by NOESY correlations between protons H6 
and H13. 
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Table 4.3 - NMR Spectroscopic Data for the Characterization of 120 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC NOESY 
1 41.5, CH2 1.13, m 2b 14  
  1.42, m  5  
2 19.3, CH2 1.57, m    
  1.84, m 1a,b; 3b; 2a  14 
3 40.1, CH2 1.62, m    
  1.65, m 2b 2; 1  
4 96.6, C   5; 3b; 13  
5 48.5, CH 1.31, m  14, 1; 9  
6 37.0, CH 1.66, m 7a 13; 12 13 
7 24.6, CH2 1.78, m 6; 8  12 
  1.31, m 8   
8 20.3, CH2 1.53, m 9b; 7a, b 7; 6; 9  
9 43.2, CH2 1.34, m  14  
  1.08, m 8   
10 34.0, C   5; 14  
11 69.7, C   13  
12 22.1, CH3 1.06, s  6 5 
13 69.6, CH2 4.00, d (11.2)    3a; 6 
  3.26, d (11.2)   6  
14 18.9, CH3 1.00, s  1; 9; 5 6 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
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Figure 4.6 - Proposed Mechanism for Formation of 120 
 The proposed mechanism for the formation of 120 is shown in Figure 4.6. The 
ozone and the alkene (C4-C14) undergo a 1,3-dipolar cycloaddition as expected, 
followed by the retrocyclization and the second 1,3-dipolar cycloaddition to give a 
trioxolane intermediate. The trioxolane is proposed to undergo a reaction with the 
alkene (C11-C12) as shown in Figure 4.6 and there is a net loss of CO.  
Once suitable conditions were developed to produce one major compound in 
greater than 70 % yield (118, P), the reaction time was halved to attempt to produce a 
mono-ketone derivative of gorgonene keeping all other reaction conditions constant. 
This resulted in lower yields of the dione 118 and increased recovery of starting 
materials. Mono-ketone containing derivatives were only detected in very small 
amounts (Q). This is presumed to be due to the ozone interacting with both olefinic 
groups simultaneously. This theory is supported by the production of the minor product 
120. The diketone 118 was therefore used as the starting materials for the next step of 
the semi-syntheses.  
4.2.2 Synthesis of Gorgonene Analogues using the Aldol Reaction  
The aldol reaction
186
 is a staple in organic chemistry, combining two carbonyl-
containing compounds to form a β-hydroxy ketone (aldol addition) or an enone (aldol 
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condensation). One of the carbonyl containing reagents must be enolizeable; that is, it 
must have an α-hydrogen atom which allows it to be converted to an enol (using an 
acid) or enolate ion (using a base). The electrons on the nucleophilic α-carbon of the 
enol(ate) are donated to the electrophilic carbonyl carbon (aldehyde), forming a new 
carbon-carbon bond. The resulting adduct is a β-hydroxy ketone that can be converted to 
an enone via condensation. The synthesis of a series of natural product derivatives with 
aromatic motifs attached to the decalin scaffold through a β-hydroxy ketone or an enone 
linker was achieved using the aldol reaction to combine several aldehydes with dione 
118. 
 
Figure 4.7 - Aldol Reaction Scheme 
A solution of dione 118 and N-methyl-pyrrole carboxaldehyde in 1:1 molar ratio 
in anhydrous THF was treated with a base (NaOH or DBU). No reaction took place at 
room temperature and so the reaction mixture was heated to reflux temperature which 
caused the reaction to go to completion in 48 hours. DBU and NaOH both effectively 
catalyzed the reaction. Two major products (121 and 122, Figure 4.8) were isolated from 
the reaction mixture using DBU. Compound 121 had an m/z ion consistent with 
molecular formula C19H25NO2. The disappearance of the methyl group C12 and HMBC 
correlations between C11/H13 confirmed the new carbon-carbon double bond was 
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formed at position C12. The olefin was determined to possess trans-geometry by the 
large vicinal 
3
J coupling constant (15.5 Hz) between H12 and H13. 
Another product was isolated from the reaction which had a molecular formula 
of C19H23NO according to HRMS corresponding to a structure with nine degrees of 
unsaturation. The carbonyl carbon (C11) was slightly shielded in the 
13
C NMR spectrum 
suggesting it is conjugated. Only one vinylic proton was present according to 
1
H NMR 
other than the pyrrolic hydrogens. 2D NMR was used to assign the structure 122. One 
other possible structure would have C4 attached to C13, however a HMBC correlation 
between C13 and H16 made the proposed structure the most likely. A cyclization had 
occurred resulting in the formation of a third, five membered ring (122, Figure 4.8). 
 
Figure 4.8 - Pyrrole-Containing Aldol Derivatives 
In an attempt to optimize the yield of the aldol reaction, a more polar aprotic 
solvent was used. Highly polar solvents can affect the rate of the reaction by lowering 
the energy of the charged enolate intermediate.
187
 The aldol reaction between N-methyl-
2-pyrrolecarboxaldehyde and 118 was carried out in DMSO; after 24 hours, TLC 
indicated complete consumption of  118. The mixture of products that was formed was 
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complex and complicated purification, this, combined with low individual yields 
discouraged the use of DMSO as a reaction solvent.  
Table 4.4 - NMR Spectroscopic Data for Compound 122 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC 
1 39.4, CH2 1.74, m 1b 19 
  
1.43, m 2b 
 2 19.2, CH2 1.74, m 
  
  
1.63, m 
  3 21.3, CH2 2.29, m 2a, b 
 
  
2.17, m 2a,b 
 4 136.9, C 
   5 174.9, C 
  
19 
6 40.7, CH 3.41, m 7a,b 13 
7 31.4, CH2 2.67, m 7b; 8a 
 
  
0.83, m 8a 
 8 21.7, CH2 1.78, m 7b; 9b 
 
  
1.68, m 
  9 42.6, CH2 1.80, m 
 
19 
  
1.40, m 8a 
 10 35.4, C 
  
19; 9b; 1a 
11 198.4, C 
  
13 
12 134.3, C 
  
13 
13 117.6, CH 7.26, s 
  14 128.4, C 
  
16; 18 
15 109.5, CH 6.24, m 
 
16 
16 114.1, CH 6.55, m 
 
13 
17 126.1, CH 6.76, m 
 
16; 18 
18 34.5, CH3 3.75, s 
  19 24.2, CH3 1.25, s 
  Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
The aldol reaction was carried out with three additional aldehydes; two 
substituted aromatic aldehydes (anisaldehyde and 2,5-dimethoxybenzaldehyde) and 
another heteroaromatic aldehyde (furan-2-carbaldehyde) using the conditions 
established with the 2-formyl-1-methylpyrrole example. The product mixtures varied 
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slightly, however the enone-containing product resulting from reaction at the less 
sterically hindered C12 acetyl position was the major product in each example. Each 
newly formed olefin possessed the expected E geometry, indicated by 
3
J coupling 
constants greater than 15 Hz between the vinylic hydrogens.  
 
Figure 4.9 - Furan-Containing Enone Derivative 
 Treatment of 118 and furan-2-carbaldehyde with NaOH in THF and heating 
resulted in modest yield of the corresponding enone 123 (Figure 4.9). The structure was 
supported by the correct HRMS M+H
+
 ion and contained two ketones and a trans, 1,2-
disubstituted olefin as expected. The alkene hydrogen atoms were HMBC correlated to 
the ketone carbon C11, confirming the proposed connectivity.  
The reaction of 118 with 2,5-dimethoxybenzaldehyde showed unique reactivity 
at the  α-position of endocyclic ketone (C3, Figure 4.10) as indicated from COSY 
correlations between H3 and H14 (125) and produced the only observed β-hydroxy 
ketone in the collection.  
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Figure 4.10 - Dimethoxybenzene - Containing Aldol Derivatives 
Partial stereochemical assignment of compound 125 was performed using 
3
J 
coupling constants between H3 and the adjacent methylene group H2. Coupling 
constants were calculated as 12.3 Hz (trans: axial-axial) and 6.7 Hz (cis: axial-
equatorial) indicating the H3 must be in the axial position. The cyclohexane rings in 
decalin favor one chair conformation where the fused rings can occupy equatorial 
positions (C5, C10, Figure 4.11). Therefore the C3 carbon must have R geometry in 
order for the H3 to occupy an axial position. This is likely due to the steric bulk of the 
dimethoxybenzene group occupying to the more stable equatorial position. The 
stereochemistry on the secondary alcohol (C14) could not be determined using NMR 
spectroscopy due to free rotation about the C3-C14 bond, but could potentially be 
determined from a Mosher’s ester of the compound. Due to the inactivity of this 
compound in biological assays, the determination of the stereochemistry was not a 
priority.  
The enone derivative (124) was also formed, as detected using UPLC/HRMS 
and NMR but was inseparable from a minor contaminant in the reaction mixture. 
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Figure 4.11 - Stable Chair Conformation of 125 
Demethylation and oxidation of the dimethoxy-benzene containing products 124 
and 125 was attempted by treatment with cerium ammonium nitrate
188
, with the 
intention of producing a quinone containing library member. The reaction resulted in the 
formation of many products making isolation of the desired compound impossible.  
 
Figure 4.12 - Methoxybenzene-Containing Aldol Derivative 
 When anisaldehyde was combined with 118 under the aldol conditions, the 
major product was the trans-enone (126, Figure 4.12) and the reaction occurred at the 
expected C12 position. HRMS and 1 and 2D NMR confirmed the proposed structure.  
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4.2.2.1 Enone vs β-Hydroxy Ketone Formation 
 β-Hydroxy ketones are readily converted to the corresponding enones via 
dehydration. Due to the elevated temperatures required to produce the β-hydroxy 
ketones in the described syntheses, the elimination presumably occurs immediately upon 
formation of the β-hydroxy ketone at C12-13 which explains why β-hydroxy ketone 
derivatives are not observed at that position. The β-hydroxy ketone 125 did not undergo 
a condensation because the formed alkene would have increased energy due to steric 
hinderance (trisubstituted double bond) and strained bond angles (attachment to the ring 
system).   
4.2.3 Synthesis of Amine Containing Gorgonene Derivatives using Condensation and 
Reductive Amination Reactions 
 Amines are ubiquitous in nature and in drugs. Nitrogen atoms are present in 
many drugs and drug candidates. The lone pair of electrons on nitrogen allows it to be 
protonated, so it may adopt a cationic charge and become more soluble in water. The 
synthesis of gorgonene derivatives that connect the sesquiterpene fragment with drug-
like motifs with an amine linker and synthesis of amine containing derivatives of 
gorgonene was purpose of the next set of reactions.  
4.2.3.1 Synthesis of Oxime Containing Derivatives of Gorgonene 
Oximes are part of the imine family of compounds and are synthesized by 
condensation between an aldehyde or a ketone and hydroxyl amine. Several oxime 
containing therapeutics exist including the veterinary drug Milbemycin oxime
189
 
136 
 
(Interceptor™, Novartis), a broad spectrum anti-parasitic and Cloximate190, an oxime 
ether containing anti-inflammatory drug (Figure 4.13). 
 
Figure 4.13 - Oxime Containing Drugs Milbemycin Oxime and Cloximate 
Synthesis of oxime containing sesquiterpene derivatives was achieved by 
treatment of 118 with NH2OH-HCl and K2CO3 in a solution of THF/MeOH/H2O.
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Two products were isolated from the product mixture that had the expected m/z ratio for 
a mono-oxime (C13H22NO2) Compound 129 is an expected oxime containing product of 
reaction with the condensation occurring at C11 (162.2 ppm) (Figure 4.14) as 
determined from its HMBC correlations to H12. Compound 130 is the result of a similar 
condensation reaction occurring at C11 (159.3 ppm) but is followed by the addition of 
the oxime oxygen atom to the adjacent carbonyl carbon (C4 – 95.2 ppm) resulting in a 
new 6-membered oxime ether containing ring (130). 
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Figure 4.14 - Oxime Synthesis 
4.2.3.2 Synthesis of Amine Derivatives of Gorgonene 
 Amine containing analogues were designed as an addition to the natural product 
derived library. Reductive amination is a two-step, one-pot reaction between a carbonyl 
containing compound and a primary or secondary amine. A mild reducing agent, 
NaBH(OAc)3, which typically reduces imine bonds preferentially over carbonyl groups 
is used so that the reduction occurs upon formation of the imine. Reductive amination 
was used as a strategy to combine 118 with aromatic moieties through an amine linker. 
Compound 118 was combined with benzylamine and NaBH(OAc)3 in a solution 
of dry THF and heated to reflux temperature for 72 hours (A, Table 4.5).
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 This resulted 
in almost complete recovery of starting materials. Acid catalysts are used in 
condensation and reductive amination reactions to protonate the carbonyl group, 
increase the electrophilicity of the carbonyl carbon and facilitate the addition of the 
nitrogen and progression of the condensation. A stoichiometric amount of acetic acid 
was used to promote the reductive amination, keeping all other conditions from A 
constant, at room temperature (B, Table 4.5) and reflux temperature (C, Table 4.5), 
however, the reaction resulted in complete recovery of 118. The use of the base NaOH 
was ineffective at catalyzing the reaction as well (D, Table 4.5). The reaction solvent 
DCE was used, with and without acid catalysis, under an atmosphere of N2 and with 
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heating and no amine containing compounds were detected (E-I, Table 4.5). Molecular 
sieves were introduced combined with heating, polar solvents (THF and ACN) and acid 
catalysis (J, K, Table 4.5). In both of these examples, complex mixtures were formed 
including alcohol containing products, indicating that NaBH(OAc)3 is capable of 
reducing the ketone moiety under these conditions.  
Table 4.5 - Toward Reductive Amination Optimization 
 Reducing 
agent 
Solvent Temp Time Acid Result 
A Na(OAc)3BH THF Reflux 72 H None 118 recovered 
B Na(OAc)3BH THF RT 24 H AcOH (1 eq) 118 recovered  
C Na(OAc)3BH THF Reflux 24 H AcOH (1 eq) 118 recovered  
D Na(OAc)3BH THF 0
 o
C -
RT 
24 H NaOH 118 recovered  
E Na(OAc)3BH DCE RT 24 H AcOH 118 recovered  
F Na(OAc)3BH DCE RT 24 H  
/N2 
None 118 recovered  
G Na(OAc)3BH DCE RT 24 H / 
N2 
AcOH (1 eq) 118 recovered  
H Na(OAc)3BH DCE Reflux 24 H / 
N2 
AcOH (1 eq) 118 recovered  
I Na(OAc)3BH DCE Reflux 24 H None 118 recovered  
J Na(OAc)3BH ACN 
Mol. 
Sieves 
Reflux 72 H AcOH Complex mixture 
K Na(OAc)3BH THF 
Mol. 
Sieves 
Reflux 24 H AcOH Mixture (alcohols 
and 131) 
L Na(OAc)3BH can RT 48 H AcOH 118 recovered, + 
mixture of products 
including 131 
M Na(OAc)3BH DMF RT 96 H AcOH Optimized for 
product 131 
N Na(OAc)3BH IPA RT 96 H AcOH Optimized for 
product 131  
O Na(OAc)3BH THF RT 96 H TFA 118 + 131 
P Na(OAc)3BH DME RT 96 H TFA 118 + 131  
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Reaction K (Table 4.5) produced one amine containing compound, 131. 
Compound 131 had an m/z of 294.1852 according to HRMS corresponding to the 
molecular formula C20H23NO; a compound with ten degrees of unsaturation. The 
HMBC spectrum of the new compound 131
 
indicated the presence of 4 disubstituted 
olefinic carbon atoms. HMBC correlations between C4 and H13 as well as C11 and H13 
suggest that the nitrogen is attached to both C4 and C11 and their chemical shifts are 
consistent with this (Table 4.6). Other key HMBC correlations for the tetrasubstituted 
alkenes were C5/H20, C6/H7, C6/H12 and C11/H12. There were only 6 CH2 groups in 
the structure (H1, H2, H7, H8, H9 and H13), none corresponding to C3 and no aliphatic 
CH groups were present in the molecule either. In addition to the presence of 6 aromatic 
carbons (C15-19), one far downfield carbon resonance at 186.6 ppm, typical of a 
conjugated ketone, was observed and was HMBC correlated to H2, suggesting it is at 
position C3. The proposed structure 131 best fit the observed chemical shift data for 
1
H 
and 
13
C as well as the 2D NMR and HRMS data. 
 
Figure 4.15 - Numbering and Key COSY and HMBC Correlations for 131 
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Table 4.6 - NMR Spectroscopic Data for Compound 131 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC 
1 40.1, CH2 1.88, m 2a,b 20 
  
1.83, m 
  2 36.5, CH2 2.84, m 1a,b 
 
  
2.39, m 1a,b 
 3 186.6, C 
  
2a 
4 122.5, C 
  
13 
5 144.0, C 
  
20 
6 115.4, C 
  
7b; 12 
7 19.6, CH2 2.31, m 8a,b; 7b 
 
  
2.53, m 8b; 7a 4; 6; 9; 8 
8 19.2, CH2 1.92, m 
  
  
2.02, m 7a,b; 9a 
 9 36.9, CH2 1.35, m 8b 
 
  
1.72, m 
  10 30.9, C 
  
20 
11 135.2, C 
  
12; 13 
12 10.0, CH3 2.04, d 
 
6; 11 
13 47.8, CH2 5.7, d (15.9) 
 
15; 19; 14; 11; 17 
  
5.42, d (15.9) 
  14 138.4, C 
  
13; 16; 18 
15;19 126.6, CH 7.06, m 
 
17 
18, 16 128.5, CH 7.3, m 
 
14; 16; 18 
17 126.9, CH 7.23, m 
 
15; 19; 13 
20 24.6, CH3 1.3, s 
 
10; 2; 1; 5 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
The proposed mechanism for the formation of 131 is shown in Figure 4.16. In 
the first step a condensation occurs followed by isomerization of the imine bond to the 
C6-C11 position to form an alkene. The ketone migration from C4 to C3 is proposed to 
occur through an oxirene intermediate. Oxirenes have been proposed as intermediates in 
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the Wolff rearrangement as the result of a α-carbonyl carbene (formed from 
diazoketone).
193, 194
 In this case the oxirene may be formed by rearrangement of an 
enolborane. The hydride H5 must be removed during the reaction, in an oxidative 
fashion, opposite of what is expected with the reagent used.       
 
Figure 4.16 - Proposed Mechanism for the Formation of 131 
Other polar solvents were used to increase yield, including DMF (M, Table 4.5) 
and isopropyl alcohol (N, Table 4.5); these reactions did optimize production of 16, but 
no other major amine containing products were isolated.   
Product fractions from several of the reductive amination reactions (H-K, Table 
4.5) were analyzed using HRMS and observed m/z ions corresponding to the chemical 
formula C22H33NO2 (M+H)
+
 suggested that the acetic acid was being integrated into the 
molecule structure of some minor products. To prevent this, TFA replaced acetic acid as 
the catalyst for the reaction (O, P, Table 4.5) and the result of both was the production of 
compound 131 as the major amine containing product.  
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Due to the low yields of the reductive amination, the condensation and reduction 
steps were performed separately to probe which step was problematic in order to 
effectively optimize the conditions. The condensation reaction was performed under 
Dean Stark conditions with catalytic toluene sulfonic acid in toluene. The result of the 
condensation was the recovery of starting materials, suggesting the condensation is not 
occurring.  No further attempts to optimize the reductive amination or produce new 
amine-containing analogues of gorgonene were made.  
4.2.4 Nucleophilic Addition to Dione 118 
 Nucleophilic addition of an organometallic compound to a carbonyl group is a 
common method in the synthesis of natural products. Organocuprate, organolithium and 
Grignard reagents can add to aldehydes and ketones in powerful C-C bond forming 
reactions. Nucleophilic addition was explored as a route to add desired substructures to 
ketone containing compound 118.  
The Grignard reagent of benzyl bromide was prepared by treatment with 
magnesium turnings and an iodine crystal in a solution of anhydrous ether. A solution of 
compound 118 in ether was then added dropwise to the mixture with cooling. After 
addition of 118 was complete, the reaction was heated to reflux for 30 minutes. The 
major product was isolated from the reaction mixture and determined to have a 
molecular formula C20H28O2 according to HRMS m/z ion at 283.2055 (M-OH). The 
quaternary carbon (C4) resonated at 73.9 and showed a HMBC correlation to H14. 
Carbonyl C11was HMBC coupled to methyl group protons of C12 and other key 
HMBC correlations used to assign the structure were between C3/H14 and C5/H14. The 
elucidation of 132 was completed using 1D- and 2D NMR.  
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Figure 4.17 - Grignard Reaction of Benzyl Magnesium-Bromide with 118 
The stereochemistry at the newly formed tertiary alcohol C4 was determined 
using NOESY correlations between H14 and H6 (Figure 4.18). 
 
Figure 4.18 - Key NOESY Correlation Supporting Stereochemistry of 132 
 A Grignard reagent of 1-bromo-2,5-dimethoxybenzene was prepared and 
combined with 118 in the same manner as described for the preparation of 132. The 
resulting mixture contained products with the desired molecular formula (C21H30O4) 
according to UPLC-HRMS and the mixture was purified using flash chromatography 
and HPLC to give two major products (133 and 134, Figure 4.19). 
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Figure 4.19 - Grignard Reaction with 1-Bromo-2,5-Dimethoxybenzene and 118 
The two isolated compounds were analyzed using NMR, having the correct m/z 
ion and 
1
H NMR data consistent with the products (e.g. aromatic and methoxy carbons, 
sesquiterpene backbone). After a short time in chloroform solution, however, the two 
products interconverted to a 50:50 ratio. The reaction was repeated and equilibration 
between the two products in a number of solvents made purification difficult and full 
characterization impossible. Compound 133 had HMBC correlations between the 
methyl hydrogens on C18 and several of the aromatic carbon atoms suggesting the 
regioselectivity shown in Figure 4.19. The carbonyl carbon C4 is observed in 133 but is 
replaced with a carbon with a chemical shift typical of a ketal in compound 134 
suggesting the equilibrium is between compounds 133 and 134. This interaction 
between the two oxygen containing groups (C4 and C11) is common among the 
reactions (119, 122 and 130) and the ring formation not surprising based on the 
cyclizations seen under several other reaction conditions discusses in this work. Since 
compounds 133 and 134 could not be separated the mixture was carried forward for 
bioassay screening. 
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4.2.5 Biological Assessment of Compound Collection 
4.2.5.1 Drug-Likeness of Compound Collection 
 One of the goals of the study was to synthesize compounds from gorgonene (73) 
that possess the properties associated with bioavailability. Each compound synthesized 
was assessed for pharmacological relevancy using 5 measurements: the number of 
proton donors and acceptors, molecular weight, Log P and rotatable bonds. Reported 
LogP’s are theoretical and calculated using ChemDraw software. Every compound 
within this chapter fits the criteria for drug-likeness using the standards of Lipinski 
(Table 4.7).
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Table 4.7 - Assessment of Drug-likeness of Compound Collection 
 Proton 
Acceptors 
Proton 
Donors 
MW Log P Rotatable 
Bonds 
118 2 0 208 2.80 1 
119 1 1 208 2.20 1 
120 2 0 222 2.90 0 
121 2 0 299 3.16 3 
122 2 1 299 2.90 1 
123 3 0 286 3.00 3 
124 4 0 356 4.13 5 
125 5 1 374 3.77 5 
126 3 0 326 4.26 4 
129 3 1 223 3.19 1 
130 3 1 223 3.37 0 
131 2 2 293 4.04 3 
132 2 1 300 4.37 3 
133 4 1 346 4.01 4 
134 4 1 346 4.26 3 
 
146 
 
4.2.5.2 Evaluation of the Cytotoxicity of Semi-synthetic Derivatives 118-134 
The compounds 118, 120, 121, 122, 124, 125, 126, 129 and 131 to 134 were 
tested for cytotoxicity against a human foreskin BJ fibroblast cell line (ATTC CRL-
2522) and/or human breast adenocarcinoma cells (ATCC HTB-26) according to the 
procedure described in Chapter 2. Compounds 119 and 123 were not tested due to 
stability issues. Compound 126 showed modest activity against the HTB-26 cell line. 
Due to its structural similarity to 126, semi-pure 124 was screened for activity against 
HTB-26 and the 85 % pure mixture did show 99 % growth inhibition at of the cell line 
at 100 µg/mL, but IC50 data was not collected. 
Table 4.8 - Evaluation of Cytotoxicity of Ketone Derived Family (IC50) 
 Cell Line 
Compound Tested HTB-26 CRL-2522 
118 >64 µg/mL >64 µg/mL 
119 NT NT 
120 >64 µg/mL >64 µg/mL 
121 >64 µg/mL >64 µg/mL 
122 >64 µg/mL >64 µg/mL 
123 NT NT 
124 <100 µg/mL NT 
125 >64 µg/mL >64 µg/mL 
126 32-64 µg/mL >64 µg/mL 
129 >64 µg/mL >64 µg/mL 
130 NT NT 
131 >64 µg/mL >64 µg/mL 
132 >64 µg/mL >64 µg/mL 
133/134 >64 µg/mL >64 µg/mL 
 
4.2.5.3 Evaluation of Compounds 118-134 for Antimicrobial Activity 
 The family of compounds described in this Chapter were tested for a range of 
antimicrobial activity in an assay with four microbes representing Gram positive 
antibiotic resistant bacteria (MRSA, VRE), Gram negative bacteria (Pseudomonas 
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aeruginosa) and fungi (Candida albicans). The compounds did not inhibit the growth of 
these microorganisms at a concentration of 128 µg/mL. 
4.2.5.4 Evaluation of Compounds 118-134 for PTP1B Inhibitory Activity 
 The compounds described in this chapter were tested for inhibition and 
selectivity for the inhibition of the PTP1B enzyme. All PTP assays were performed by 
Michel Tremblay`s group at McGill University. The compounds were tested for 
inhibition of seven protein tyrosine phosphatases from class I (Figure 2.9) including 
PTP1B at 50 µM. 
Three compounds (121, 122 and 123) containing five-membered heteroaromatic 
rings showed inhibition of the entire family of PTP enzymes. None of the other 
compounds discussed in this Chapter showed significant inhibition of the PTP1B 
enzyme at 50 µM. Table 4.9 shows the PTP inhibition of these compounds, calculated as 
the rate of pNPP de-phosphorylation, relative to the control. The compounds did not 
show sufficient selectivity for the PTP1B enzyme to be studied further.  
Table 4.9 - Results of PTP Inhibition Assay of Compounds 122-124 
Enzyme Screening Relative Rate, % Control 
 122 123 124 
PTP1B  0.57 0.67 0.35 
SigmaD1D2 0.63 0.68 0.49 
SHP-1 0.63 0.68 0.40 
MKPX 0.72 0.73 0.65 
LAR D1D2 0.96 0.94 1.05 
TC-PTP 0.53 0.69 0.29 
PRL2 A/S 0.94 0.84 0.94 
Papain Not tested Negative Not tested 
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4.3 Conclusion 
A family of novel natural product-like compounds were designed, synthesized 
and characterized spectroscopically. The compound collection was evaluated 
biologically using pharmacological standards for drug likeness and screened for activity 
in bioassays for antimicrobial, anticancer and protein tyrosine phosphatase inhibition. 
One compound in the library showed moderate anticancer activity against a human 
breast cancer cell line HTB-26. 
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4.4 Experimental Section 
General Procedure for Optimization of Ozonolysis of Gorgonene - Table 4.1 
 Ozone (formed by passing compressed air through ozonator at 70 V) was 
bubbled through a solution of 73 (300 mg, 1.47 mmol) in the indicated solvent (10 mL) 
at the specified temperature and length of time (Table 4.1).  The ozone bubbler was 
removed from the solution and the workup reagent was added. The solution was allowed 
to warm to room temperature and stirring continued overnight and then the solvent was 
removed in vacuo. The crude product was purified using silica gel chromatography 
(gradient: 80:20 hexanes:ethyl acetate – 60:40 hexanes:ethyl acetate) and the fractions 
were analyzed using UPLC-HRMS and NMR.  
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Synthesis of Compound 118, 119 and 120 
Ozone was bubbled through a solution of 73 (300 mg, 1.47 mmol) in dichloromethane 
(10 mL) at -78 
o
C for 1.5 hours until all starting materials were consumed according to 
TLC. The ozone bubbler was removed from the solution and triethyl amine (500 µL) 
was added at -78 
o
C. The solution was allowed to warm to room temperature and was 
stirred overnight and then the solvent was removed in vacuo. The crude product was 
purified using silica gel chromatography (gradient: 80:20 hexanes:ethyl acetate – 60:40 
hexanes:ethyl acetate) and was further purified using reversed-phase C18 semi-prep 
HPLC (88:12 MeOH:H2O) to give the three compounds 118, 119 and 120.  
Compound 118 
(217 mg, 71.1 % yield). 
 
1
H NMR (600 MHz, CDCl3) 2.69 (ddd, J = 12.0, 4.5, 3.0 Hz, 1H), 2.63 (d, J = 11.3 Hz, 
1H), 2.33 (m, 1H), 2.24 (m, 1H), 2.22 (s, 3H), 1.92 (m, 1H), 1.90 (m, 1H), 1.85 (m, 1H), 
1.63 (m, 1H), 1.58 (m, 1H), 1.52 (m, 1H), 1.51 (m, 1H), 1.46 (m, 1H), 1.32 (m, 1H), 
1.05 (m, 1H), 0.75 (s, 3H). 
13
C NMR (151 MHz, CDCl3) 212.4, 211.6, 59.4, 45.0, 41.1, 40.5, 39.9, 39.4, 29.7, 29.2, 
22.6, 20.8, 17.5. 
FTIR (CH2Cl2): νmax 2938.9, 1704.8  cm
-1
. 
(+) HRESIMS m/z 231.1373 [M + Na]
+
 (calcd for C13H20O2Na, 231.1361).  
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Compound 119 
 
(33.6 mg, 11 % yield). 
1
H NMR (600 MHz, CDCl3) 4.55 (d, J = 18.5 Hz, 1H), 4.35 (d, J = 18.5 Hz, 1H), 2.77 
(d, J = 10.9 Hz, 1H), 2.67 (ddd, J = 3.8, 12.4, 12.4 Hz, 1H), 2.31 (m, 2H), 1.97 (m, 1H), 
1.97 (m, 1H), 1.84 (m, 1H), 1.69 (m, 1H), 1.64 (m, 1H), 1.60 (m, 1H), 1.54 (m, 1H), 
1.39 (m, 1H), 1.23 (m, 1H), 0.80 (s, 3H), 1.90 (m, 1H), 1.56 (m, 1H). 
13
C NMR (151 MHz, CDCl3) 213.5, 211.6, 67.7, 59.6, 41.0, 40.8, 40.5, 39.8, 39.5, 29.9, 
22.4, 20.7, 17.5. 
FTIR (CH2Cl2): νmax 3365.8, 2931.4, 1708.1 cm
-1
. 
 (+) HRESIMS m/z 209.1530 [M + H]
+
 (calcd for C13H20O2, 209.1542).  
 
Compound 120 
 
 (19.8 mg, 6.0 %). 
1
H NMR (600 MHz, CDCl3) 4.00 (d, J = 11.3 Hz, 1H), 3.26 (d, J = 11.3 Hz, 1H), 1.84 
(m, 1H), 1.78 (m, 1H) 1.66 (m, 1H), 1.65 (m, 1H), 1.62 (m, 1H), 1.57 (m, 1H) 1.53 (m, 
2H), 1.42 (m, 1H), 1.34 (m, 1H), 1.31 (m, 1H), 1.31 (m, 1H), 1.13 (m, 1H), 1.08 (m, 
1H), 1.06 (s, 3H), 1.00 (s, 3H). 
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13
C NMR (151 MHz, CDCl3) 96.6, 69.7, 69.6, 48.4, 43.2, 41.5, 40.1, 37.0, 34.0, 24.6, 
22.1, 20.3, 19.3, 18.9. 
FTIR (CH2Cl2): νmax 2924.5 cm
-1
. 
(+) HRESIMS m/z 223.1686 [M + H]
+
 (calcd for C14H23O2, 223.1698).  
 
Synthesis of Compound 121 and 122 
All glassware was dried in an oven overnight prior to use. Compound 118 (62 mg, 0.21 
mmol) and 1-methyl pyrrole 2-carbaldehyde (34 mg, 0.35 mmol) were dissolved in a 
solution of dry THF (10 mL) in a dry flask equipped with a condenser and drying tube. 
NaOH (38 mg) was added as a solid and the mixture was heated to reflux temperature 
for 24 hours with stirring. The reaction was cooled and diluted with ethyl acetate, 
washed with 0.1 % HCl (3 x 75 mL) and distilled water (2 x 75 mL) and dried with 
MgSO4. The solvent was removed in vacuo and the crude product was purified using 
flash chromatography (C18, gradient 50:50 MeOH:H2O – 100 % MeOH (0.1 % FA)), 
followed by HPLC purification (phenyl hexyl semi-prep column, isocratic, 92:8 
MeOH:H2O) to give major products 121 and 122.  
153 
 
Compound 121 
 
(21 mg, 34 % yield). 
1
H NMR (600 MHz, CDCl3) δ 7.53 (d, J = 15.5 Hz, 1H), 6.75 – 6.73 (m, 1H), 6.75 – 
6.72 (m, 1H), 6.64 (d, J = 15.5 Hz, 1H), 6.18 – 6.14 (m, 1H), 3.70 ( s, 3H), 2.89 – 2.82 
(m, 1H), 2.86 – 2.77 (m, 1H), 2.46 – 2.40 (m, 1H), 2.32 – 2.26 (m, 1H), 2.01 – 1.92 (m, 
2H), 1.97 – 1.82 (m, 2H), 1.75 – 1.66 (m, 1H), 1.66 – 1.56 (m, 2H), 1.57 – 1.49 (m, 1H), 
1.54 – 1.44 (m, 1H), 1.41-1.39 (m, 1H), 0.81 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 210.7, 201.7, 129.2, 128.5, 126.5, 119.7, 111.5, 108.7, 
58.4, 43.4, 40.6, 39.9, 39.2, 38.9, 33.6, 29.0, 22.0, 20.1, 16.8. 
FTIR (CH2Cl2): νmax 3055.5, 2929.5, 1707.1 cm
-1
. 
(+) HRESIMS m/z 322.1782 [M + Na]
+
 (calcd for C19H25NO2Na, 322.1783)  
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Compound 122 
 
(5 mg, 8 % yield). 
1
H NMR (600 MHz, CDCl3) δ 7.26 (s, 1H), 6.76 (s, 1H), 6.55 (d, J = 3.8 Hz, 1H), 6.26 
– 6.23 (m, 1H), 3.75 (s, 3H), 3.42 (m, 1H), 2.69 – 2.61 (m, 1H), 2.29 (m, 1H), 2.19 – 
2.11 (m, 1H), 1.84 – 1.75 (m, 1H), 1.79 – 1.73 (m, 1H), 1.74 – 1.65 (m, 1H), 1.73 – 1.62 
(m, 1H), 1.70 – 1.61 (m, 1H), 1.69 – 1.57 (m, 1H), 1.46 – 1.37 (m, 1H), 1.46 – 1.33 (m, 
1H), 1.24 (s, 3H), 0.87 – 0.78 (m, 1H). 
13
C NMR (151 MHz, CDCl3) δ 198.4, 174.9, 137.0, 134.4, 128.4, 126.2, 117.7, 114.2, 
109.6, 42.7, 40.8, 39.5, 35.5, 34.6, 31.5, 24.3, 21.8, 21.4, 19.3. 
FTIR (CH2Cl2): νmax 3059.9, 2928.6, 1680.0 cm
-1
. 
(+) HRESIMS m/z 282.1842 [M + H]
+
 (calcd for C19H24NO, 282.1858)
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Synthesis of 123 
 
Glassware was dried in an oven overnight. Compound 118 (70.0 mg, 0.34 mmol), was 
combined with furanaldehyde (40 mg, 0.41 mmol) and NaOH (40 mg, 1.6 mmol) in 
anhydrous THF (10 mL) in a dry flask equipped with a condenser and a drying tube. 
The mixture was heated to reflux temperature for 24 hours with stirring. The reaction 
was allowed to cool, diluted with ethyl acetate and washed with 0.1 % HCl (3 x 75 mL) 
and distilled water (2 x 75 mL). The solvent was removed in vacuo and the crude 
product was purified using flash chromatography (C18 stationary phase, gradient 50:50 
MeOH:H2O – 100 % MeOH (0.1 % FA) and the product containing fraction was further 
purified using HPLC (phenyl hexyl semi-prep column, isocratic, 90:10 MeOH: H2O) to 
give compound 123 as a white solid (30 mg, 31 % yield). 
1
H NMR (600 MHz, CDCl3) δ 7.48 (d, J = 1.4 Hz, 1H), 7.34 (d, J = 15.7 Hz, 1H), 6.76 
(d, J = 15.7 Hz, 1H), 6.64 (d, J = 3.4 Hz, 1H), 6.46 (dd, J = 3.4, 1.8 Hz, 1H), 2.96 – 2.90 
(m, 1H), 2.83 (d, J = 11.0 Hz, 1H), 2.41 (m, 1H), 2.29 (m, 1H), 2.01 – 1.97 (m, 1H), 
1.98 – 1.94 (m, 1H), 1.93-1.89 (m, 1H), 1.71 (m, 1H), 1.65 – 1.56 (m, 2H), 1.60 – 1.55 
(m, 1H), 1.55 – 1.51 (m, 1H), 1.40 (m, 1H), 1.17 (m, 1H), 0.83 (s, 3H).  
13
C NMR (151 MHz, CDCl3) δ 210.9, 203.1, 152.3, 144.8, 128.7, 123.5, 115.5, 112.6, 
59.4, 43.8, 41.4, 40.8, 40.0, 39.8, 29.8, 22.9, 21.0, 17.7. 
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FTIR (CH2Cl2): νmax 3053.8, 2930.1, 1708.7 cm
-1
. 
 (+) HRESIMS m/z 309.1464 [M + Na]
+
 (calcd for C18H22O3Na, 309.1467). 
Synthesis of Compound 124 and 125 
All glassware was dried in an oven overnight. Compound 118 (70.0 mg, 0.34 mmol) 
was combined with 2,5-dimethoxy-1-benzaldehyde (80 mg, 0.481 mmol) and NaOH (40 
mg, 1.6 mmol) in anhydrous THF (10 mL) in a dry flask equipped with a condenser and 
a drying tube. The mixture was heated to reflux temperature for 24 hours with stirring, 
allowed to cool and diluted with ethyl acetate. The solution was washed with 0.1 % HCl 
(3 x 75 mL) and distilled water (2 x 75 mL). The solvent was removed in vacuo and the 
crude product was purified using flash chromatography (C18 stationary phase, gradient 
50:50 MeOH:H2O – 100 % MeOH (0.1 % FA) to give compounds 124 and 125. 
 Compound 124 
 
(46 mg, 32 % yield based on 85 % purity). 
(+) HRESIMS m/z 357.2045 [M + H]
+
 (calcd for C22H29O4, 357.2066). 
FTIR (CH2Cl2): νmax 3057.2, 2923.1, 2853.4, 1705.9 cm
-1
. 
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Compound 125 
 
(36 mg, 26 % yield). 
1
H NMR (600 MHz, CDCl3) δ 7.06 (s, 1H), 6.74 (s, 1H), 6.74 (s, 1H), 5.55 (s, 1H), 3.77 
(s, 3H), 3.74 (s, 3H), 3.13 (s, OH, 1H)  2.85 (m, 1H), 2.84 – 2.76 (m, 1H), 2.71 (d, J = 
11.0 Hz, 1H), 2.32 (s, 3H), 2.03 – 1.96 (m, 1H), 1.98-1.94 (m, 1H), 1.68-1.64 (m, 1H), 
1.61-1.55 (m, 1H), 1.60 – 1.55 (m, 2H), 1.50 – 1.45 (m, 1H), 1.44-1.41 (m, 1H), 1.35 – 
1.28 (m, 1H), 1.10 (m, 1H), 0.78 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 215.1, 212.6, 153.7, 149.7, 130.6, 113.4, 112.5, 110.9, 
65.9, 59.6, 55.9, 55.8, 52.9, 45.3, 40.3, 40.0, 39.9, 29.6, 28.9, 21.8, 20.9, 17.6. 
FTIR (CH2Cl2): νmax 3521.8, 3063.6, 2925.5, 2853.6, 1701.12 cm
-1
. 
 (+) HRESIMS m/z 397.2013 [M + Na]
+
 (calcd for C22H30O5Na, 397.1991). 
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Synthesis of Compound 126 
 
All glassware was dried in an oven overnight. Compound 118 (70.0 mg, 0.34 mmol) 
was combined with anisaldehyde (60 mg, 0.44 mmol) and NaOH (40 mg, 1.6 mmol) in 
anhydrous THF (10 mL) in a dry flask equipped with a condenser and a drying tube. 
The mixture was heated to reflux for 24 hours with stirring. The solution was allowed to 
cool and diluted with ethyl acetate before being washed with 0.1 % HCl (3 x 75 mL) and 
distilled water (2 x 75 mL). The solvent was removed in vacuo and the crude product 
was purified using flash chromatography (Diol stationary phase, isocratic, 20:80 ethyl 
acetate:hexanes) to give compound 126 as a white solid (51 mg, 46 % yield). 
1
H NMR (600 MHz, CDCl3) 7.92 (d, J = 16.2 Hz, 1H), 7.57 (m, 1H), 7.33 (m, 1H), 6.94 
(m, 1H), 6.91 (d, J = 16.2 Hz, 1H), 6.90 (m, 1H), 3.87 (s, 3H), 3.01 (m, 1H), 2.86 (d, J =  
10.9 Hz, 1H), 2.42 (ddd, J = 7.5, 13.5, 13.5 Hz, 1H), 2.29 (m, 1H), 2.02 (m, 1H), 1.96 
(m, 1H), 1.90 (m, 1H), 1.71 (m, 1H), 1.63 (m, 2H), 1.58 (m, 1H), 1.53 (m, 1H), 1.40 (m, 
1H), 1.19 (m, 1H), 0.85 (s, 3H). 
13
C NMR (151 MHz, CDCl3) 211.4, 203.4, 158.7, 137.6, 131.5, 128.9, 126.4, 124.0, 
120.8, 111.2, 59.3, 55.6, 43.4, 41.4, 40.8, 40.1, 39.8, 30.0, 22.9, 21.0, 17.8. 
FTIR (CH2Cl2): νmax 3061.0, 2931.6, 1708.7, 1683.82 cm
-1
. 
(+) HRESIMS m/z 349.1776 [M + Na]
+
 (calcd for C21H26O3Na, 349.1780). 
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General Procedure for Demethylation/Oxidation of 124{{491 Jacob,Peyton. 1976;}} 
To a solution of 124 (10 mg, 0.028 mmol) in 1:1 ACN:DMF (2 mL) was added a 
solution of cerium ammonium nitrate (70 mg, 0.132 mmol) in 1:1 (H2O:ACN) (2 mL) 
slowly at room temperature. The mixture was heated to 70 
o
C overnight. The reaction 
was allowed to cool, diluted with ether (5 mL), washed with brine (2 x 5 mL), dried with 
MgSO4 and the solvent removed in vacuo. The mixture was fractionated using C18 
chromatography and analyzed using UPLC-HRMS and NMR spectroscopy. 
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Synthesis of Compounds 129 and 130 
Compound 118 (90 mg, 0.43 mmol) was combined with hydroxyl amine hydrochloride 
(167 mg, 2.40 mmol) and K2CO3 (332 mg, 2.40 mmol) in solution of THF (5 mL) H2O 
(10 mL) and MeOH (10 mL). The reaction was stirred at room temperature overnight at 
which time it was partitioned between H2O and ethyl acetate, dried with MgSO4 and the 
solvent removed in vacuo. The crude product was fractionated using C18 flash 
chromatography (50:50 H2O:MeOH-100 % MeOH) and the product containing fractions 
were combined and further purified using HPLC (C18 semi-prep column, isocratic, 
70:30 MeOH:H2O) and 129 was isolated as a white solid (11.4 mg, 12 % yield). 
Compound 129 
 
1
H NMR
 
(600 MHz, CDCl3) δ 7.83 (bs, 1H), 2.69 (d, J = 11.5 Hz, 1H), 2.41 – 2.34 (m, 
1H), 2.37 – 2.29 (m, 1H), 2.25 (m, 1H), 1.99 – 1.95 (m, 1H), 1.96 – 1.85 (m, 2H), 1.92 
(s, 3H), 1.65 (m, 1H), 1.59 – 1.51 (m, 1H), 1.60 – 1.49 (m, 2H), 1.53 – 1.47 (m, 1H), 
1.35 (m, 1H), 1.15 – 1.06 (m, 1H), 0.78 (s, 3H).  
13
C NMR (151 MHz, CDCl3) δ 211.8, 162.2, 59.9, 42.2, 41.1, 40.9, 40.6, 39.0, 32.0, 
23.6, 21.2, 17.4, 14.4.7  
FTIR (CH2Cl2): νmax 3355.9, 2929.6, 1711.6 (s), 1660.0 (w) cm
-1
  
(+) HRESIMS m/z 224.1640 [M + H]
+
 (calcd for C13H22NO2, 224.1651). 
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Compound 130 
 
Compound 130 was purified using HPLC (C18 semi-prep column, isocratic 75:25 
MeOH:H2O) and was isolated as a white solid (14.0 mg, 14.5 % yield). 
1
H NMR (600 MHz, CDCl3) δ 2.44 (bs, OH), 2.20 – 2.12 (m, 1H), 2.13 – 2.07 (m, 1H), 
1.89 (s, 3H), 1.86 – 1.82 (m, 1H), 1.83 – 1.77 (m, 1H), 1.67 – 1.63 (m, 1H), 1.66 – 1.59 
(m, 2H), 1.62 – 1.55 (m, 1H), 1.52 – 1.46 (m, 1H), 1.40 (m, 1H), 1.34 (m, 1H), 1.18 – 
1.10 (m, 1H), 1.14 – 1.08 (m, 1H), 1.08 (m, 1H), 1.01 (s, 3H). 
13
C NMR
 
 (151 MHz, CDCl3) δ 159.3, 95.2, 47.5, 42.0, 40.9, 37.2, 33.1, 29.4, 29.2, 
21.4, 19.0, 18.7, 17.7.  
FTIR (CH2Cl2): νmax 3357.5, 2929.7 cm
-1
, 1713.5 cm
-1
. 
(+) HRESIMS m/z [M + H]
+
 224.1634 (calcd for C13H22NO2, 224.1651). 
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General Procedure for Optimization of Reductive Amination (Table 4.5) 
All glassware was dried in an oven overnight, solvents were dried over molecular sieves 
and starting materials were dried in a desiccator overnight. To solution of 118 (40 mg, 
0.19 mmol), benzylamine (100 mg, 0.93 mmol) and NaBH(OAc)3 (100 mg, 0.47 mmol) 
in the specified solvent (under N2 where indicated) was added acid,base and/or 
molecular sieves (if used) the reaction was stirred at the temperature and length of time 
stated in Table 4.5. The solution was then cooled, extracted with distilled water (neutral 
reaction conditions) 1M HCl (basic reaction conditions) or NaHCO3(aq) (acidic reaction 
conditions),dried with MgSO4 and the solvent removed in vacuo. The reaction mixture 
was fractionated using silica or C18 flash chromatography before analysis using HRMS 
and 
1
H NMR. 
Dean Stark Condensation Reaction Procedure 
In a Dean Stark apparatus a solution of 118 (50 mg, 0.24 mmol), benzylamine (25 mg, 
0.23 mmol) and toluene sulfonic acid (10 mg, 0.06 mmol) in toluene (25 mL) was 
heated to reflux temperature for 4 hours. The reaction was then cooled, extracted with 
distilled water and filtered through a plug of C18 before the solvent was removed in 
vacuo and the product mixture was analyzed using UPLC-HRMS and NMR.  
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Synthesis of Compound 131 
 
To a solution of 118 (75 mg, 0.36 mmol) and benzyl amine (50 mg, 0.46 mmol) in 
acetonitrile (3 mL) was added activated molecular sieves and glacial acetic acid (50 µL). 
The solution was stirred under an atmosphere of N2 for 48 hours at room temperature 
and then filtered, diluted with ethyl acetate (15 mL) and washed with NaHCO3(aq) (2 x 
15 mL). The solvent was removed in vacuo and the product was purified using C18 
combiflash (50:50 MeOH:H2O-100 % MeOH) followed by HPLC purification (phenyl 
hexyl semi-preparatory column, isocratic, 92:8 MeOH:H2O, 2.5 ml/min) to give 
compound 131 as a white solid (36 mg, 34 % yield). 
1
H NMR (600 MHz, CDCl3) δ 7.30-7.24 (m, 2H), 7.24 – 7.17 (m, 1H), 7.06-7.02 (m, 
2H), 5.77 – 5.65 (m, J=15.6 Hz, 1H), 5.47 – 5.35 (d, J=15.6 Hz, 1H), 2.89 – 2.76 (m, 
1H), 2.57 – 2.47 (m, 1H), 2.43 – 2.35 (m, 1H), 2.35 – 2.25 (m, 1H), 2.03 (s, 3H), 2.02 – 
1.96 (m, 1H), 1.96 – 1.90 (m, 1H), 1.90 – 1.79 (m, 1H), 1.74 – 1.68 (m, 1H), 1.61 – 1.53 
(m, 1H), 1.39 – 1.32 (m, 1H), 1.30 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 186.6, 144.0, 138.5, 135.2, 128.5 (2C), 126.9, 126.6 
(2C), 115.4, 47.8, 40.1, 36.9, 36.5, 30.9, 24.6, 19.6, 19.2, 10.0. 
 (+) HRESIMS m/z [M+H]
+
 294.1852 (calcd for C20H24NO, 294.1858)  
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Synthesis of Compound 132 
 
All glassware was dried in an oven overnight. In a two neck flask equipped with a 
condenser and drying tube, benzyl bromide (100 mg, 0.59 mmol) was dissolved in dry 
ethyl ether (5 mL) and a crystal of iodine was added to the flask. The solution began to 
bubble and after bubbling ceased the solution was heat to reflux for another 30 mins. A 
solution of 118 (37 mg, 0.178 mmol) in dry ethyl ether (10 mL) was added to the 
solution dropwise with cooling. After addition was complete the reaction was heated to 
reflux for another 30 mins and then cooled to room temperature. The reaction was 
diluted with ethyl acetate (20 mL), extracted with 1M HCl (15 mL) and brine (15 mL). 
The organic layer was dried with magnesium sulfate and the solvent was removed in 
vacuo. The mixture was purified using flash chromatography (silica gel, 80:20 - 100 % 
MeOH, and HPLC (phenyl hexyl column, isocratic 93:7 MeOH:H2O) to give compound 
132 as a colorless solid (40.5 mg, 76 %). 
1
H NMR (600 MHz, CDCl3) δ 7.28 – 7.24 (m, 2H), 7.20 (dd, J = 7.3, 7.0 Hz, 1H), 7.10 
(d, J = 7.0 Hz, 2H), 3.08 – 3.00 (m, 1H), 2.54 (d, J = 13.0 Hz, 1H), 2.37 (s, 3H), 2.35 (d, 
J = 13.0 Hz, 1H), 2.16 (s, 1H), 1.89 (m, 1H), 1.76 (d, J = 11.1 Hz, 1H), 1.68 – 1.62 (m, 
1H), 1.64 – 1.58 (m, 1H), 1.53 (m, 1H), 1.43 (m, 1H), 1.41 – 1.34 (m, 1H), 1.36-1.32 
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(m, 1H), 1.35-1.31 (m, 1H), 1.34 – 1.25 (m, 2H), 1.27 – 1.22 (m, 1H), 1.24 – 1.16 (m, 
1H), 1.12 (s, 3H).  
13
C NMR (151 MHz, CDCl3) δ 214.5, 137.5, 130.7 (2C), 128. (2C), 126.3, 73.9, 53.1, 
50.7, 47.5, 43.8, 41.8, 38.5, 34.6, 32.2, 31.1, 20.3, 19.9, 17.1. 
FTIR (CH2Cl2): νmax 3483.7, 3062.9, 2927.3, 1705.8 cm
-1
. 
(+) HRESIMS m/z 283.2055 [M - OH]
+
 (calcd for C20H27O, 283.2062). 
 
Synthesis of 133 and 134 
All glassware was dried in an oven overnight and assembled hot, the flask was equipped 
with a condenser and drying tube. A solution of 2,5-dimethoxy-1-bromobenzene (200 
mg, 0.92 mmol) in dry ether (4 mL) was slowly added to a solution of Mg turnings (300 
mg) and an iodine crystal in dry either. The solution was warmed slightly and the color 
disappeared and some bubbling occurred a white precipitate was observed. The solution 
was heated to reflux temperature for 30 minutes and then cooled to 0 
o
C.  A solution of 
118 (50 mg, 0.24 mmol) in ether (5 mL) was added dropwise to the reaction and the 
resulting solution was heated to reflux temperature for one hour before allowing to cool. 
The reaction was filtered and then extracted with NaHCO3(aq) (2 x 15 mL), dried with 
MgSO4 and the solvent removed in vacuo.  The crude mixture was purified using C18 
flash chromatography (70 :30 MeOH:H2O – 100 % MeOH) and then HPLC (Phenyl-
hexyl semi-prep column, isocratic, 80:20 ACN:H2O) to give compound 133 as a white 
solid (8.0 mg, 10 % yield).   
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Compound 133 
Proposed Structure 
 
(+) HRESIMS m/z 329.2111 [M - OH]
+
 (calcd for C21H29O3, 329.2117). 
Compound 134 
Proposed Structure 
 
(8.0 mg, 10 % yield).   
(+) HRESIMS m/z 329.2110 [M - OH]
+
 (calcd for C21H29O3, 329.2117). 
Mixture of 133 and 134: FTIR (CH2Cl2): νmax 3461.3, 3072.5, 2927.3, 1700.5 (w) cm
-1
. 
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General Procedure for Preparation of Organolithium Reagent and Reaction with 
118 
Reaction flasks and stir bars were dried in an oven overnight and cooled under an 
atmosphere of argon. N-BuLi was titrated prior to use to confirm concentration. 2,5-
dimethoxy-1-bromobenzene (40 mg, 0.186 mmol) was weighed in the flask, dissolved in 
anhydrous THF (15 mL) and the solution was cooled to – 78 oC. N-Butyl lithium (2M in 
cyclohexane, 90 µL, 0.19 mmol) was added dropwise to the solution at -78 
o
C and the 
reaction was stirred for 20 min at this temperature. A solution of 118 (19 mg, 0.09 
mmol) in anhydrous THF (5 mL) was added dropwise and the solution was stirred and 
monitored by TLC. The reaction was allowed to come to room temperature and stirred 
for 3 hours. Chilled isopropyl alcohol was slowly added to the reaction, which was then 
extracted with saturated NaHCO3, dried with MgSO4 and the solvent removed in vacuo. 
The product mixture was filtered through a plug of C18 and analyzed using UPLC-
HRMS and NMR. Although a compound with the correct mass ionized in the HRMS, 
the NMR determined that the starting materials were the major product. 
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Chapter 5 - Route to a Novel Glycosylated Derivative via 
Hydroxylation of Gorgonene 
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5.1 Introduction 
Terpene glycosides are natural products that very often possess excellent 
biological activity.
195
 The pseudopterosin family of compounds
131, 132, 134, 196, 197
, isolated 
from a sea whip, belong to this family and exhibit excellent anti-inflammatory and 
analgesic properties. The fuscosides (diterpene glycosides)
137,198
 were also extracted 
from a sea whip and possess potent anti-inflammatory activity. Eleutherobin and its 
derivatives were isolated from an Australian coral and possess potent anticancer activity 
comparable to Taxol™.199 Inspired by these molecules, a glycoside-affixed derivative of 
gorgonene (73) became a synthetic target.  
A glycosylation reaction occurs between a carbohydrate moiety (glycosyl donor) 
and another molecule (glycosyl acceptor) typically containing a hydroxyl group that 
ultimately connects the two.
200
 In order to prepare gorgonene for this type of reaction, a 
hydroboration/oxidation reaction was performed to install a hydroxyl motif (Figure 5.1). 
The hydroxyl moiety may then be used directly in a glycosylation reaction and also may 
be used as a starting point for syntheses targeting other functionalities. The 
regioselective hydroxylation of gorgonene is synthetically challenging, however, 
derivatives of gorgonene with glycosyl moieties at any position of attachment on the 
scaffold are desirable. 
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Figure 5.1 - Retrosynthesis of Glycosylated Gorgonene Analogue 
5.2 Results and Discussion 
5.2.1 Dihydroboration / Oxidation of Gorgonene as a Route to Dihydroxygorgonene 
Derivatives 
A hydroboration/oxidation was performed on 73 in one pot. Gorgonene (73) was 
treated with BH3 in THF, followed by the dropwise addition of NaOH and H2O2 at O 
o
C. 
The resulting product mixture was complex but two major components were isolated, 
both with molecular formulae consistent with a dihydroxylation taking place 
(C15H28O2). Compound 135 was an expected product with both alcohols adding in an 
anti-Markovnikov fashion. C12 and C15 of 135 are methylenes connected to an oxygen 
atom appearing at 61.0 and 64.0 ppm, whose hydrogen atoms are COSY correlated to 
H11 and H4 respectively; no alkenyl carbons remained in the molecule. The structure 
135 was assigned based on the 1D and 2D NMR data listed in Table 5.1, however, the 
stereochemistry at C11 could not be assigned with certainty with the information 
available.  
171 
 
 
Table 5.1 - NMR Spectroscopic Data for Compound 135 (CDCl3) 
 δC, type δH (J in Hz) COSY HMBC NOESY 
1 42.9, CH2 1.38, m 
 
15 1b 
  
1.07, ddd (4.75, 
13.5, 13.5) 
   2 17.4 CH2 1.58, m 
 
1b 
 
  
1.39, m 
   3 28.5 CH2 1.97, m 3b; 2a 14a, b 3b 
  
1.30, m 
   4 37.9 CH 1.93, m 14a; 3b 14a 12 
5 38.7 CH 1.44, m 6; 4 6; 8b; 13 
 6 48.9 CH 1.27, m 7a,b 15 
 7 22.2 CH2 1.40, m 
   
  
1.49, m 
   8 27.6 CH2 1.82, m 8b 3 8b; 13 
  
0.82, m 
   9 44.7 CH2 1.22, m 
 
1b; 15 13 
  
1.03, m 
   10 34.6 CH 
 
15 
  
11 34.4 CH 1.87, m 
12a,b; 
13 
  12 64.1 CH2 3.67, m 
 
13 6; 11; 4 
  
3.22, m 
   13 17.0 CH3 1.03, d (6.8) 9 12a,b 
 14 61.0 CH2 3.57, m 
 
6 15; 2a 
  
3.48, m 
  
15; 5; 11 
15 19.7 CH3 0.74, s 
 
1b; 5; 9b 1a; 7a; 14b 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
 The other major product 136 which crystallized easily from solution had one of 
the alcohols add to the more substituted position of the alkene (C4, 136, Figure 5.2). 
This was supported by the quaternary substitution on the hydroxyl substituted carbon, 
C4 appearing at 74.6 ppm in the 
13
C spectrum and the methyl protons on C15 appearing 
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as a singlet in the 
1
H NMR spectrum. The structure of 136 was confirmed using X-ray 
crystallography (Figure 5.3).   
 
Figure 5.2 - Hydroboration / Oxidation of Gorgonene 
  
Figure 5.3 - Crystal Structure of Hydroboration/Oxidation Product 136 
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5.2.1.1 Mechanism of Dihydroboration of Gorgonene Resulting in the Formation of 
136 
To gain insight into the reaction mechanism favoring products 135 and 136, a 
hydroboration reaction was performed using a 1:3 stoichiometric ratio of 
borane:gorgonene to facilitate the production of mono-hydroxylated derivatives. 
Interestingly, diols 135 and 136 were produced as the major alcohol-containing 
products, mono-hydroxy derivatives were only formed in minute yields and starting 
materials were re-isolated in greater than 50 % yield. This result confirms that 
dihydroboration occurs preferentially with BH3 in gorgonene’s 1,5-diene system.  
The formation of products 135 and 136 suggested that the reaction does not 
proceed through a simple single-step mechanism. Figure 5.4 shows a putative 
mechanism for the formation of the borane-73 complex that leads to the production of 
compound 136. In the first step the hydroboration of the C11-C12 olefin occurs and then 
the C4-C14 double bond is ideally situated to undergo a rapid second hydroboration 
through a cyclic intermediate. The formation of the 1,5-diol (136) suggests that the 
intramolecular BH addition occurs forming a six membered cyclic organoborane (136a-
Figure 5.4), but a seven membered ring (135a) is the proposed intermediate in the 
formation of 135. Six membered rings are energetically favorable to seven membered 
rings due to reduced ring strain.
201
 Anti-Markovnikov addition typically occurs during 
the hydroboration reaction because H-B adds to the carbon-carbon double bond in a 
concerted fashion with no carbocation intermediate being formed. Therefore the 
stereochemical outcome of the addition is determined mainly by steric effects with the 
larger boron atom adding to the less substituted carbon. The formation of 135 is the 
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result of both hydroborations occurring in the expected anti-Markovnikov way. The 
approximately equal formation of products 135 and 136 suggests that the two opposing 
forces (steric hindrance vs. ring strain) are approximately equal in their effect. 
Monohydroboration would presumably be favorable if a disubstituted hydroborane 
reagent was used containing one B-H bond such as chatecholborane.
202
 
 
Figure 5.4 - Proposed Mechanism for the Formation of Products 135 and 136 
5.2.2 Synthesis of Glycosylated Analogue of (+)-β-Gorgonene 
Compound 136 was purified via crystallization and glycosyl donor 139 was 
prepared in two steps to couple with it. D-Glucose was first converted to the 
corresponding benzoyl protected sugar 138 by treatment with DMAP and subsequent 
addition of benzoyl chloride with stirring and cooling. After workup, the crude 
benzoylated sugar 138 was combined with an equivalent of acetyl bromide in methanol 
and DCM in the absence of light.
203
 A second equivalent of acetyl bromide was required 
to complete the reaction according to TLC. 
1
H NMR confirmed the production of the 
glycosyl bromide 139 which was unstable under ambient conditions and was used 
immediately in the next step without further purification.  
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Figure 5.5 - Glycosylation Reaction Scheme 
Glycosyl bromide (139) was coupled to glycosyl acceptor 136 using a modified 
Koenigs-Knorr reaction with a silver trifluoromethanesulfonate catalyst and silver 
carbonate under anhydrous conditions.
204
 The product mixture was purified using C18 
chromatography and the fraction containing the product 140 was identified using HRMS 
(m/z of 841.3606 (M + Na)
+
 corresponding to the expected molecular formula 
C49H54O11) . The product was further purified using HPLC to give a 7.1 % isolated yield. 
In the final step of the synthetic sequence, the benzoyl deprotection of 140 was 
first attempted by treatment with K2CO3 in a methanol solution, but only partial 
deprotection was achieved.
204
 Compound 140 was then treated with NaOMe in a 
DCM/MeOH solution until a pH of 12 was reached and the reaction was stirred for 
several hours before workup.
205
 The glycoside 141 was purified using HPLC and 
analyzed using UPLC-HRMS and 
1
H NMR. An m/z ion of 425.2508 confirmed the 
expected molecular formula of the product C21H38NaO7. Many of the 
13
C chemical shifts 
were identified using HSQC and HMBC, however limited material prevented a full 
13
C 
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spectrum from being recorded. The structure and stereochemistry of the starting alcohol 
(136) was known before the reaction and is expected to be unchanged during the 
glycosylation. Primary alcohol glycosyl accepters are more reactive than tertiary 
alcohols due to steric reasons, directing the regioselectivity to favor attachment of the 
glycosyl moiety to the decalin scaffold at C12. Although the HMBC signals between the 
sugar moiety and the sesquiterpene fragment were too weak to be detected, 
1
H NMR 
resonances for H12 and H13 were shifted downfield and H1, upfield, supporting 
reaction at position H12. The stereochemical outcome of the anomeric carbon of the 
sugar moiety is predicted to have the S configuration due to the neighboring group 
effects of the benzoyl group.
206
 This would cause a trans-configuration between 
anomeric H16 and the adjacent H17 in the final product, (likely equatorial-equatorial, 
but possibly axial-axial). Vicinal hydrogen atoms with bond angles approaching 0 
o
 or 
180 
o
 will display a large 
3
J coupling constants (>7 Hz) according to the Karplus 
equation.
207
 If the anomeric carbon has the reverse stereochemistry and H16-H17 are 
cis, then a bond angle closer to 90 
o
 (axial-equatorial) would show a smaller 
3
J coupling 
constant between the two vicinal protons (< 5 Hz). The anomeric proton is the most 
deshielded in the 
1
H
 
NMR spectrum and is clearly distinguishable from the other peaks. 
A coupling constant of 8.0 Hz is observed between H16 and H17, suggesting that the 
predicted trans geometry is indeed formed and confirming the structure of the product as 
141 (Figure 5.5). 
5.2.3 Reactivity of Gorgonene Derivatives 135 and 136  
A retrosynthetic analysis of dimethoxybenzene derivative (142) of gorgonene is 
shown in Figure 5.6. A disconnection of the C13-C14 bond of structure 142 leads to 
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synthons 143 and 144. Tosylate esters (143), which act as good leaving groups for a 
subsequent nucleophilic substitution reactions, can be synthesized from hydroxyl groups 
in one step by treatment with toluenesulfonyl chloride in pyridine. Novel analogues of 
gorgonene with attached aromatic groups via an ethylene or methylene linker were 
envisaged using this approach.  
 
Figure 5.6 - Retrosynthetic Analysis of Aromatic Containing Derivative of 
Gorgonene 
5.2.3.1 Unexpected Reactivity of Tosylation Reaction Leading to Cyclic Ether 145 
In order to produce a tosylate containing intermediate, compound 136 was 
treated with toluenesulfonyl chloride in a solution of pyridine. The major isolated 
compound (C18 chromatography) of the reaction had a molecular formula of C15H23O as 
indicated from HRMS (m/z ion of 223.2058 (M + H)
+
). The compound contained 3 
degrees of unsaturation but no peaks in the 
13
C NMR spectrum more deshielded than 
100 ppm indicated the absence of a tosyl moiety. Quaternary carbon C4 and methylene 
carbon C13 are attached to the ether oxygen with 
13
C NMR chemical shifts of 74.1 and 
67.4 ppm respectively. 1D and 2D NMR elucidation revealed the novel tricyclic 
compound 145 had been formed particularly a strong HMBC correlation between C4 
and H13 as well as one between C13 and H15. 
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Figure 5.7 - Tosylation of 136 Produces Tricyclic Ether 145 
The new 6-membered ether containing ring presumably formed as shown in 
Figure 5.8. The tosylate was likely first formed on C13, then deprotonation and 
nucleophilic attack of C4-O
-
 replacing the tosylate on C13 completed the formation of 
the ring.  
 
Figure 5.8 - Proposed Mechanism for Formation of 145 
5.4.3.2 Tosylation of 135 as a Route to Aromatic Substituted Gorgonene Derivative 
Tosylate ester 146 was successfully synthesized by treatment of 135 with 
toluenesulfonyl chloride in a pyridine solution, as indicated by an HRMS m/z ion of 
566.2599 (M+NH4)
+
. Compound 146 was used in the next reaction after partial 
purification using silica gel flash chromatography.  
A nucleophilic substitution reaction was attempted with 135 by addition of an 
organocuprate salt of dimethoxybenzene to an anhydrous solution of compound 135, 
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however this resulted in recovery of starting materials. Treatment of 135 with Grignard 
reagent, 2,5 dimethoxyphenyl magnesium bromide also resulted in recovery of mainly 
starting materials and low yields of multiple products complicated purification. This 
phase of the study was not continued after multiple failed attempts.  
 
Figure 5.9 - Synthesis of Tosylate Ester 146 
5.2.3 Riley Allylic Selenium Dioxide Oxidation of Gorgonene 
The Riley allylic selenium dioxide oxidation was pursued as a route to a new 
hydroxy-derivative of gorgonene. Selenium dioxide allylic oxidations proceed through a 
two-step mechanism; first an ene-reaction occurs between the allylic group and the 
selenium dioxide, followed by a sigmatropic rearrangement with the net result of an 
allylic substituted alcohol (Figure 5.10). 
 
Figure 5.10 - Riley Allylic Selenium Dioxide Oxidation Mechanism 
The major isolated product of the reaction of gorgonene (73) with selenium 
dioxide in a solution of 1,4-dioxane was compound 147. After an aqueous workup the 
major product contained a selenium atom according to the HRMS m/z ions of 299.1073 
and 301.1065 (C15H25OSe (M+H)
+
 for the two most abundant isotopes 
78
Se and 
80
Se). 
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The molecular formula indicated the compound had four degrees of unsaturation, but 
only two olefinic 
13
C resonances appeared in the NMR spectrum (C11, C12), a 1,1-
disubstituted alkene. The key HMBC correlation is between C4/H13 indicated there is a 
bridge between those two carbons. C3 and C4 are HMBC correlated to H13, placing the 
alcohol H13 at the C4 position. H15/OH COSY correlations indicate that the oxygen 
that is attached to H15 is an alcohol and not an ether or part of the bridge. The C13 is 
much more shielded (21.7 ppm) than would be expected if it was attached to two carbon 
atoms (~40-45 ppm) and there is significant literature precedent that carbon atoms 
attached to selenium atoms are more shielded than C-C atoms
208
 suggesting that there is 
a selenium atom bridging the two atoms C13 and C4. The H13 hydrogens are more 
deshielded than expected (3.11, 3.57 ppm), but this may be due to their proximity to the 
C15-OH. Bridged selenanes have been reported to be formed from the reaction of dienes 
with selenium dioxide.
209
 The proposed structure of 147 is based on the HRMS, 1D and 
2D NMR data (Table 5.2) and the literature (Figure 5.11). The stereochemistry at C4 
was assigned using a NOESY correlation between H6/H15.  
 
Figure 5.11 - Synthesis of Selenide Derivative of 73 
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Figure 5.12 - Key NMR Correlations for 147 
Selenium is found in biological systems in low quantities, although it is toxic in 
large amounts. Several commercial drugs contain selenium such as PBISe for the 
treatment of malignant melanoma.
210
 For this reason compound 147 was tested for 
activity in cancer cell line assays. 
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Table 5.2 - NMR Spectroscopic Data for Compound 147 (CDCl3) 
 δC, type δH (J in Hz) COSY 
HMBC NOESY 
1 45.2, CH2 1.32, m 
 
5; 14 
 
  
1.21, m 
   2 19.1, CH2 1.60, m 3b 3b 
 
  
1.40, m 
   3 38.2, CH2 2.33, m 3b 15b 3b 
  
1.80, m 
   4 55.6, C 
  
3; 5; 13; 15 
 5 56.0, CH 2.04, d, (12.0) 6 14 3b 
6 40.0, CH 2.44, ddd (3.2, 12.0, 12.0) 7a; 5 12; 13b; 5 5; 14 
OH 
 
2.27, dd (10.3, 3.3) 15a,b 
  7 36.4, CH2 1.50, m 6; 8 
 
13a 
  
1.67, m 
   8 21.9, CH2 1.65, m 7a; 9 
  9 42.1, CH2 1.50, m 
 
14 
 
  
1.27, m 
   10 36.5, C 
    11 150, C 
  
12; 13; 6 
 12 109.9, CH2 4.92, s 13a 13; 6 13b 
  
4.74, s 
  
6 
13 21.7, CH2 3.57, d (10.0) 13b 
 
13b; 5 
  
3.11, d (10.0) 
   14 20.6, CH3 0.99, s 
 
5 6 
15 62.7, CH2 3.60, d, (11.3) OH 3b; 5 14, oh 
  
3.70, m 
OH, 
15a 
 
6 
 
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC and NOESY experiments. HMBC correlations 
from the carbon stated to the indicated proton. 
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5.2.4 Biological Assessment of Compounds 135, 136, 141, 145 and 147 
5.2.4.1 Analysis of Cytotoxicity of Gorgonene Derivatives 
Compounds 135, 136, 141, 145, 147 were tested for cytotoxicity against human 
foreskin BJ fibroblast cell line (ATCC CRL-2522) and human breast adenocarcinoma 
cell line (ATCC HTB-26) according to the procedure described in Chapter 2. Compound 
136 did show inhibition of cancer cell growth in the initial screening at 100 µg/mL, but 
when an IC50 was performed it did not inhibit cancer growth at 64 µg/mL. Compound 
135 and 145 did not show any activity in the anticancer assays up to 64 µg/mL. 
Compound 147 displayed modest anticancer activity in the 32-64 µg/mL range for both 
cell lines. Due to limited material, 141 was only tested in the assay at a concentration of 
32-64 µg/mL and was not cytotoxic at that level. 
Table 5.3 - Cytotoxicity Data for Compounds 135, 136, 141, 145 and147 (IC50) 
 Cell Line 
Compound BJ HTB-26 
135 >64 µg/mL >100 µg/mL 
136 >64 µg/mL 64-100 µg/mL 
141 >32 µg/mL >32 µg/mL 
145 >64 µg/mL >64 µg/mL 
147 32-64 µg/mL 32-64 µg/mL 
 
5.2.4.2 Antimicrobial Assessment of Gorgonene Derivatives 
The compounds 135, 136, 141, 145 and 147 were screened for antimicrobial 
activity and did display growth inhibition 128 µg/mL against Gram positive bacteria: 
MRSA or VRE, Gram negative bacterium: Pseudomonas aeruginosa or fungus: 
Candida albicans. The assays were performed according to the procedure described in 
Chapter 2. 
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5.2.4.3 Evaluation of Protein Tyrosine Phosphatase Inhibition of Gorgonene 
Derivatives 
Compounds 135, 136, 141, 145 and 147 were screened for protein tyrosine 
phosphatase inhibition according to the procedure described in Chapter 2. None of the 
compounds displayed inhibition at the concentration tested (50 µM). 
5.3 Conclusion and Significance 
 Five new natural product derivatives of gorgonene were synthesized, fully 
characterized and screened for biological activity in three bioassays. The reactivity of 73 
with BH3 and SeO2 gives insight into the tendency for the 1,5-diene to react 
intramolecularly through pericyclic rearrangements to favor the formation of 6 
membered rings. The bioassays performed did not identify any significant activity, 
however, further biological screening of these compounds may reveal a biomedical 
application. Of particular interest would be to test glycoside 141 for anti-inflammatory 
properties.   
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5.4 Experimental Section 
Synthesis of 135 and 136 
All glassware was dried in an oven overnight and allowed to cool to room temperature 
under an atmosphere of argon. To a solution of 73 (5g, 24.5 mmol) in anhydrous THF 
(100 mL) was added a 1M solution of BH3-THF (20 mL, 20 mmol)) dropwise at 0 
o
C. 
The solution was allowed to come to room temperature and was stirred for two hours. 
The reaction was then cooled to 0 
o
C and a 3M solution of NaOH (15 mL, 45 mmol) 
was added dropwise, followed by the dropwise addition of H2O2 (35 %, 5 mL). The 
solution was then heated to 50 
o
C and stirred at that temperature for two hours. It was 
then allowed to cool and diluted with ethyl acetate, extracted with distilled water, dried 
with MgSO4 and the solvent removed in vacuo. The product mixture was purified using 
C18 chromatography (70-85 % MeOH:H2O) to give 135 as a white powder (1.8 g, 31 % 
yield). Compound 136 was crystallized from MeOH to give clear colorless crystals (2.2 
g, 37 % yield). 
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Compound 135  
 
1
H NMR (600 MHz, CDCl3) δ 3.67 (dd, J = 10.4, 2.9 Hz, 1H), 3.57 (ddd, J = 10.2, 10.2, 
2.1 Hz, 1H), 3.48 (dd, J = 10.2, 1.3 Hz, 1H), 3.21 (dd, J = 15.9, 7.3 Hz,  1H), 2.89 (bs, 
2OH), 1.97 (m, 1H), 1.91 (m, 1H), 1.86 (m, 1H), 1.80 (m, 1H), 1.61 – 1.52 (m, 1H), 
1.50 - 1.48 (m, 1H), 1.48 - 1.42 (m, 1H), 1.43 – 1.38 (m, 1H), 1.41 - 1.38 (m, 1H), 1.40 - 
1.36 (m, 1H), 1.34 - 1.29 (m, 1H), 1.30 - 1.26 (m, 1H), 1.25 - 1.21 (m, 1H), 1.11 – 1.06 
(m, 1H), 1.08 – 1.04 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 0.84 – 0.77 (m, 1H), 0.75 (s, 
3H). 
13
C NMR (151 MHz, CDCl3) δ 64.0, 61.0, 48.9, 44.6, 42.8, 38.6, 37.9, 34.6, 34.4, 28.5, 
27.6, 22.2, 19.7, 17.4, 17.0. 
FTIR (CH2Cl2): νmax 3310.1, 2921.9, 2854.5 cm
-1
. 
(+) HRESIMS m/z 223.2058 [M - OH]
+
 (calcd for C15H27O, 223.2062). 
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Compound 136 
 
1
H NMR
 
 (600 MHz, CDCl3) δ 3.54 (dd, J = 10.3, 10.3 Hz, 1H), 3.48 (dd, J = 10.3, 5.4 
Hz, 1H), 2.96 – 2.86 (m, 1H), 1.82-1.80 (m, 1H), 1.72 – 1.69 (m, 1H), 1.67 (d, J = 11.2 
Hz, 1H), 1.58 (OH, 2H), 1.58 - 1.55 (m, 1H), 1.56 - 1.54 (m, 1H), 1.56 - 1.53 (m, 1H), 
1.52 – 1.48, (m, 1H), 1.51 - 1.49 (m, 1H), 1.50 – 1.46 (m, 1H), 1.34 – 1.30 (m, 1H),  
1.32 - 1.29 (m, 1H), 1.31 - 1.29 (m, 1H), 1.25 (s, 3H), 1.25 – 1.19 (m, 1H), 1.16 - 1.13 
(m, 1H), 0.91 (s, 3H), 0.83 (d, J = 7.1 Hz, 3H). 
13
C NMR (151 MHz, CDCl3) δ 74.6, 65.8, 56.2, 46.0, 45.3, 42.4, 40.0, 36.3, 33.7, 26.8, 
24.3, 22.2, 19.7, 19.0, 17.4. 
FTIR (CH2Cl2): νmax 3254.3, 2928.4 cm
-1
. 
(+) HRESIMS m/z 241.2165 [M + H]
+
 (calcd for C15H29O2, 241.2164). 
Mp. 216-217 
o
C. 
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Synthesis of 138
211
 
 
To a solution of glucose (3 g, 16.6 mmol) in pyridine (30 mL)  was added DMAP (14 
mg, 0.12 mmol). The solution was cooled in an ice bath and benzoyl chloride (17.6 g, 
125.0 mmol) was added slowly with stirring. The reaction was stirred for 24 hours at 
room temperature and then the solvent removed in vacuo. The residue was dissolved in 
DCM and H2O was added with cooling and stirring. The DCM layer was separated and 
the solvent removed in vacuo. The product was used in the formation of 139 without 
further purification. 
Synthesis of 139
203
 
 
In the absence of light, a solution of acetyl bromide (0.05 mL, 1.4 mmol) and MeOH 
(0.03 mL, 1.4 mmol) was combined with DCM (5 mL) and the solution was stirred for 
15 mins at room temperature. Compound 138 was added to the reaction and stirred 
overnight. A second equivalent of acetyl bromide/MeOH (0.05 mL/5mL) was added and 
the reaction was stirred overnight. The reaction was then washed with cold NaHCO3 and 
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then brine. The organic phase was dried over MgSO4 and the solvent removed in vacuo. 
The product was used in the next step without further purification.  
Synthesis of 140
204
 
 
All glassware was dried in an oven overnight and allowed to cool under an atmosphere 
of N2. All reagents were dried in a dessicator for 24 hours or more, and solvents were 
dried over 3Å molecular sieves. To a solution of AgOTf (15 mg, 0.05 mmol) and 
Ag2CO3 (193 mg, 0.7 mmol) in anhydrous DCM (20 mL) containing activated 
molecular sieves under an atmosphere of N2 was added compound 135 (42 mg, 0.175 
mmol). The resulting solution was stirred for 15 minutes at room temperature then 
cooled to -78 
o
C. A solution of 139 (480 mg, 0.728 mmol) in anhydrous DCM was 
added dropwise to the reaction and it was stirred for 4 days under N2 and allowed to 
come to room temperature. The reaction was diluted with ethyl acetate and filtered 
through a plug of celite. The filtrate was washed with saturated Na2SO4 and then brine 
solution. The organic layer was dried with MgSO4 and the solvent removed in vacuo. 
The product mixture was purified using silica gel flash chromatography (10:90 – 50:50 
ethyl acetate:hexanes) and C18 flash chromatography (30:70 H2O:MeOH-100 % 
MeOH) to give the product 140 (10.5 mg, 7.1 % yield). 
(+) HRESIMS m/z 841.3606 [M + Na]
+
 (calcd for C49H54NaO11, 841.3564) 
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K2CO3 benzoyl group deprotection of 140
204
 
 To a solution of 140 (10 mg) in methanol (1 mL) was added K2CO3 and the 
solution was stirred overnight, then neutralized with Amberlyst 15 resin, filtered, and 
the filtrate was evaporated to dryness in vacuo. The crude product mixture was analyzed 
using UPLC-HRMS and no ions corresponding to the desired product (fully deprotected 
glycoside 141) were visible in the chromatogram. 
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Synthesis of 141
205
  
 
To a solution of 140 (3.5 mg, 0.004 mmol) in a 3:1 solution of MeOH:DCM (1 mL) was 
added a 1M solution of NaOMe in MeOH dropwise until the reaction reached a pH of 
12. The reaction was then stirred for 4 hours at room temperature and the product 
mixture was neutralized using 1M HCl and purified using HPLC chromatography 
(phenyl-hexyl semi-preparatory column, isocratic, 80:20 MeOH:H2O) to afford 141 (0.4 
mg, 25 % yield).
 
1
H NMR (600 MHz, CDCl3) δ 4.27 (d, J = 8.0 Hz, 1H), 4.08 - 4.06 (m, 1H), 3.87 (m, 
1H), 3.83 (m, 1H), 3.61 – 3.52 (m, 1H), 3.51 - 3.48 (m, 1H), 3.49 (bs, OH), 3.38 (m, 
1H), 3.28 - 3.32 (m, 1H), 3.21 - 3.16 (m, 1H), 2.89 - 2.84 (m, 1H), 1.82 (m, 1H), 1.75 
(m, 1H), 1.63 (s, OH), 1.59 – 1.55 (m, 1H), 1.55 – 1.51 (m, 1H), 1.51 – 1.48 (m, 1H), 
1.48 – 1.45 (m, 1H), 1.45 – 1.42 (m, 1H), 1.41 – 1.39 (m, 1H), 1.39 – 1.37 (m, 1H), 1.32 
– 1.30 (m, 1H), 1.30 – 1.27 (m, 1H), 1.27 – 1.23 (m, 1H), 1.19 (s, 3H), 1.16 – 1.14 (m, 
1H), 1.14 - 1.11 (m, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.89 (s, 3H).  
FTIR (CH2Cl2): νmax 3337.7, 2923.3, 2854.0 cm
-1
. 
 (+) HRESIMS m/z 425.2508 [M + Na]
+
 (calcd for C21H38NaO7, 425.2515) 
Synthesis of 145 
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A solution of 136 (210 mg, 0.87 mmol) in pyridine (5 mL) was cooled in an ice bath and 
toluenesulfonyl chloride (498 mg, 2.6 mmol) was added as a solid. The reaction was 
stirred for 30 mins at 0 
o
C then placed in the fridge (5 
o
C) overnight. The solution was 
then carefully poured into a solution of ice water with stirring and extracted with TBME 
(3x25 mL). The organic layer was washed with cold 1M HCl (3x15 mL), dried with 
MgSO4 and the solvent removed in vacuo. The product mixture was purified using silica 
gel chromatography (0-10 % ethyl acetate:hexanes) and 145 was isolated as a white 
solid (106 mg, 54.9 % yield).  
1
H NMR (600 MHz, CDCl3) δ 3.90 (dd, J = 11.7, 2.6 Hz, 1H), 3.32 (dd, J = 1.0, 11.8 
Hz, 1H), 1.83 – 1.71 (m, 1H), 1.61 – 1.56 (m, 1H), 1.57 – 1.55 (m, 2H), 1.56 – 1.52 (m, 
1H), 1.47 – 1.40 (m, 1H), 1.42 – 1.38 (m, 1H), 1.37 – 1.31 (m, 1H), 1.30 - 1.26 (m, 1H), 
1.29 - 1.26 (m, 1H), 1.27 – 1.24 (m, 1H), 1.21 (s, 3H), 1.22 - 1.20 (m, 1H), 1.12 – 1.04 
(m, 1H), 1.03 – 1.00 (m, 1H), 1.00 (d, J = 7.2 Hz, 3H), 0.81 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ 74.1, 67.4, 49.4, 45.2, 41.6, 40.7, 33.6, 33.5, 31.3, 30.6, 
20.7, 20.0, 19.9, 19.8, 13.6. 
FTIR (CH2Cl2): νmax 2927.6, 2864.5 cm
-1
. 
(+) HRESIMS m/z 223.2058 [M + H]
+
 (calcd for C15H27O, 223.2062). 
Synthesis of 146 
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A solution of 135 (220 mg, 0.92 mmol) in pyridine (5 mL) was cooled in an ice bath and 
toluenesulfonyl chloride (522 mg, 2.75 mmol) was added as a solid. The reaction was 
stirred for 30 mins at 0 
o
C then placed in the fridge (5 
o
C) overnight. The solution was 
then carefully poured into a solution of ice water with stirring and extracted with TBME 
(3x25 mL). The organic layer was washed with cold 1M HCl (3x15 mL) dried with 
MgSO4 and the solvent removed in vacuo. The product mixture was purified using silica 
gel chromatography (0-10 % ethyl acetate:hexanes) and isolated as a white solid (261 
mg, 52 % crude yield). 
(+) HRESIMS m/z 566.2598 [M + NH4]
+
 (calcd for C29H44O6NS2, 566.2610)  
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Synthesis of 147
212
 
 
To a solution of 73 (200 mg, 0.98 mmol) in 1,4-dioxane (7 mL) under an atmosphere of 
N2 at room temperature was added SeO2 (140 mg, 1.26 mmol) as a solid. The reaction 
was stirred for 16 hours at which time the solution had changed to an orange-yellow 
color. The reaction was diluted with H2O and extracted with DCM. The organic layer 
was washed with H2O (3 x 15 mL), dried with MgSO4 and the solvent removed in 
vacuo. The title compound was purified using silica gel flash chromatography (0-10% 
acetone:hexanes) and isolated as a yellow solid (172.2 mg, 54 % yield).  
1
H NMR (600 MHz, CDCl3) δ 4.92 (s, 1H), 4.74 (s, 1H), 3.73 - 3.67 (m, 1H), 3.62 – 
3.57 (d, J = 11.3 Hz, 1H), 3.58 – 3.55 (d, J = 10.0 Hz, 1H), 3.11 (d, J = 10.0 Hz, 1H), 
2.44 (ddd, J = 3.2, 10.0, 10.0 Hz, 1H), 2.33 (m, 1H), 2.27 (bs, OH), 2.04 (d, J = 12.0 Hz, 
1H), 1.80 (m, 1H), 1.70 - 1.64 (m, 1H), 1.66 - 1.64 (m,  1H), 1.62 - 1.58 (m, 1H), 1.56 - 
1.54 (m, 1H), 1.53 – 1.46 (m, 1H), 1.52 - 1.48 (m, 1H), 1.43 - 1.37 (m, 1H), 1.34 – 1.30 
(m, 1H), 1.30 – 1.25 (m, 1H), 1.25 – 1.18 (m, 1H), 0.99 (s, 3H). 
 
13
C NMR (151 MHz, CDCl3) δ 150.0, 109.9, 62.7, 56.0, 55.6, 45.2, 42.1, 40.0, 38.2, 
36.5, 36.4, 21.9, 21.7, 20.6, 19.0. 
FTIR (CH2Cl2): νmax 3402.5, 3063.5, 2926.3, 2846.9 cm
-1
. 
 (+) HRESIMS m/z 301.1065 [M + H]
+
 (calcd for C15H25OSe, 301.1071). 
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Chapter 6 - Microbial Transformation of the Sesquiterpene (+)-β-
Gorgonene 
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6.1 Introduction to the Use of Biotransformation in Organic Synthesis 
Biocatalysis is a useful tool for generating complexity in organic synthesis
213
 and 
can be performed by whole organisms (biotransformation), isolated enzymes or cell-free 
extracts. Biotransformation can be an attractive alternative to traditional synthetic 
methods and is desirable for this project for the following reasons: 
 Regio- and stereoselective functionalization of gorgonene. 
 Functionalization of sites within the gorgonene skeleton that are 
otherwise inaccessible using synthetic methods.  
 Environmentally friendly alternative to harsh chemicals, catalysts and 
organic solvents.  
Problems associated with selectively synthetically modifying gorgonene 
prompted the use of microbial transformation as a method of introducing oxygen atoms 
to 73 and the synthetic compound 74 in a stereo- and regio-selective manor. Fungi are 
the most commonly used microorganism for hydroxylation of terpenes and 
sesquiterpenes in the literature.
214-216
 No biocatalytic studies on gorgonene have been 
reported, however, the biohydroxylation of (-)-maalioxide (77), a sesquiterpene with a 
similar framework to gorgonene (73), using Mucor plumbeus,
214
 Aspergillus cellulosae 
and Aspergillus niger
215
 indicated they all had the biosynthetic hardware required to 
hydroxylate terpenoids (Figure 6.1). 
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Figure 6.1 - Fungal Biotransformations of (-)-Maalioxide (77) 
Enzymes isolated from Pleurotus sapidus, an edible mushroom
216
, were capable 
of hydroxylating valencene (153), a sesquiterpene hydrocarbon containing a decalin 
core (Figure 6.2). Based on these literature precedents, the metabolism of 73 and 74 by 
select fungi was investigated.   
 
Figure 6.2 - Biocatalysis of Valencene (153) by Pleurotus sapidus 
6.2 Biotransformation Method Development 
Several experiments were performed to optimize culture conditions (type of 
media, duration of incubation, surfactant use and concentration of substrate) prior to 
large scale fermentation. 
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6.2.1 Extraction of Metabolites from Biotransformation Culture 
Freeze-drying is a technique used to remove water from a sample at low 
temperatures under reduced pressure. It was identified as a way to prepare the 
biotransformation cultures for solvent extraction without using elevated temperatures 
and risk degrading the metabolites. There was concern that the freeze-drying process 
would also evaporate the volatile starting materials (73 or 74) and biotransformation 
products along with the water. In order to determine if gorgonene would remain after the 
sample was freeze-dried, three samples containing media (5 mL) and 73 (50, 20 and 2 
µL) were freeze-dried and extracted with DCM (5 mL). The crude extract was then 
filtered and visualized using 
1
H NMR. The gorgonene was recovered in > 90 % yield 
and freeze-drying did not affect the mass recovered of 73. 
6.2.2 GCMS as a Screening Tool for Biotransformation Extracts 
GCMS was an ideal tool for biotransformation screening for several reasons. 
Only low-boiling compounds elute on the GCMS, resulting in a relatively clean 
chromatogram due to the media components and primary metabolites not being 
detected. Gorgonene and its related metabolites, however, are volatile and observable 
using GCMS. Minimal processing of the fermentations is therefore required and no 
purification step need be performed to prepare the extracts for injection onto the GCMS. 
This is desirable when large numbers of extracts are to be screened. The hydrophobic 
nature of the starting materials 73 and 74 also makes them poor candidates for reversed-
phase LCMS analysis. The m/z data provided in the GCMS chromatogram aids the 
identification of gorgonene and any related biotransformation products which would 
have predictable molecular ions corresponding to formula: C15H24 + O(n) +/- H(n). 
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6.2.3 Optimization of Substrate Concentration in Biotransformation Culture 
The optimal concentration of substrate 73 and 74 in the biotransformation was 
investigated. Oversaturation of the starting compound can prevent detection of 
metabolites due to low relative abundance of the new compounds. A minimal amount of 
starting compound should be used, slightly above what the organism is capable of 
processing. To determine the range of concentration to use in the fermentations, the 
compounds were incubated with Aspergillus aculeatus in three concentrations of 73 and 
74: 0.4, 3.0 and 10 mg per 5 mL culture. After incubation for 7 days the fermentations 
were freeze-dried, extracted and 0.1 mg of the crude extract was dissolved in 1 mL of 
hexanes and analyzed using GCMS. No starting material or metabolites were reliably 
detected in the GCMS profile of the culture containing 0.4 mg of 73 or 74. In the more 
concentrated examples, 73 and 74 were both consistently detected in the GCMS 
however no transformation products were observed in either case. This experiment did 
not give insight into the rate of biotransformation but a concentration on the lower end 
of the range between the two was chosen for use in future biotransformations to avoid 
oversaturation. 
6.2.4 Selection of Fungi for Biotransformation 
The Kerr Lab collection of fungal isolates has over 1300 members. Five fungi 
from this library were selected, based on their taxonomic similarity to fungi known to 
perform oxidations on compounds structurally related to gorgonene (e.g. sesquiterpene 
hydrocarbons and decalin containing sesquiterpenes). Known pathogens were avoided.  
The five species of fungi that were chosen to screen for biotransformation of 73 
and 74 were Pleurotus djamor, Beauveria geodes, Curvularia lunata, Aspergillus 
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aculeatus and Bionectria ochroleuca. Pleurotus djamor was chosen for its genus-level 
similarity to Pleurotus sapidus, a fungus known to contain peroxidases and to regio-
specifically transform (+)-valencene (153), a sesquiterpene, to a flavor compound, (+)-
nootkatone.
216
 Aspergillus aculeatus was included because many Aspergillus species are 
known to perform oxidations on sesquiterpenes including Aspergillus niger
217
 and 
Aspergillus cellulosae.
218
 Beauveria geodes was chosen for its relation to Beauveria 
bassiana, known to transform aryltetralone.
219
 Curvularia lunata is known to perform 
oxidations on several substrates including the 6β-acetoxyeudesmanols and 6β-
acetoxyeudesmanones.
217, 220, 221
 
6.2.5 Optimization of Duration of Fermentation 
A study investigating the effect of the duration of fermentations on the product 
yields of the biotransformation was undertaken. Fermentations were shaken for 18 and 
32 days from the addition of the sesquiterpene (73 and separately 74) before GCMS 
analysis and comparison. The five species of fungi were each cultured in five different 
liquid media and each was analyzed at the two time points. The five media were chosen 
based on fungal biotransformation studies in the literature.
217, 218, 222, 223
Two of the five 
(C and D) media contained low concentrations of nutrients and A, B and D were 
comparatively rich in nutrients with different nutrient sources and metal salts. All media 
recipes are included in the experimental section.  
The biotransformations of 73 and 74 were performed in 5 mL of culture media in 
15 mL glass tubes. The growth of the fungi was evaluated visually and the extent of 
biotransformation of 73 and 74 was assessed using GCMS. The samples were processed 
using the established freeze-dry/extraction method to prepare for evaluation by GCMS. 
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Each was compared to fungal cultures not containing either of the sesquiterpenes. Table 
6.1 summarizes the results of the qualitative growth evaluation and Table 6.2 displays 
the percent conversion of starting materials to biotransformed products as estimated 
using GCMS. 
Table 6.1 - Qualitative Analysis of Fungi Growth and Sporulation in Various 
Media 
Fungi
Beauveria geodes Pleurotus djamor Curvularia lunatus Aspergillus aculateus Bionectria ochroleuca
Media 73 and 74 growth sporulation growth sporulation growth sporulation growth sporulation growth sporulation
A Blank 8 ns 5 s 8 s 9 s 5 s
73 8 ns 2 ns 8 ns 7 s 6 s
74 7 ns 4 ns 7 ns 7 s 6 s
B Blank 8 s 7 s 7 s 7 s 5 s
73 5 ns 5 ns 6 s 6 s 5 s
74 5 ns 5 ns 7 s 8 s 6 s
C Blank 10 s 2 ns 8 s 10 s 9 s
73 10 s 1 ns 7 ns 10 s 9 s
74 10 s 1 ns 8 u 10 s 8 s
D Blank 6 s 7 s 6 s 6 s 4 s
73 6 ns 5 ns 4 ns 5 s 4 s
74 7 s 4 ns 5 s 5 s 5 s
E Blank 9 s 6 s 9 s 10 s 8 s
73 9 s 4 ns 9 ns 10 s 7 s
74 9 s 2 ns 8 ns 10 s 8 s  
# - Qualitative Visual Rating of Fungal Growth (1 (very little growth) - 10 (significant 
growth)); s - Spores Visible; ns - No Spores Visible; u - Unable to Determine if Spores 
are Present. 
 
Four of the fungi experienced optimal growth on media C and E although 
Pleurotus djamor grew best on media B and D. The growth ratings of the fungi did not 
directly correlate to the extent of biotransformation measured by GCMS. Low-nutrient 
media appeared to promote biotransformation better than richer nutrient broths. This 
observation may be due to the fungus processing the compound as a food source in an 
environment with low abundance of carbon sources, removing them from the extract 
and increasing the observed (GCMS) ratio of hydroxylated products.   
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Table 6.2 - Evaluation of Biotransformation Conversion at Two Time Points Using 
GCMS 
Fungi
Beauveria geodes Pleurotus djamor Curvularia lunatus Aspergillus aculateus Bionectria ochroleuca
Media 73 or 74 t1 t2 t1 t2 t1 t2 t1 t2 t1 t2
A 73 0 0 0 0 0 0 0 0 0 2
74 0 2 3 3 0 N 2 1 0 1
B 73 0 0 N 0 0 N 0 0 3 3
74 3 4 3 3 3 N 1 3 N N
C 73 0 0 0 0 0 0 0 0 N N
74 0 0 1 2 0 0 0 3 2 3
D 73 0 0 0 0 0 0 0 0 N 0
74 2 4 3 3 3 4 3 3 0 N
E 73 0 0 0 0 0 0 0 0 4 N
74 0 0 1 1 0 0 2 2 N N  
0 – No Transformation (Only Sm Visible). 1 - New Compound(s) Visible but Starting Material 
is Largest Peak in the GCMS Chromatogram. 2 - New Compound(s) Visible in GCMS 
Chromatogram, Approximately Equal in Height to Starting Material Signal. 3 - New 
Compounds(s) Present in GCMS Chromatogram, in Higher Intensity than Starting Materials.  
4 - New Compounds Visible and Little or No Starting Materials Visible in the GCMS 
Chromatogram. N – No Starting Materials or Transformation Products Visible in the GCMS 
Chromatogram. T1 – 18 days. T2 – 32 days. 
 
Incubation of compound 73 with Bionectria ochroleuca resulted in new 
metabolites visible in the GC eluting at 7.62, 8.23 and 8.66 minutes. Within the 
Bionectria fermentations, media had very little effect on the ratio of product formation 
and low-nutrient media B was chosen to use in the large scale fermentation. No 
transformation of 73 was observed by any of the other four fungi. 
The GCMS analysis of the fermentation extracts suggested that 74 was more 
susceptible to biotransformation by multiple fungi than 73. Two fungi were chosen to do 
large-scale biotransformations that produced different metabolites: Pleurotus djamor 
and Beauveria geodes. Again, no significant difference was observed between types of 
media used and media B was chosen for the large-scale fermentation.  
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6.3 Large Scale Biotransformation Fermentation 
 The fungi were innoculated into 1 L of media B in a 2.2 L flask and incubated 
for 7 days before 1 g of the reagent (73 or 74) was added. The flask was shaken at 
ambient temperature for 30 days before the cultures were freeze-dried and extracted 
sequentially with DCM, ethyl acetate and methanol. The solvent was removed from the 
extracts and the mass was recorded (Table 6.3). 
Table 6.3 - Masses of Biotransformation Extracts 
 Beauveria 
geodes 
Pleorotus 
djamour 
Bionectria 
ochroleuca 
DCM Extract 52.1 mg 40.5 mg 129.2 mg 
DCM Extract after C18 
Filteration 
44.6 mg 30.9 mg 101.3 mg 
Ethyl Acetate Extract 13.0 mg 23.0 mg 21.0 mg 
Methanol Extract 8617.9 mg 6593.5 mg 6380.9 mg 
 
6.3.1 Bionectria ocroleuca Biotransformation of 73 
The DCM extract of the Bionectria ochroleuca culture was separated into two 
major fractions using HPLC and the desired metabolites were present in fraction 1 
according to LCMS and NMR data. Fraction 1 was further purified using HPLC and the 
compound mixture ionized in the LCMS with m/z ions of 237.184 (C15H25O2)
+
, 
(73+2O+H)
+
 and 277.1776 (C15H26O3Na)
+
- (73+3O+2H+Na)
+
 and appeared to have 
peaks typical of sesquiterpenoids in the 
1
H NMR spectrum. Although peak 1 appeared to 
contain compounds derived from 73, it was not analyzed further due the low product 
yield and complexity of the product mixture.  
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6.3.1.1 Structure Elucidation of Bionectria ocroleuca Biotransformation Product 
The second compound to elute was a compound that accounted for 40 % of the 
crude DCM extract. Metabolite 157 was obtained as a white amorphous solid and was 
determined to have a molecular formula of C15H26O3 with a m/z (M+Na)
+
 ion of 277.177 
corresponding to 73+3O+2H+Na
+
. 
 Table 6.4 shows the data from the 1D and 2D NMR that assisted in the 
elucidation of the structure of 157. Indeed the final structure has a skeleton modified 
from 73. The compound containined 15 carbons according to the 
13
C NMR spectrum, 
three of which had chemical shifts typical of aclohols, C9, C11 and C12. Methine 
carbon C9 appeard at 79.3 ppm and was HMBC correlated to H15 and its connected 
hydrogen was COSY correlated to H8. C11 was a quaternary carbon resonating at 76.6 
ppm in the 
13
C spectrum and had HMBC correlations to H6 and H13. C12 was a bound 
to two hydrogen atoms (67.8 ppm) and had HMBC correlations to H6 and H13. The C4-
C14 olefin remained in the molecule and the alkene hydrogens appeared between 4.9 
and 5.2 ppm in the 
1
H NMR spectrum. The planar structure elucidation of 157 was 
completed using the COSY and HMBC data shown in (Figure 6.3) The stereochemistry 
of the tertiary alcohol at C9 was assigned using NOESY correlations between the H9 
and both H1b and H7b. The stereochemistry of C11was more difficult to assign due to 
free rotation around the C7-C11 bond making  the use of through-space coupling in 2D 
NMR as a means of stereochemical assignment more challenging and the quaterinary 
geometry of C11 prevents the use of typical chiral shift reagents. NOESY and ROESY 
data however do support the stereochemistry assigned in Figure 6.3. Neither H12 or H13 
have NOESY correlations to H14 suggesting that they are positioned away from the 
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olefin in the global energy minimum conformation and this is further supported by 
NOESY correlations H12/H7b and H13/H7a. H13 is also correlated to H6 suggesting it 
is positioned on the back side of the decalin skeleton (as drawn, Figure 6.3). 
Correlations between between H12 and H5 complement those results and place C12 on 
the front side of the decalin skeleton. These correlations are summarized in Figure 6.3 
and support an S configuration at C11.    
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Table 6.4 - NMR Spectroscopic Data for Compound 157 (CDCl3) 
 
δC, type δH (J in Hz) COSY HMBC NOESY ROESY 
1 38.0, CH2 1.92, m 1b; 2b 15     
    1.27, m         
2 25.7, CH2 1.82, m 1b; 2b; 8b 3a,b; 1b     
    1.64, m 1b       
3 39.4, CH2 2.35, m 2b; 3b 14a,b     
    2.09, m 2a,b       
4 153.1, C     5; 3b     
5 52.1, CH 2.22, m 6 3; 6; 14; 15   1b; 9 
6 39.9, CH 2.05, m 5; 7a,b 8a; 13     
7 26.1, CH2 1.95, m 8a, 7b 8a,b; 13     
    1.33, m       12a,b 
8 29.0, CH2 1.71, m 7b; 9 7a,b 7b   
    1.59, m 7b; 9   7b   
9 79.3, CH 3.34, m 8a,b 7a; 15 1b; 8b 1b; 7b 
10 43.5, C     
1b; 5; 8a; 
15     
11 76.6, C     6; 13     
12 67.8, CH2 3.63, d (11.0 Hz)   6; 13 5; 7b 5 
    3.40, d (11.0 Hz)     7b   
13 25.3, CH3 1.19, s   9; 12a 6; 7a   
14 
109.4, 
CH2 5.16, s 3b 5; 3b   3a 
    4.93, s 5     8 
15 11.4, CH3 0.80, s   1b; 5; 9 
1a; 5; 6; 
14b   
  OH  2.29, m   12a,b     
Data was obtained in CDCl3 solution, δ in PPM relative to solvent signal. Assignments 
were aided by COSY, HSQC and HMBC, NOESY and ROESY experiments. HMBC 
correlations from the carbon stated to the indicated proton. 
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Figure 6.3 - Key NMR Correlations for the Structure Elucidation of 
Biotransformation Product 157 
6.3.1.2 Metabolic Conversion of 73 to 157 
The conversion of an olefin (C11-C12, 73) to a glycol (C11-C12, 157) by a 
fungus is similar to a result Asakawa et al. observed when transforming (+)-Nootkatone 
with Aspergillus niger (Figure 6.4).
224
 
 
Figure 6.4 - Biotransformation of (+)-Nootkatone by Aspergillus niger 
Asakawa et al. proposed that cytochrome P450 is responsible for the conversion 
of the alkene to an epoxide in an initial step which is then readily converted to the glycol 
moiety (159) in water. They concluded that a cytochrome P450 is involved based on the 
ability of 1-aminobenzotriazole, an inhibitor of cytochrome P450, to hinder the 
transformation. A cytochrome P450 may be responsible for the production of the glycol 
moiety in 157 as well. Below is a proposed mechanism for the dihydroxylation 
extrapolated from Asakawa’s findings (Figure 6.5). 
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Figure 6.5 - Proposed Mechanism for Formation of Glycol in 157 
 There are no examples of a biotransformation of (+)-β-gorgonene (73) in the 
literature, however, hydroxylation of C9 on similar decalin containing terpenoids is 
known (Figure 6.1) .
214, 215
  
The regio- and stereoselective hydroxylation of gorgonene was successfully 
performed by Bionectria ochroleuca. The resulting metabolite 157 was obtained in a 4 
% isolated yield. Although this is low for the purposes of this project, yields between 1-
10 % are typical for this type of transformation.
219, 223
 The disappearance of starting 
materials, however suggests that the product is being completely degraded by the 
fungus. This result is supported by the pathogenic nature of B. ochroleuca to plants
225
 
since sesquiterpenes are known to be major components of plants.
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6.3.1.3 Evaluation of Biological Activity of Compound 157 
Compound 157 was tested for antimicrobial activity against a panel of 6 
microbes (MRSA, VRE, C. albicans, P. aeruginosa, P. vulgaris and S. warneri) using 
the assay protocol described in Chapter 2 and was not active at 128 µg/mL. Compound 
157 did not display cytotoxicity at a concentration of 64 µg/mL against human foreskin 
BJ fibroblast cell line (ATCC CRL-2522) or human breast adenocarcinoma cells (ATCC 
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HTB-26) when tested according to the procedure described in Chapter 2. Finally, 
compound 157 was not an inhibitor of the PTP1B enzyme at 50 µg/mL.  
6.3.2 Fermentation of Beauveria geodes with 74 
The DCM extract of the fermentation of Beauveria geodes with 74 was analyzed 
using UPLC-HRMS and several compounds ionized with m/z values within the range 
for predicted products (e.g. 277.131 (74+3O-4H)). HPLC purification of the crude 
extract was initiated but not successful due to exceptionally low yields of multiple 
product containing fractions.  
6.3.3 Pleurotus djamor Fermentation with 74 
The DCM extract from the Pleurotus djamor fermentation with compound 74 
was analyzed using UPLC-HRMS and some promising ions were observed. There were 
two separate compounds that ionized with an m/z of 219.173, which are consistent with 
by the molecular formula C15H23O
+
 (74+O-2H). There was also a compound with an m/z 
of 217.158, corresponding to the molecular formula C15H21O (74+O-4H).  Further 
attempts to purify the compounds were unsuccessful due to the complexity of the 
product mixture.  
6.4 Future work 
The successful production of one trihydroxylated metabolite was achieved and 
several other related metabolites were observed in amounts too low to fully characterize. 
The low yield of 157 prevented the use of biotransformation as an initial step of a semi-
synthesis. Further optimization of this transformation would be necessary to warrant this 
as useful first step in a synthetic route.  
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A time trial experiment would be a logical next step in this study. Quantitative 
monitoring of disappearance of starting materials and the appearance of 
biotransformation products on a daily basis would provide more insight into the optimal 
end-time for the fermentations and perhaps help reduce loss of starting material. Should 
an optimized yield be achieved, this compound would be a candidate for further 
chemical modification.  
The metabolite 157 did not show any biological activity in the assays tested. It 
may possess activity in another indication and should be included in a screening library 
for other indications.  
6.5 Significance 
Decalin containing sesquiterpenes are of interest for their varying biological 
activity and are often studied for their fragrance. Relatively little is known about the 
biotransformation of sesquiterpene hydrocarbons. Biocatalysis is an emerging field with 
great potential but much more exploratory work is warranted to establish an advanced 
understanding of the topic such as ability to predict the reactivity of specific organisms 
with substrates and make it a more useful tool for chemists. Bionectria ochroleuca, also 
known by several other names including Clonostachys rosea and Gliocladium roseum 
has been reported to perform an ester cleavage of an estrogenic compound
227 
and 
hydroxylate sesquiterpenoids.
228
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6.6 Experimental Section 
Procedure for Concentration Optimization and Use of Tween 
Each fermentation was performed in duplicate and compared to a blank 
fermentation of the fungus. A cryovial containing A. aculeatus was thawed and 0.5 mL 
was inoculated into a sterile tube of seed media (E) and incubated for 7 days at ambient 
temperature. 1 mL of the seed inoculum was then transferred via pipette to a prepared, 
autoclaved 15 mL glass tube containing 5 mL media A. The tubes were shaken at 150 
rpm at 22 
o
C for 4 days. Compound 73 or 74 was added to the cultures in the stated 
amount (2, 15 or 50 µL). Quadruplicates were performed of each compound at each 
concentration. The fermentations were allowed to stand for 7 days at 22 
o
C, then were 
freeze-dried and extracted with DCM (2x5 mL) with sonication. The extracts were 
combined, the solvent removed in vacuo, weighed and then injected to the GCMS at a 
concentration of 100 µg/mL in hexanes.  
General Procedure for Optimization of Duration, Fungi and Media 
Each fermentation was performed in duplicate and compared to a blank 
fermentation of the fungus. A cryovial containing the fungus (Pleurotus djamor, 
Beauveria geodes, Curvularia lunata, Aspergillus aculeatus or Bionectria ochroleuca) 
was thawed and 0.5 mL was inoculated into a sterile tube of seed media (E, 15 mL) and 
incubated for 7 days at ambient temperature. The seed inoculum (1 mL) was transferred 
via pipette to a prepared, autoclaved 15 mL glass tube containing 5 mL media (A-E). 
The tubes were shaken at 150 rpm at 22 
o
C for 4 days. Compound 73 or 74 (20 µL) was 
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added to the culture. The fermentations were allowed to stand for 14 days at 22 
o
C and 
duplicates of each fungus and media type were freeze-dried and extracted with DCM 
(2x5 mL). The extracts were combined, weighed and the injected to the GCMS at a 
concentration of 100 µg/mL in hexanes. The remaining fermentations (2 replicates of 
each fungi and media) were left to stand for a further 14 days before being rated for 
growth and sporulation, freeze-dried and extracted with DCM (2x5 mL). The solvent 
was removed from the extracts in vacuo and a 100 µL/mL solution in hexanes was 
prepared and injected to GCMS for analysis.   
General Procedure for Large-Scale Biotransformation  
A cryovial containing the fungus (Bionectria ochroleuca, Pleorotus djamor or 
Beauveria geodes) was  thawed and innoculated (0.5 mL) into a autoclaved glass tube 
containing media E (15 mL) and microscope slides. The seed fermentation was allowed 
to shake (200 rpm, 25 
o
C) for 5 days. Media B (1 L) (autoclaved) was placed in a 2.2 L 
fernbach flask and media B (100 mL) was placed in a 250 mL earlenmeyer flask for a 
control. The seed fermenation was transferred via pipette to the 250 mL flask (1mL) and 
the fermbach flask (14 mL). The flasks were incubated with shaking (200 rpm) for 7 
days at 25 
o
C. Gorgonene (1 mL) or 74 (1 mL) was added (neat) to the fernbach. The 
fungi were continually shaken at 200 rpm and 25 
o
C for 5 weeks. The fermentations 
were freeze-dried, extracted with DCM (2x 300 mL with sonication at 35 
o
C, 1 x 300 
mL with soaking (12 hours)). The filtrates were decanted and combined and the solvent 
removed in vacuo. The freeze-dried cultures were then extracted with ethyl acetate (2 x 
250 mL) and methanol (2 x 250 mL). The ethyl acetate fractions were combined and the 
methanol fractions were combined, the solvent removed and weighed. All of the extracts 
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were screened using GCMS and those with promising profiles were analyzed using 
NMR.  
Biosynthesis of 157 
 
The biotransformation of 73 was performed according to the general procedure 
described above using Bionectria ochroleuca. The DCM and ethyl acetate fractions we 
combined and fractionated using reversed-phase HPLC (phenyl hexyl semi-prep 
column, isocratic, 75:25 MeOH:H2O) and the second fraction to elute was further 
purified using reversed-phase HPLC (phenyl hexyl semi-prep column, isocratic 55:45, 
MeOH:H2O). The second compound to elute was a pure white amorphous solid (4 % 
yield, 40 mg). 
1
H NMR (600 MHz, CDCl3) δ 5.16 (s, 1H), 4.94 (s, 1H), 3.63 (d, J = 11.0 Hz, 1H), 3.41 
(d, J = 11.0 Hz, 1H), 3.34 (m, 1H), 2.35 (m, 1H), 2.21 (m, 1H), 2.11 – 2.06 (m, 1H), 
2.08 – 2.01 (m, 1H), 1.97 – 1.92 (m, 1H), 1.94 – 1.89 (m, 1H), 1.84-1.80 (m, 1H), 1.74 – 
1.68 (m, 1H), 1.65-1.61 (m, 1H), 1.60 – 1.53 (m, 1H), 1.36 – 1.30 (m, 1H), 1.28-1.23 
(m, 1H), 1.19 (s, 3H), 0.80 (s, 3H). 
13
C NMR (151 MHz, CDCl3) δ153.0, 109.4, 79.2, 76.6, 67.7, 52.0, 43.4, 39.9, 39.3, 
37.9, 29.0, 26.1, 25.6, 25.3, 11.4. 
(+) HRESIMS m/z 277.1766 [M + Na]
+
 (calcd for C15H26O3, 277.1780) 
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Media Recipes 
Media A218 
1.5 % Sucrose, 1.5 % glucose, 0.5 % polypeptone, 0.1 % K2HPO4, 0.05 % KCl, 0.001 % 
FeSO4-7H2O, in distilled water.  
Media B222 
0.5 % Glucose, 0.5 % malt extract, 0.2 % peptone, 0.5 % yeast extract and1.8 % instant 
ocean in distilled water.  
Media C217 
3 % Glucose, 3 % glycerol, 1.5 % peptone, 1.5 % yeast extract, 1.5 % K2HPO4 and 1.5 
% instant ocean in distilled water 
Media D 223 
0.5 % Glucose, 0.1 % peptone, 0.1 % yeast, 0.1 % beef extract and distilled water. 
Adjust to pH 5.7 with NaOH.  
Media E (SYMA) 
4.0 % Maltose, 1.0 % peptone, 1.0 % yeast extract, 0.1 % agar and 1.8 % instant ocean 
in distilled water.  
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Chapter 7 - Conclusion and Future Work 
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7.1 Synthesis and Biological Evaluation of Gorgonene Derivatives 
Several small collections of compounds derived from the sesquiterpeneoid (+)-β-
gorgonene were synthesized, purified and characterized using HRMS, NMR and IR.  A 
number of synthetic strategies were applied to produce the analogues, none of which 
were more than four steps from gorgonene. The series of non-natural sesquiterpene-like 
compounds were screened for biological activity in three assays for PTP inhibition, 
cytotoxicity and antimicrobial activity and analyzed for drug-likeness. Several of the 
library members showed modest cytotoxicity, the most potent of which displayed IC50’s 
between of 16-32 µg/mL (106 and 107) against human breast adenocarcinoma cells. 
Although many of the gorgonene derivatives displayed inhibition of the PTP1B enzyme, 
those that were selective for the PTP1B enzyme were only modest inhibitors.  
7.2 Reactivity of Gorgonene 
One recurring observation in this project was intramolecular cyclizations of 
gorgonene and its derivatives, particularly the dione and glycol-containing analogues. 
The proximal functional groups (terminal alkenes, ketones, hydroxyl groups) are 
positioned to interact with each other instead of intermolecularly. Gorgonene can be 
viewed as a unactivated 1,5-diene model system providing precedence for other 
comparable systems to react similarly under the same synthetic conditions. Pericyclic 
reactions within gorgonene have produced several novel tri- and tetracyclic structures, 
useful for the expansion of the synthetic library and providing new routes to these 
desirable frameworks in other systems.  
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7.3 Future Work   
Although a high hit rate of compounds possessing modest biological activity in 
the cytotoxicity and PTP assays were observed, none of the compounds were potent 
enough to warrant a second generation library based on a single lead compound. 
Synthesis of a library of similarly functionalized compounds based on the more common 
bicyclofarnesol sesquiterpene skeleton may produce derivatives with more potent 
activity and provide insight on the effect of the substitution pattern of the decalin 
skeleton on biological activity.  
This semi-synthetic collection described in this work has been archived and a 
large portion of it is available for future screening in additional bioassays. 
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